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The immune system protects us from harmful microbial infections. Such protection 
results from the interplay between innate and adaptive (acquired) immunity, both 
of which involve differential recognition of self from infectious non-self. While innate 
immunity relies upon antigen-nonspecific pattern-recognition receptors to broadly 
sense offensive signals, adaptive immunity utilizes far more specific antigen 
receptors. These antigen receptors are expressed by B and T cells, and function to 
better discriminate various antigenic epitopes in order to achieve specific immunity 
and immunological memory (1, 2). 
 
Bone marrow 
Hematopoiesis is the process of production of mature blood cells, which primarily 
takes place in the bone marrow (3). Here, pluripotent stem cells reside that give 
rise to the various types of blood cells. Pluripotent stem cells maintain, in contrast 
to differentiated blood cells, their proliferative ability throughout the life of an 
individual. These pluripotent stem cells divide to produce two types of stem cells. A 
common myeloid progenitor that gives rise to the myeloid lineage, which comprises 
erythrocytes, platelets and most of the cells of the innate immune system, such as 
granulocytes, macrophages, mast cells, monocytes, and dendritic cells. A common 
lymphoid progenitor gives rise to the lymphoid lineage, which comprises the natural 
killer cells of the innate immunity and lymphocytes of the adaptive immune system. 
There are two types of lymphocytes, B lymphocytes (B cells) and T lymphocytes (T 
cells) (4). 
 
Normal B cell development 
In the body, the humoral immune response is mediated primarily by B cells and 
requires enormous variability in immunoglobulins to deal with all possible antigens. 
Immunoglobulins, or antibody molecules, consist of a constant region and a 
variable region. The constant region takes one of only five distinguishable forms 
which determine the effector function. The variable region is the actual antigen 
binding site and can be composed of an apparently endless variety of different 
amino acid sequences, forming subtle differences that allow antibodies to bind 
specifically to an equally infinite variety of antigens. In addition, multiple regulatory 
mechanisms are required to discriminate self from non-self and to yield long-lasting 
immunological memory.  
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B cells arise in the bone marrow from stem cells and differentiate through a 
complicated and highly regulated process into cells that can produce antibodies 
capable of recognizing specific foreign antigens. The development of B cells in the 
bone marrow is initiated by the assembly of genes for the variable regions of the 
heavy and light chains of antibodies in B cell progenitors which is obligatory for B 
cell antigen receptor (BCR) expression (5). The BCR is a membrane bound 
immunoglobulin and consists of two heavy and two light chains. First, the heavy 
chains of the BCR are produced, thereafter the light chains (6).  
The variable regions of heavy and light chains are formed by DNA rearrangement of 
multiple different segments on the heavy and light chain loci (Fig. 1). This process 
is called V(D)J recombination, in which the gene rearrangements start at the heavy 
chain locus in pro-B cells with first random combinatorial joining of the D (diversity) 
and J (joining) gene segments (7). Subsequently, rearrangements of V (variable) 
gene segments to DJ-rearranged segments are induced and if successful at one 
allele, the other allele is turned off by allelic exclusion (8). Light chains consist of 
and rearrange V and J gene segments and are combined with the heavy chain. The 
recombination process generates an enormous antigen receptor diversity, which is 
further increased by random nucleotide introduction in the joining regions during 
recombination. An intact pre-BCR is expressed at the cell surface of the dividing 
pre-B cell. 
 
B cell selection 
During B cell proliferation, positive and negative selection checkpoints are set to 
test the competence of the (pre-)BCR (Fig. 2). In the bone marrow, positive 
selection occurs in cells expressing a transmembrane pre-BCR. This selection 
means that signaling from the pre-BCR is required to suppress V(D)J recombination 
and an appropriate pre-BCR signals for proliferative expansion (9). Whether pre-
BCR cross-linking by an unknown ligand or simple surface expression is sufficient is 
still debated. Pre-B cells that fail to fulfill proper receptor requirements are 
developmentally arrested or forced into apoptosis (10). Thus, B cells expressing an 
appropriate pre-BCR will continue to develop. These immature B cells undergo 
negative selection at later stages of development, since most of the generated 
BCRs are self-reactive (11). This negative selection occurs before the immature B 
cells leave the bone marrow; if a BCR reacts with self-antigen in the bone marrow, 
receptor editing is induced. The process of receptor editing rescues the B cells when 
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secondary V(D)J rearrangements induce the replacement of the autoreactive 
antigen receptors to non-self reactive antigen receptors (12, 13). Immature B cells 
progress from a receptor-editing competent, apoptosis-resistant stage into a 
receptor-editing incompetent, apoptosis-sensitive stage (14). A B cell that passes  
 
 














































Figure 1. The heavy chain genes have no complete exon encoding the variable region domain, 
instead this is split into arrays of gene segments. Light chain genes are similarly organized on 
different chromosomes but they have no diversity gene segments. Immunoglobulin genes rearrange 
segments with the looping out of intervening DNA. This is done in a precise order: first the heavy 
chain rearranges, then if a functional heavy chain (always IgM initially) results (many joins are out of 
frame), the light chains rearrange also in order, first kappa then if kappa is unproductive (or cannot 
pair with the heavy chain) lambda.  
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both positive and negative selection checkpoints expresses a functional, non-self 
reactive BCR that is able to encounter foreign antigen as it leaves the bone marrow. 
The rearranged genes code for both the BCR at the cell surface and for secreted 
immunoglobulins after the B cell has differentiated into plasma cell. Thus, the BCR 
and the produced antibodies of one B cell have the same specificity for a particular 
antigen. 
 
Germinal center reaction 
After leaving the bone marrow, the immature B cells pass from the blood into 
secondary lymphoid organs: lymph nodes, spleen and mucosa-associated lymphoid 
tissue (MALT). Immature B cells that migrate from the bone marrow to the 
periphery are referred to as transitional B cells. Transitional B cells can be 
distinguished from mature B cells by the absence of the ATP-binding cassette 
(ABC)B1 transporter (15) and because they express low levels of recombination 
activating gene (RAG) mRNA (16). Transitional B cells are short-lived and only 
10−30% of these cells become long-lived mature, naïve B cells and are localized 
together with follicular dendritic cells (FDCs) in discrete clusters called primary 
follicles. These FDCs are thought to provide signals essential for the survival and 
continued recirculation of the naïve B cells. FDCs have taken up foreign antigen, 
which is presented on their membrane. B cells monitor the antigens present on 
FDCs and upon recognition of the antigen by their BCR the germinal center reaction 
is initiated (17). In addition to FDCs recently identified ‘antigen transport cells’ and 
mariginal zone B cells in the spleen have been implicated in the process of antigen 
presentation to B cells (18).  
During the germinal center reaction the activated B cells start to divide forming a 
secondary follicle, the germinal center. Here their genomic DNA may undergo 
modifications, a process called somatic hypermutation (SHM). During SHM, small 
changes, mainly single nucleotide exchanges but also deletions and duplication, are 
introduced at a high rate into the variable-region genes of the BCR. Because of 
these changes a wide variety of B cells is made, all recognizing the same antigenic 
epitope but with a different affinity. B cells with a BCR with the highest affinity for 
the antigen are positively selected for survival (19). Depending on the antigen, the 
BCR can acquire another constant region in a process called class switch 
recombination (CSR) (20) by switching from IgM expression to heavy chain 
expression of other immunoglobulin classes: IgG, IgA or IgE, leaving the antigen 
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specificity unaltered (21). The subclass of the constant region confers functional 
specialization on the antibody: e.g. IgG1-3 and IgM can activate the classical 
pathway of complement activation, IgA1 the alternative pathway of complement 
activation, IgG1-3 can be transferred across the placenta, IgE has high-affinity 
binding to mast cells and basophils and, except for IgG2 and IgM, all (sub)classes 
can bind Fc receptors on macrophages and phagocytes. IgD is coexpressed with 
IgM on the surface of almost all mature B cells, although this isotype is secreted in 
only small amounts of plasma cells and its function is unknown. Although germinal 
center formation strongly facilitates CSR and SHM, other environments can also 
support CSR and SHM. B cells from patients of which the CD40 ligand gene is 
mutated (X-linked hyper-IgM syndrome type I), have a certain level of 
hypermutation, although there are no germinal centers (22). Also, T-cell-
independent antigens initiate IgA class switching by linking B cells with multiple 
innate immune pathways. Whereas some T-cell-independent antigens activate B 
cells through Toll-like receptors (TLRs) (e.g. LPS), others activate B cells through 
their BCR (e.g. polysaccharides). T-cell-independent antigens can also provide 
additional B-cell-stimulating signals through DCs, which release soluble class-
switch-inducing factors related to CD40L, including B-cell activating factor (BAFF; 
also known as BLyS) and a proliferation-inducing ligand (APRIL) (reviewed in (23)). 
 
Terminal B cell differentiation 
B cells that have successfully bound antigen and survived selection leave the 
germinal center and migrate into the periphery, where they become either memory 
B cells or plasma cells (24, 25). IL-10 has been put forward as the key cytokine 
that terminates the expansion of memory B cells by inducing differentiation into 
plasma cells (26). Plasma cells predominantly migrate to the bone marrow and 
have different live spans. Productive signaling events lead to the generation of 
short-lived antibody-secreting cells that survive only for a few weeks (27). Memory 
B cells reside in secondary lymphoid organs and rapidly proliferate and differentiate 
upon exposure to the same antigen without further involvement of germinal 
centers, generating high amounts of long-lived immunoglobulin secreting plasma 













































































Figure 2. B-cell development occurs in both the bone marrow and peripheral lymphoid tissues such as 
the spleen. In the bone marrow, development progresses through the pro-B-cell, pre-B-cell and 
immature-B-cell stages. During this differentiation, rearrangements at the immunoglobulin locus 
ultimately result in the expression of a mature BCR that is capable of binding antigen. At this 
immature stage of development, B cells undergo a selection process to prevent any further 
development of self-reactive cells. Both receptor editing and clonal deletion have a role at this stage. 
Cells successfully completing this checkpoint leave the bone marrow as transitional B cell, eventually 
maturing into mature follicular B cell (or marginal-zone B cell). Following an immune response, 
antigen-specific B cells develop into either plasma cell or memory B cell. 
 
Salmonella infection 
Antibodies produced by antigen-specific B cells are important in the clearance of 
bacterial infections. On the one hand they opsonize bacteria to activate the 
complement system that will ultimately lead to lysis of the bacteria. On the other 
hand, antibodies opsonize bacteria to be recognized by phagocytic cells and 
subsequent destruction of the bacteria by phagocytes. Salmonella enterica is a 
Gram-negative, enteric pathogen responsible for disease syndromes of significant 
morbidity and mortality (29). After oral uptake, the bacterium crosses the intestinal 
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epithelium via M cells (or microfold cells). M cells are found in the follicle-associated 
epithelium of the Peyer's patch and differ from normal enterocytes in that they lack 
microvilli on their apical surface. Instead, M cells possess broader microfolds and 
the filamentous brush border glycocalyx, an extracellular polysaccharide layer 
found throughout the intestine attached to enterocytes, is much thinner or absent 
on M cells. This allows M cells to sample antigen/bacteria from the lumen and 
deliver it via transcytosis to the Peyer’s patches (30). Another way of bacterial 
invasion in the intestinal mucosa is via dendritic cells (DCs). DCs express tight-
junction proteins, open the tight-junctions between epithelial cells and send 
dendrites outside the epithelium into the lumen to directly sample microorganisms. 
In this way, DCs can transport bacteria to the basolateral side while preserving the 
integrity of the epithelial barrier (31). The bacteria are ultimately internalized by 
macrophages, dendritic cells, and neutrophils (32, 33). Entry into these cells is 
actively induced by the bacterium through an impressive array of effector proteins 
that orchestrate uptake by manipulating the host cellular machinery (34). 
Salmonellae manipulate host cells upon infection in order to alter the actin 
cytoskeleton allowing phagosomal cup formation and entry of the relatively large 
pathogen into the host cell. Bacterial effector proteins are therefore introduced into 
the host cytosol through the Salmonella Type III Secretion System (TTSS). After 
invasion, Salmonella forms an intracellular vacuole called the Salmonella-containing 
vacuole (SCV). Here another set of effectors is secreted into the host cytosol for 
vacuole maintenance and interference with the endosomal system to obtain 
nutrients and to prevent maturation and fusion with lysosomes (35, 36). 
Salmonella replicates in an expanding SCV (37, 38) and escapes detection by the 
immune system (39, 40). This feature of Salmonella is considered crucial for their 
survival and pathogenicity (41). Although Salmonella replicates in the phagosome, 
it remains unclear how they are released from the infected cell. This may follow 
from apoptosis or necrosis of the infected cell, but this is not established. 
When Salmonella has passed the intestinal epithelium, it spreads via mesenteric 
lymph nodes to liver, bone marrow and spleen where replication continues (42). 
How Salmonella reaches these organs is unclear. So far, especially neutrophils, 
CD18-expressing phagocytes and DCs have been implicated (43, 44). Being 
facultative intracellular pathogens, immunity to Salmonella requires adequate 




Antigen presentation by MHC class II molecules after BCR recognition 
Antigen presentation by B lymphocytes is needed to generate high-affinity Abs (5, 
47). Development of an effective humoral immune response is mediated by two 
actions of the BCR: transmembrane signaling through BCR-complexes to induce B 
cell differentiation and antigen internalization for processing followed by MHC class 
II-mediated presentation to acquire T cell help. The proper execution of both 
actions requires binding of a polyvalent antigen to multiple BCR molecules on one B 
cell.  
Since primary B cells are not classical phagocytic cells, it is unclear how they 
acquire antigens from bacteria for antigen presentation. B cells can present 
particulate antigens in the context of MHC class II (48-51) and are able to extract 
antigen from a non-internalizable surface (52). Indeed, many B cell antigens are 
polyvalent as they are present in multiple copies to the particulate surfaces of 
microbes or cells (53). B cells use their BCR to concentrate specific antigen to the 
antigen loading compartments (termed MIIC for MHC class II containing 
compartment, see later) for loading of antigenic fragments onto newly synthesized 
MHC class II molecules (53). Besides internalization of antigen, the BCR drives 
intracellular targeting by accelerating the delivery of antigen to MIICs (54). 
Furthermore, BCR signaling ignited by antigen induces acidification of the MIICs 
which favors antigen loading onto newly synthesized MHC class II molecules (55). 
Together, these cellular adaptations enable B cells to preferentially present specific 
antigens that have been internalized via the BCR to CD4+ T cells. However, the 
exact regulation of MHC class II antigen presentation after BCR-specific recognition 
of particulate antigens is not clear. 
 
The regulation of MHC class II antigen presentation 
Regulation of the MHC class II antigen presentation pathway may affect the efficacy 
of MHC class II antigen presentation. MHC class II molecules are heterodimeric cell 
surface glycoproteins that present antigens to CD4+ T cells. After synthesis, the α 
and β subunits of the MHC class II molecule associate in the endoplasmic reticulum 
(ER) together with the invariant chain (Ii or CD74) (Fig. 3). The Ii folds in part 
through the antigen binding groove of the MHC class II molecule, stabilizing the αβ 
heterodimer and preventing the binding of ER polypeptides. Another function of Ii is 
to direct MHC class II molecules to the lysosomal-like MIIC compartments (56), 
where the majority of MHC class II antigen loading occurs, as it contains two short 
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leucine-based sequences in the cytoplasmic tail that are responsible for trafficking 
through the endocytic pathway (57). During transport to the MIIC compartments, 
the Ii is progressively degraded by various proteinases depending on the cell type 
(58), leaving only a small fragment (class II-associated invariant chain peptides 
(CLIP)) in the class II peptide binding groove (59). The dissociation of the CLIP 
peptide and subsequent loading of antigenic peptide is an essential step in antigen 
presentation. Release of CLIP is facilitated by the specialized chaperone HLA-DM 
(DM) (60), a nonclassical MHC molecule composed of an α and β subunit. In 
addition to displacing CLIP, DM catalyses the natural process of peptide dissociation 
(61) by associating to DR to generate a peptide-receptive conformation by opening 
the peptide-binding groove. DM dissociates the peptide-MHC class II complex that it 
recognizes by perturbing a critical hydrogen bond between a conserved histidine 
residue on the β-chain of the MHC class II molecule and the peptide backbone (62). 
DM thus releases both CLIP and other nonstable binding peptides. Consequently, 
DM acts as a peptide editor, favoring presentation of high affinity peptides (63-66). 
HLA-DO (DO), another nonclassical αβ heterodimer, is expressed in human B cells 
(also in thymic medullary epithelium (67) and in subsets of DCs (68)). Association 
with DM is necessary for efficient exit of DO from the ER and for accumulation in 
lysosomal vesicles (69). DO acts as a negative modulator of antigen loading by 
inhibiting the catalytic action of DM on class II peptide loading (70, 71). As a result, 
cells expressing DO show elevated cell surface levels of CLIP on HLA-DR3 
molecules, paralleled by a reduced, but not abolished, presentation of antigenic 
peptides (70). DO does not act as a simple inhibitor of DM, but modulates in a pH-
dependent manner. The activity of DM itself is optimal at pH 5.0, but it still 
catalyzes class II-peptide loading at pH 6.0. Association of DO with DM still allows a 
respectable amount of DM function at lysosomal-like pH, but abolishes it completely 
at pH 6.0, the pH of early endosomes. Thus, DO acts as a sort of pH sensor to 
control the activity of DM (72, 73). Thus, DO reduces MHC class II-mediated 
presentation of antigenic peptides in general and modulates the antigenic peptide 
repertoire by facilitating presentation of particular antigens, while suppressing 
others. DO therefore both limits and skews the class II-associated antigenic peptide 
repertoire in B cells (70, 72, 74).  
The relative levels of DR, DM and DO determine the efficacy of MHC class II antigen 
presentation together with cellular processes that determine antigen processing and 
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intracellular trafficking of antigens, DR, DM and DO and eventually trafficking of 





































Figure 3. MHC class II αβheterodimers assemble in the endoplasmic reticulum (ER) with the 
assistance of invariant chain (Ii). The cytoplasmic tail of Ii contains a motif that targets the Ii–MHC 
class II complex to the endosomal/lysosomal pathway. During transport to the MIIC, Ii is degraded by 
a series of endosomal proteases with the CLIP fragment remaining, which prevents premature peptide 
loading. HLA-DM assists exchange of CLIP for relevant exogenous antigenic fragments in the MIICs 
prior to transport of stable MHC class II-antigen complexes to the plasma membrane. HLA-DO can 




Regulation of MHC class II, DM and DO expression. 
The relative expression of DO and DM (or the number of DM molecules in 
association with DO) related to the level or MHC class II expression control antigen 
presentation in B cells. Aberrant expression of DM, DO and/or DR could lead to an 
altered MHC class II peptide repertoire. Not surprisingly, DO and DM expression are 
very consistent and tightly regulated at different cellular levels in healthy B cells 
(75) and during B cell differentiation (76, 77). Expression of DR, DM and DO is 
regulated at the transcriptional as well as the post-translational level. 
Transcription of MHC class II, DM and DO is regulated by a master regulator termed 
the class II transactivator (CIITA) (78, 79). CIITA is transcriptionally controlled by 
four distinct promoters, each transcribing a unique first exon and yielding a unique 
CIITA transcript (80). The promoters I, III and IV are differentially used in different 
cell types and in response to inflammatory stimuli. A physiological role for CIITA-PII 
is questioned as transcripts originating from this promoter are rare. CIITA-PI is 
constitutively active in myeloid dendritic cells (DCs) and CIITA-PIII constitutively in 
B cells, plasmacytoid DCs, monocytes and activated T cells (81). CIITA-PIV has 
been shown to be the promoter predominantly involved in IFN-γ-inducible CIITA 
expression (82, 83). In healthy B cells transcription of the MHC class II genes is 
tightly regulated by CIITA, but dysregulation has been observed in tumors (84, 85). 
 
MHC-mediated antigen presentation and cancer 
A successful anti-tumor T cell response is achieved by the two effector arms of the 
immune system. On the one hand, CD8+ CTLs ensure specific elimination of tumor 
cells upon recognition of MHC class I-antigen complexes. On the other hand CD4+ T 
helper cells generate the required T cell help upon activation by MHC class II-
antigen complexes (86). The absence of T cell help can lead to abortive induction of 
CTL responses and subsequent tolerance (87). Moreover, T cell help is required for 
the maintenance of CTL responses, which is essential in diseases like cancer (88, 
89). It has been shown that CD4+ T cell inclusion in adoptive T cell transfer studies 
improved tumor clearance by the CD8+ T cells (90, 91). MHC class II molecules 
play a pivotal role in the induction and regulation of an antigen-specific immune 
response. MHC class II antigen presentation activates antigen-specific CD4+ T cells. 
Over the last years it has become clear that the establishment of an effective CD4+ 
T cell response is required for both the induction and maintenance of anti-tumor 
CD8+ cytotoxic T lymphocytes (CTL) responses (92). Indeed, loss of MHC class II 
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expression has been observed in diffuse large B cell lymphomas with fewer tumor-
infiltrating CD8+ T cells in MHC class II-negative tumors (93, 94). 
 
B-cell chronic lymphocytic leukemia 
During B cell differentiation, uncontrolled growth of B cells can occur, resulting in 
the formation of lymphomas or leukemia. 
B-cell chronic lymphocytic leukemia (B-CLL) is the most common form of leukemia 
in adults in the Western world. Typical for the disease is the highly variable clinical 
course, with survival rates varying between a few months and two decades (95). B-
CLL is characterized by a progressive accumulation of a malignant B cell population 
that fails to undergo apoptosis. Apparently the immune system is unable to deal 
with this abnormal cell population. Indeed, B-CLL is characterized by striking 
immune incompetence in which not only the number but also the function of the B 
and T cells is impaired (96). Prognostic factors for survival of B-CLL patients are the 
mutational status of the immunoglobulin IGHV genes, cytogenetic aberrancies, 
CD38 and ZAP-70 expression (97). Today, the strongest predictor for survival in B-
CLL is the mutational status of the IGVH genes. 
 
MHC-mediated antigen presentation and B-CLL 
In B-CLL patients, malignant B cells accumulate in the bone marrow and periphery. 
Apparently, these cells are not recognized by the immune system in such a way 
that the malignant cells are effectively cleared. This may be due to immune escape 
by the malignant cells by preventing CD4+ T cell activation, since B-CLL cells lack 
significant expression of CD80 and CD86 costimulatory molecules (98). However, 
the absolute numbers of T cells are increased in B-CLL patients. Whether this 
expansion is a result of (altered) MHC class II antigen presentation by malignant B 
cells has not been established. 
A shift in MHC class II antigen presentation by B-CLL cells may lead to altered T 
helper cell activation and subsequent help to CD8+ CTLs. It is unclear whether the T 
cell expansion in B-CLL is indicative for attempted but unsuccessful tumor clearance 
or contributes in another way to the disease, for instance by creating an 
environment that supports survival of neoplastic cells (99). Antigen-independent 
mechanisms have been implicated in the T cell expansion in B-CLL (reviewed in 
(100)). The TCR-dependent oligoclonal/monoclonal expansion of CD4+ T cells in B-
CLL however, points to an antigen-driven process. How malignant B cells present 
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antigens via MHC class II molecules to CD4+ T cells and whether this may be an 
explanation for observed T cell expansion in B-CLL is unclear. If so, modulation of 
these MHC class II responses would be an interesting approach to control these 
tumors. 
 
Acute myeloid leukemia 
Acute myeloid leukemia (AML) is a myeloproliferative disorder, characterized by an 
arrest in differentiation of hematopoietic stem cells due to acquired mutations. This 
results in accumulation of immature non-lymphoid cells in the bone marrow and 
peripheral blood, often accompanied by suppression of the normal blood cells. AML 
is a heterogeneous disease in which subgroups can be defined with different stages 
of immature blasts present and each group is characterized genetic lesions, clinical 
behavior, prognosis and therapy (101). With chemotherapy and stem cell 
transplantation approximately 70 % of patients achieve complete remission, but 
half of these patients relapse (102). Although AML blasts generally express MHC 
class II molecules (103), they have escaped the initial immune response in acute 
disease status. How efficient AML blasts present antigens via MHC class II 
molecules is unclear.  
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Scope of this thesis 
In this thesis, the role of MHC class II antigen presentation in the immune response 
against bacterial infections and tumors was investigated.  
MHC class II antigen presentation is indispensable for activation of CD4+ T helper 
cells, which give help to B cells for antibody production. So far it is unclear how 
particulate antigens induce MHC class II antigen presentation and CD4+ T helper 
activation, as B cells are considered to be non-phagocytic. In Chapter 2 we 
investigate how B cells deal with particulate antigens, using beads coated with 
antibodies specific for the BCR or the bacterium Salmonella typhimurium as model 
systems. We demonstrate that B cells phagoyctose the beads and Salmonella upon 
antigen-recognition by the BCR and that these B cells subsequently activate CD4+ T 
cells. Since Salmonella is a facultative intracellular bacterium, we investigated the 
fate of Salmonella inside the B cell in Chapter 3. For elimination of infected cells, 
an effective induction of antigen-specific CD8+ T cells, which can kill infected target 
cells, is desirable. In Chapter 4 we demonstrate that B cells are able to cross-
present bacterial antigens via MHC class I to induce an effective CD8+ T cell 
response. We also show that the ability of B cells to activate Salmonella-specific 
CD8+ T cells requires help of CD4+ T cells.  
Induction of CD4+ T cells is indispensable for the generation of an effective and 
long-lasting immune response. Some types of cancer escape immune surveillance 
by interfering with antigen presentation. Most AML blasts express MHC class II 
molecules on their cell surface which could induce CD4+ T cells activation. In 
Chapter 5 we analyzed cell surface expression of HLA-DR and the efficacy of MHC 
class II antigen presentation by analyzing the amount of the self-peptide CLIP 
inside the peptide binding groove of HLA-DR. Chapter 6 describes the efficacy of 
MHC class II antigen presentation in B-CLL and we correlated this to the ex vivo 
analysis of the T cell compartment in B-CLL patients. Evaluation of the MHC class II 
antigen presentation components at the mRNA level in Chapter 7 revealed that all 
components are significantly higher transcribed in B-CLL patients. Survival analysis 
of patients showed that the level of DOA mRNA at the time of sample acquisition 
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The present paradigm is that primary B cells are non-phagocytosing cells. In this 
study, we demonstrate that human primary B cells are able to internalize bacteria 
when the bacteria are recognized by the B cell receptor (BCR). BCR-mediated 
internalization of Salmonella typhimurium results in B cell differentiation and 
secretion of anti-Salmonella Ab by the Salmonella-specific B cells. In addition, BCR-
mediated internalization leads to efficient Ag delivery to the MHC class II Ag-loading 
compartments, even though Salmonella remains vital intracellularly in primary B 
cells. Consequently, BCR-mediated bacterial uptake induces efficient CD4+ T cell 
help, which boosts Salmonella-specific Ab production. BCR-mediated internalization 
of Salmonella by B cells is superior over extracellular Ag extraction to induce rapid 
and specific humoral immune responses and efficiently combat infection. 
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BCR-mediated bacterial uptake 
Introduction 
Defense against pathogens is essential for survival and is controlled by the innate 
and acquired arms of the immune system. Ag presentation by B lymphocytes is 
needed to generate high-affinity Abs (1, 2). Development of an effective humoral 
immune response is mediated by two actions of the BCR: transmembrane signaling 
through BCR complexes to induce B cell differentiation and Ag internalization for 
processing followed by MHC class II-mediated presentation to acquire T cell help. 
The proper execution of both actions requires binding of a polyvalent Ag to multiple 
BCR molecules. Indeed, many B cell Ags are polyvalent as they are bound in 
multiple copies to the particulate surfaces of microbes or cells (3). 
The role of CD4+ T cells in the induction of protective immunity against pathogens 
is well established (4, 5). CD4+ T cell activation requires MHC class II Ag 
presentation after Ag processing in the endocytic pathway and subsequent binding 
of antigenic peptides to MHC class II molecules, a process controlled by the MHC 
class II chaperones HLA-DM and HLA-DO (6-8). B cells use their BCR to concentrate 
specific Ag to the Ag-loading compartments (termed MIIC for MHC class II 
containing compartment) for loading of Ag onto newly synthesized MHC class II 
molecules (3). Besides internalization of Ag, the BCR drives intracellular targeting 
by accelerating the delivery of Ag to MIICs (9). Furthermore, BCR signaling ignited 
by Ag induces acidification of the MIICs, which favors Ag loading onto newly 
synthesized MHC class II molecules (10). Together, these cellular adaptations 
enable B cells to preferentially present specific Ags that have been internalized via 
the BCR to CD4+ T cells. 
Since primary B cells are considered to be not phagocytic, it is unclear how they 
acquire Ags from bacteria for Ag presentation. B cells can present particulate Ags in 
the context of MHC class II (11-14) and are able to extract Ag from a non-
internalizable surface (15). Studies on MHC-mediated presentation of BCR-specific 
Ags are mainly performed with soluble Ags or with pre-cross-linked anti-BCR Abs. 
We used Salmonella typhimurium as a model system to study MHC class II Ag 
presentation of particulate, polyvalent Ags, and B cell activation. Being facultative 
intracellular pathogens, immunity to Salmonella requires adequate humoral and 
cell-mediated immune responses (16, 17). Salmonella invades host macrophages, 
but also many other cells and establishes an intracellular niche inside discrete 
vacuoles, known as Salmonella-containing vacuoles or SCV (18). This feature of 
Salmonella is considered crucial for their survival and pathogenicity (19, 20). 
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In this report we show that B cells are highly efficient phagocytes of inert particles, 
like beads, when these particles are recognized by the BCR. B cells are thus ligand-
selective phagocytic cells. BCR-mediated internalization of Salmonella generates 
autonomous B cell activation and rapid anti-Salmonella Ab secretion. Immediate 
intimate contact and fusion occurs between MIICs and SCVs. Consequently, Ag 
presentation and proliferation of Salmonella-specific CD4+ T cells is induced. 
Although BCR-mediated internalization suffices to drive Ab production, T cell help 
further improves the response. The observation that B cells can proliferate and 
differentiate autonomously after Salmonella uptake is important in light of the 
remaining Ab responses to pathogens when CD4+ T cell help fails, as is the case in 
HIV patients. 
 
Materials and methods 
Antibodies, beads and fluorophores 
Goat anti-mouse IgG-conjugated Dynabeads M-450 (Dynal Biotech) were coated 
with mAb anti-human IgM (MH15; Sanquin). The anti-human IgM antibody (MH15) 
was mixed with mAb anti-S. typhimurium LPS (1E6; Biodesign International) and 
rat anti-mouse IgG1 (RM161.1; Sanquin) to generate BCR-LPS tetrameric Ab 
complexes. The mAb anti-human HLA-DR (L243) (21) was used to block MHC class 
II-TCR interaction in T cell proliferation assays. For immunoelectron microscopy 
(EM), mAb anti-human CD63 (435; Sanquin), rabbit anti mouse (Nordic) and gold 
(10 nm)-conjugated protein-A (EM Laboratory, Utrecht University, The Netherlands) 
were used. F(ab’)2 fragments of MH15 were generated by standard pepsin 
digestion. 
PE-conjugated anti-IgM was obtained from Sanquin (MH15-PE), anti-CD27-PE and 
IgG1-PE isotype control from BD Biosciences. Fluorescent secondary Ab goat anti-
mouse Alexa Fluor 633 and Texas Red-phalloidin were obtained from Molecular 
Probes and 4’,-diamidino-2-phenylindolyne (DAPI) from Sigma-Aldrich. 
 
Transfectant cell lines 
The pcDNA3 DOβGFP (22) and DR1βGFP (23) constructs have been described 
before. DOβGFP and DR1βGFP were demonstrated to form complexes with their 
respective endogenous α-chain. Transfections were performed by electroporation 
using a Gene Pulser II with Capacitance Extender (Bio-Rad). Stable transfectants of 
the human B cell line Ramos were selected and maintained in RPMI 1640 
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supplemented with 5% FCS (Bodinco), 100 U/ml penicillin, 100 μg/ml streptomycin, 
2 mM L-Glutamine, 50 μM 2-ME in the presence of 2000 µg/ml G418 (Life 
Technologies). Stable expression of the GFP-tagged proteins was verified by 
Western blotting and ensured by regular selection of positive cells by FACS sorting. 
NIH3T3 fibroblasts expressing human CD40L (3T3-CD40L) (24) were cultured in 
IMDM supplemented with 5% FCS (Bodinco), 100 U/ml penicillin, 100 μg/ml 
streptomycin, 2 mM L-Glutamine, 50 μM 2-ME and 500 µg/ml G418 (Life 
Technologies). 3T3-CD40L cells were harvested, irradiated with 30 Gy (Gammator 
M38-1, MDS Nordion) and seeded without antibiotics in 96 wells flat bottom plates 
(2*104 cells per well) to form a confluent monolayer overnight. 
 
Bacterial Strains 
S. typhimurium SL1344 (Salmonella) (25), GFP-Salmonella (26) and mRFP-
Salmonella (27) were described before. GFP-Salmonella defective in SPI-1 (invA 
mutant) or SPI-2 (ssrA mutant) were a kind gift from M. Rescigno. Staphylococcus 
aureus expressing GFP (RN4220 with pWVW189GFP) was a kind gift from S.A.J. 
Zaat. Bacteria were grown in Luria-Bertani (LB) broth with antibiotics overnight at 
37°C while shaking, subcultured at a dilution of 1/33 in fresh LB media, and 
incubated at 37°C while shaking for 3.5 hours. Bacteria were washed twice with 
PBS, incubated 1/25 with the BCR-LPS tetrameric Ab complexes for 30 min at room 
temperature, and washed twice to remove unbound Abs. Dead Salmonellae were 
bacteria fixed with paraformaldehyde (3.7% in PBS).  
 
Lymphocyte isolation and proliferation assay 
Human PBMCs were isolated by centrifugation on a Ficoll-Hypaque gradient (Axis-
Shield PoC AS) from a buffycoat obtained from healthy donors after informed 
consent (Sanquin). B and T cells were subsequently purified using anti-CD19 and 
anti-CD4, anti-CD8 Dynabeads and DETACHaBEAD (Dynal Biotech), according to 
the manufacturer's instructions. 
B lymphocytes were incubated for 40 min at 37°C with Salmonella without 
antibiotics. Next, cells were washed four times and cultured for 1 h in medium 
containing 100 µg/ml gentamycin (Invitrogen) to eliminate non-internalized 
bacteria. Cells were washed and cultured in RPMI 1640 medium without phenol red, 
supplemented with 5% FCS (Bodinco), 100 U/ml penicillin, 100 μg/ml streptomycin, 
2 mM L-Glutamine, 50 μM 2-ME, 20 μg/ml human apo-transferrin (Sigma-Aldrich); 
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depleted for human IgG with protein G sepharose (Amersham Biosciences)), and 10 
µg/ml gentamycin. One x 105 B cells and 5 x 104 T cells were cultured in 200 μl at 
37°C in the presence of 5% CO2 in 96 wells round bottom plates (Greiner Bio-One). 
The maximum proliferation capacity of T lymphocytes (varying between 35 to 60 x 
103 cpm) was established by stimulation with anti-CD3 (CLB.T3/4.E, Sanquin) and 
anti-CD28 (CLB.CD28/1, Sanquin) which were both used at 1 μg/ml. After 5 and 12 
days, 150 μl of supernatant was collected for Ab measurement and fresh medium 
was added. To study the kinetics of Ag presentation, B cells incubated with 
Salmonellae were irradiated with 60 Gy at indicated time points before incubation 
with T cells. For B/T cell proliferation assays, after 5 days of culturing [3H]thymidine 
(GE Healthcare) was added at a final concentration of 1 μCi/ml (37 kBq/ml) for 16 
h. Cells were harvested on glass fiber filters (Wallac) and radioactivity was 
measured with a 1205 Betaplate liquid scintillation counter (Wallac). For blocking 
experiments, B cells were preincubated with 5 μg/ml anti-HLA-DR (L243) for 30 
minutes before T cells were added. For the Ag-specificity assay, CD4+ T cells were 
CFSE labeled and cocultured with B cells that had taken up Salmonellae. The 
dividing T cells were sorted after 6 days and cultured with 10 IU/ml IL-2 (Chiron) 
for 6 more days. PBMCs were labeled with CFSE and incubated with tetanus toxoid 
(7,5 μg/ml; Statens Serum Institut, Copenhagen, Denmark) for 11 days, with 10 
IU/ml IL-2 added on day 6, and proliferating CD4+ T cells were sorted. B cells from 
the same donor were incubated with Salmonellae and PBMCs from the same donor 
with Tetanus Toxoid, irradiated after 18 h and then the sorted T cells were added 
for 2 days before [3H]thymidine was added for 16 h.  
 
FACS analyses 
Freshly isolated primary B cells were incubated with Salmonella, washed four times, 
and cultured for 1 h in medium containing 100 µg/ml gentamycin. Cells were 
incubated with directly labeled Abs and for LPS staining cells were incubated with 
anti-LPS Ab and subsequently with Alexa Fluor 633-conjugated goat-anti-mouse Ab. 
Cells were washed with PBS containing 0.1% BSA. Lymphocytes were gated by 
forward and side scatter and dead cells were excluded by staining with DAPI. Two 
hundred thousand events were acquired on an LSR II (BD Biosciences) and 
analyzed using FACSDiva software (BD Biosciences). 
FACS sorting of B cells that had internalized uncoated living bacteria was performed 
on a MoFlo Sorter (Dakocytomation), populations were >75% purified. 
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Live cell imaging and EM analyses 
For CLSM analysis, coverslips were coated with 1 mg/ml Poly-L-lysine (Sigma-
Aldrich) for 1 h and washed thoroughly with Aquadest and dried on air. Cells were 
allowed to attach on the coated coverslips for 15 min and subsequently beads or 
Salmonellae were added. For visualization of the actin cytoskeleton, cells were fixed 
with 3.7% paraformaldehyde and stained with Texas Red-phalloidin and DAPI. 
Confocal analysis was performed at 37°C using a Leica TCS SP confocal laser 
scanning microscope equipped with an argon/krypton laser with x63 oil objective 
and 1.4 aperture (Leica Microsystems). Green fluorescence was detected at λ > 515 
nm after excitation at 488 nm. For dual analyses, green fluorescence was detected 
at 520–560 nm. Red fluorochromes were excited at 568 nm and detected at λ > 
585 nm. All experiments presented were repeated several times on different days 
and results were consistent and reproducible. Further image processing was 
performed using the ImageJ software package. 
For EM, cells were allowed to take up beads or bacteria for 40 min or 4 h (to study 
MIIC-SCV fusion) and fixed in a mixture of paraformaldehyde (4%) and 
glutaraldehyde (0.5%). After embedding in a mixture of methyl cellulose and uranyl 




For enumeration of intracellular surviving bacteria, freshly isolated primary B cells 
were incubated with anti-IgM coated Salmonellae and Ramos cells with uncoated 
Salmonellae as a control, washed, and cultured in medium with 10 µg/ml 
gentamycin as described above. At the indicated time points, cells were washed 
with PBS and lysed in 0.1% Triton X-100 (Merck) for 10 min on ice, washed with 
PBS, and a dilution series was plated onto LB agar plates. Plates were incubated 
overnight at 37°C and colonies were counted. 
 
ELISA assays 
To determine IgM levels in culture supernatants, flat-bottom Maxisorb plates 
(Nunc) were coated with polyclonal anti-IgM (SH15; Sanquin) in 100 μl of PBS (pH 
7.4; NPBI International) overnight at room temperature. Plates were washed with 
PBS/0.02%Tween 20 (Mallinckrodt Baker) and samples were incubated for 2 h in 
 35 
Chapter 2 
high-performance ELISA buffer (Sanquin). As a standard, pooled human serum was 
used. Plates were washed and incubated for 1 h with 1 μg/ml mAb anti-human IgM-
HRP (MH15-HRP; Sanquin).  
Whole-cell Salmonella ELISA was performed by coating overnight at 37°C of 
Salmonella to Maxisorb plates in 100 μl 0.1 M sodium bicarbonate at pH 9.6 
supplemented with 10 µg/ml gentamycin. Plates were washed extensively with 
PBS/0.02%Tween-20 and supernatants were incubated in high-performance ELISA 
buffer. Plates were washed and incubated for 1 h with 1 μg/ml mAb anti-human 
IgM-HRP (MH15-HRP, Sanquin). 
After washing, peroxidase activity was visualized by incubation with 100 μl 
3,5,3’,5’-tetramethylbenzidine (Merck), 100 μg/ml in 0.11 M sodium acetate (pH 
5.5), containing 0.003% H2O2 (Merck). The reaction was stopped by addition of an 
equal volume of 2 M H2SO4 (Merck) and the absorbance at 450 and 540 nm was 
measured immediately in a Titertek plate reader. Results were calculated with 
LOGIT software (http://www.xs4all.nl/~ednieuw/Logit/logit.htm). 
 
Statistical analysis 
Statistical significance was determined using the Mann-Whitney U test. 
 
Results 
Efficient BCR-mediated phagocytosis of large particulate Ags by B cells 
Unlike other professional Ag presenting cells, primary B cells show very limited 
phagocytic capacity. Ag uptake by B cells is critically dependent on the selectivity of 
the B cell receptor (BCR) (10, 28). The current view on BCR-mediated Ag uptake by 
B cells mainly centers on soluble Ags like small foreign proteins or shedded 
bacterial coat products (29). Accordingly, most B cell activation studies involve the 
global triggering of BCR using soluble cross-linking Ags rather than pathogen-
associated Ags. We opted to study BCR-mediated recognition of particulate Ags in B 
cells by inducing localized clustering of the BCR using beads decorated with mAb 
against the BCR. When anti-IgM coated beads contacted a Ramos B cell stably 
expressing MHC class II HLA-DR1 tagged with GFP (DR-GFP, which localizes to the 
plasma membrane and lysosomal MIIC vesicles), rapid and efficient internalization 
of the bead ensued (Fig. 1A and supplemental movie 1). Ramos cells polarized 
themselves toward the contact site during uptake of the beads such that the 
nucleus moved to the side opposite of the bead, analogous to the situation 
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 Figure 1. Efficient BCR-mediated phagocytosis of large particulate Ags. 
(A) Living Ramos B cells expressing DR-GFP and anti-IgM-coated beads were imaged every 30 s. 
Depicted are time points after initial contact, top panel: transmission image, bottom panel: GFP 
signal. Scale bar = 10µm. Images are frames from supplemental movie 1. (B) Ramos cells were 
fixed 10 min after addition of anti-IgM coated beads and analyzed by cryoelectron microscopy. 
Scalebar = 500nm. Zoom-ins of the thin membrane extrusions surrounding the bead are shown for 
indicated regions. The tip of the protrusion is indicated with an arrowhead in inset 2. (C) Cells 
were fixed 10 min after addition of anti-IgM coated beads and processed for immunofluorescence 
confocal microscopy. Depicted is the overlay of the signals from DAPI nuclear staining (blue), 
phalloidin-stained actin-cytoskeleton (red), and DR-GFP (lower left cell only). Scalebar = 10µm. 
Figure represents one section from a Z-stack. A three-dimensional reconstruction is provided as 











following Th cell contact (30) or following cytotoxic CTL-target cell interactions 
(31). Internalization reached completion within 10-20 min and required an intact 
cytoskeleton (as the microtubule-disruptive agent nocodazole prevented 
phagocytosis, supplemental movie 2). In addition, uptake was BCR dependent 
because beads coated with an irrelevant Ab were not internalized (supplemental 
movie 3). Ramos cells do not express FcγRs, which excludes their involvement in 
bead uptake. A detailed analysis by cryoelectron microscopy revealed some of the 
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impressive cellular events underlying uptake of large particulate Ags. During the 
initial phase of contact, Ramos cells surrounded the bead with a surprisingly thin 
double membrane originating from the cell surface (Fig. 1B). Staining with 
phalloidin of Ramos cells in the process of bead phagocytosis revealed extensive 
actin fibers in the membrane protrusions surrounding the bead (Fig. 1C and 
supplemental movie 4). Together, these data show that B cell are able to internalize 
inert particles in a process that fulfills the criteria of phagocytosis. Thus, different 
from the general concept that primary B cells are essentially nonphagocytic cells, B 
cells are very efficient phagocytes when particle recognition is facilitated by the 
BCR.  
 
B cell lines can internalize Salmonella via their BCR 
We generated a stable transfectant of the Ramos B cell line with the MHC class II 
Ag presentation chaperone HLA-DO tagged with GFP (DO-GFP). DO-GFP localizes to 
the MIICs in living cells. As the Ag specificity of the BCR of Ramos cells is unknown, 
we coated the bacteria with anti-IgM-anti-LPS tetrameric Ab complexes. Within 1 
mi after first contact, Ramos cells efficiently internalized GFP-Salmonella coated 
with tetrameric Ab complexes (Fig. 2A and supplemental movie 5). Uncoated 
Salmonella were ignored by Ramos B cells (supplemental movie 6), showing that 
Salmonella by itself is not able to invade the Ramos B cell line. To investigate the 
internalization process in more detail, we used cryoelectron microscopy on Ramos 
cells shortly after encounter of the coated bacteria. This showed the formation of a 
phagocytic cup and the extension of pseudopodia around the bacteria, 
demonstrating that B cells actually seem to phagocytose the Salmonella bacteria 
(Fig. 2B). To study the interaction between the green MIICs in Ramos DO-GFP with 
the SCVs, we used a red mRFP-Salmonella. Ramos DO-GFP cells incubated with 
coated mRFP-Salmonella showed bacterial uptake and rapid translocation of the 
MIICs to the SCVs (Fig. 2C and supplemental movie 7). Multiple intimate contact 
events were observed between the membrane of the SCVs and the DO-GFP positive 
MIICs, suggesting fusion events of the MIICs with the SCV immediately after 
bacterial uptake. 
To study the acquisition of MHC class II molecules on the SCV membrane, we used 
Ramos cells expressing DR-GFP. MHC class II molecules already localized to the 
membrane of the SCV during the actual process of BCR-mediated uptake of coated 
mRFP-Salmonella (Fig. 2D and supplemental movie 8). Similar to the DO+ vesicles,  
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Figure 2. Efficient BCR-mediated internalization of Salmonella.  
(A) Living Ramos cells, expressing DO-GFP, and GFP-expressing Salmonella were imaged every 3 
s. Depicted are time points after initial contact. GFP signal is projected on top of the transmission 
image. Scale bar = 10µm. Images are frames from supplemental movie 5. (B) Electron microscopic 
analysis of Ramos cells in the process of phagocytosing anti-BCR-coated Salmonella. Scale bar = 
800nm. Note the cup-shaped pseudopodia of the B cell at contact places with the bacteria. (C) 
Living Ramos cells expressing DO-GFP and mRFP-Salmonella were imaged every 10 s. Depicted are 
time points after initial contact, top panel: transmission image, middle panel: GFP signal, bottom 
panel: overlay of GFP and mRFP signal. Scale bar = 5µm. Inset shows zoom-in on bacterium. 
Images are frames from supplemental movie 7. (D) Living Ramos cells expressing DR-GFP and 
mRFP-Salmonella were imaged every 10 s. Depicted are indicated time points after initial contact, 
top panel: transmission image, middle panel: GFP signal, bottom panel: overlay of GFP and mRFP 
signal. Scale bar = 5µm. Inset shows zoom-in on bacterium. Images are frames from supplemental 
movie 8. (E) Immunoelectron microscopic analysis of primary B cells with internalized anti-BCR 
coated Salmonella and CD63 (10-nm gold particles). Black asterisks mark bacteria, the white 















we observed extensive docking of DR-GFP+ vesicles with the SCV membrane within 
minutes after entry. Because molecular exchange between the MIIC vesicles and 
the SCVs is critical for generation of MHC class II molecules complexed with 
Salmonella Ags, we visualized MIIC-SCV fusion by EM. Indeed, fusion between the 
characteristic multivesicular MIICs and the SCVs was frequently observed. 
Immunostaining showed that, next to the MIICs, the SCV membrane stained 
positive for CD63 (Fig. 2E). Quantification of the fusion events between MIICs and 
100 SCVs showed that in 10% of the SCVs the actual process of MIIC-SCV fusion 
was captured in the time frame of cell fixation. Thus, the combined acquisition of 
MHC class II on the SCVs and the frequent fusion events between SCVs and MIICs 
generates all conditions required for Ag presentation of Salmonella Ags. 
 
BCR-mediated internalization of Salmonella by primary human B cells 
Since Ramos cells are at least 1.5 times larger than primary B cells, we tested 
whether primary B cells could internalize Salmonella as well. To distinguish between 
binding of bacteria to the BCR and actual uptake, we used a mAb against 
Salmonella-LPS. Completely internalized GFP-positive bacteria will not be stained, 
while extracellular and partially engulfed bacteria will be accessible to the anti-LPS 
antibody. Incubation of primary human B cells with uncoated GFP-Salmonella 
consistently revealed a small but significant population of B cells (4.3%, SD = 1.1, 
n = 6) that recognized and internalized the native bacterium via direct recognition 
of Salmonella Ags by the B cell's BCR (Fig. 3A). A similar proportion of primary B 
cells recognized and captured dead uncoated GFP-Salmonella via their BCR (4.1%, 
SD = 1.5, n = 4), but failed to internalize dead Salmonellae since these B cells 
stained all positive for LPS (Fig. 3A). Analysis by confocal microscopy confirmed 
that internalized viable Salmonellae are completely taken up by primary B cells, 
resulting in one to three intracellular bacteria per B cell (Fig. 3B, left panel). 
Incubation with fixed bacteria only showed binding but no uptake of Salmonella 
(Fig. 3B, right panel). To address the possible involvement of FcγRs on primary B 
cells, we preincubated primary B cells with F(ab)2 fragments of the anti-IgM 
antibody MH15 to block the internalization of anti-IgM coated Salmonella by 
primary B cells. This resulted in inhibition of 80%, illustrating that internalization is 
indeed BCR-mediated (supplemental Fig. 1). Ideally, we would also like to block 
BCR-mediated internalization of Salmonella via direct recognition of Salmonella Ags 
by the BCR. However, since blocking of the Ag binding site of the BCR is impossible 
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due to lack of anti-Id Abs, we studied the effect of BCR internalization before 
addition of the bacteria on the efficiency of bacterial uptake. We combined Abs 
against the H chain of IgM with cross-linking goat-anti-mouse antibodies. This 
resulted in a partial internalization of the BCR (mean fluorescence intensity for 
membrane-bound IgM dropped from 3767 to 2275) and a concomitant reduction in 
GFP+/LPS- B cells that had completely internalized Salmonella (supplemental Fig. 
2). In addition, Ramos cells efficiently internalized GFP-Salmonella in a BCR 
dependent manner only when Salmonella was coated with anti-IgM (Fig. 3C). No 
GFP-positive Ramos cells were found without the anti-IgM coat, showing that 
Salmonella is unable to infect Ramos cells autonomously. As a control for IgM-type 
BCR-mediated uptake of Ramos, Salmonella coated with anti-IgG were incubated 
with Ramos cells, and (similar to uncoated bacteria) these were not internalized. 
Incubation of the IgG-type BCR-expressing B cell line Cess with anti-IgG-coated 
bacteria showed that the anti-IgG coated-bacteria were efficiently taken up by Cess 
(data not shown). Up to 90% of the Ramos cells acquired one or more anti-IgM 
coated bacteria. However, ~ 25% of Ramos cells contained internalized GFP-
Salmonella only, while >60% of Ramos cells were also positive for LPS staining. 
Confocal microscopy of cells labeled by anti-LPS antibodies showed that these 
represented Ramos cells that had internalized some but not all bound bacteria (data 
not shown). 
Since dead bacteria were not internalized, Salmonella may be requiring both 
recognition by BCR and bacterial-mediated processes to enter primary human B 
cells. Salmonella can invade host cells by expressing type III secretion systems 
encoded either by Salmonella pathogenicity island (SPI)-1 to translocate effector 
proteins into host cell cytoplasm that trigger internalization of the bacteria or by 
SPI-2 to modulate intracellular trafficking and replication of Salmonella within a 
modified vacuolar compartment. Recent studies however have modified this 
concept to some extent as they show a partial overlap in SPI-1 and SPI-2 functions 
(32). To address involvement of these type III secretion systems, we used 
Salmonella defective in SPI-1 (invA mutant) or SPI-2 (ssrA mutant). Incubation of 
primary B cells with SPI-1 defective Salmonella showed a reduction in internalized 
bacteria and no bacteria adhering to primary B cells. Incubation with SPI-2-
defective Salmonella showed a milder reduction in internalized bacteria and a 
minimal reduction in adhering bacteria (Fig. 3D). This indicates that SPI-1 is 
involved in attachment to primary B cells in conjunction with the BCR. Components 
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of SPI-1, and to a lesser extent SPI-2, are involved in BCR-mediated uptake of 






















Figure 3. BCR-mediated internalization and survival of Salmonella in primary B cells.  
(A) CD19+ B cells were incubated with viable GFP-Salmonella for 40 minutes and FACS analyzed. 
Anti-LPS-APC versus GFP scatter plots are depicted. (B) Living primary human B cells were 
incubated with viable (left) or dead (right) GFP-Salmonella for 40 min and imaged using confocal 
microscopy. Left panel: transmission image, right panel: GFP signal projected on transmission 
image. Scalebar = 5µm. (C) Ramos B cells were incubated with viable GFP-Salmonella for 40 min, 
stained with an antibody against Salmonella LPS and analyzed by FACS. Depicted are anti-LPS-APC 
vs. GFP scatter plots of 50.000 events. (D) CD19+ B cells were incubated with viable wild-type 
GFP-Salmonella or mutant for SPI-1 (invA-) or SPI-2 (ssrA-) for 40 minutes and analyzed by FACS. 
Intracellular indicates B cells that are GFP+LPS- and extracellular indicates GFP+LPS+ B cells. Data 
are from two independent experiments with cells from four different donors, error bars indicate 
SEM. (E) B cells were incubated with anti-IgM-coated Salmonella and Ramos cells with uncoated 
Salmonellae, lysed and plated onto LB-agar plates. Data are from duplicates of experiments 













BCR-mediated bacterial uptake 
Phagocytosed Salmonella grow in many cell types but can efficiently be destroyed 
in specialized cells like macrophages and neutrophils (33). To examine survival of 
internalized Salmonella in primary B cells, we performed plating assays. B cells 
were incubated with anti-IgM coated Salmonella and washed and cells with 
internalized bacteria were followed in time. At different time points, cells were lysed 
and intracellular bacteria were plated onto agar. Internalized Salmonella remained 
vital for the 18 h that we tested (Fig. 3E). Ramos cells incubated with uncoated 
Salmonella were used as a control, since uncoated Salmonella are not taken up by 
Ramos cells (supplemental movie 6). Indeed, hardly any Salmonellae were 
recovered after incubation with Ramos (Fig. 3E). Thus, Salmonella survives 












 Figure 4. Both naive and memory B cells internalize Salmonella. 
 (A) Primary B cells were incubated with GFP-Salmonella and stained for IgM before and after 
FACS sorting. The open histogram represents the IgG1 isotype control. (B) The cells from 3A 
were analyzed for expression of CD27. Percentages of CD27+ B cells are given. For IgG1 




Which peripheral B cell type is able to internalize Salmonella? Most peripheral B 
cells express the IgM surface Ig receptor (34). To confirm that internalization of 
Salmonella occurs via the BCR, we analyzed IgM expression on Salmonella-
containing B cells. This showed that B cells that have internalized Salmonella 
expressed surface IgM (Fig. 4A). The mean fluorescence intensity of IgM for the 
total B cell pool is 478 and for the Salmonella-containing B cells 825. Two major 
subsets of B cells can be identified in adult peripheral blood according to the 
expression of CD27. CD27 expressing B cells comprise memory B cells while CD27-
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negative B cells represent naive and transitional B cells (35). FACS analysis showed 
that IgM memory B cells (CD27+) internalized Salmonella more efficiently than 
IgM+CD27- naïve B cells (Fig. 4B). Although a proportion of the naive IgM+ B cells 
are able to take up Salmonella, Salmonella is preferentially internalized by the 
circulating IgM+ memory B cells. 
 
Presentation of BCR-internalized Ags by B cells to T cells 
When Salmonella survives within the phagosome (see Fig. 3E) following BCR-
mediated internalization, does this result in MHC class II mediated presentation of 
Salmonella Ags? To test this, primary human B cells were incubated with anti-IgM-
coated Salmonellae to achieve BCR-mediated uptake by all IgM+ B cells and 
maximize the number of Ag-presenting B cells. These cells were subsequently 
cultured in the presence or absence of autologous primary T cells. After 5 days, 
[3H]thymidine was added and cells were harvested after 18 h. Incubation of B cells 
with anti-BCR-coated Salmonella induces proliferation of the B cells (green line, Fig. 
5A), demonstrating that BCR ligation and BCR-mediated internalization of 
Salmonella effectively activated B cells. B cells incubated with coated Salmonella 
and cultured with autologous T cells results in an Ag-specific proliferation of T cells 
(red line) (Fig. 5A).  
To study whether primary B cells with a BCR directed against Salmonella also 
induce T cell proliferation, we incubated uncoated Salmonella with primary B cells 
(Fig. 5B, left panel). Addition of autologous T cells yielded a Salmonella-specific T 
cell proliferation response (blue vs pink line). B cells incubated with uncoated dead 
Salmonella that could not be internalized were able to induce T cell proliferation 
(Fig. 5B, right panel). However, T cell proliferation is optimal when viable 
Salmonellae have been internalized by B cells (Fig. 5B: left vs right panel). 
Incubation of only T cells with uncoated or coated bacteria did not result in B cell-
independent proliferation of the T cells (data not shown).  
To demonstrate that the T cell proliferation in Fig. 5B was indeed induced by the 
fraction of B cells that had captured Salmonella, we FACS sorted the GFP-
Salmonella-positive B cells in fractions positive and negative for anti-LPS staining 
and cultured these with autologous T cells. T cells only proliferated when cultured 
with B cells that had captured GFP-Salmonella (Fig. 5C). It may be that complete 
internalization is not required for Ag presentation but that only capturing of the 
bacteria by the BCR suffices.  
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We can however not exclude that GFP-Salmonella+LPS+ B cells also contain 
completely internalized bacteria as we have shown that B cells are able to take up 
more than one Salmonella. Moreover, even though Salmonella survives in the 
vacuole and suppresses MHC class II Ag presentation in phagosomes (27), 
Salmonella Ags are still efficiently presented by B cells. This probably reflects Ag 
degradation and loading on MHC class II molecules in normal MIICs after content 
exchange between phagosome and MIICs due to the observed intimate contact and 
extensive fusion events.  
To demonstrate the Ag-specificity of the proliferating T cells, we performed 
restimulation assays in which we sorted the T cells that proliferated in response to 
B cells that had taken up Salmonella, and restimulated these Salmonella-primed T 
cells with autologous B cells that had taken up Salmonella or Staphylococcus. This 
showed that the Salmonella-primed T cells are indeed for the large part Ag specific, 
as they proliferate better in response to B cells that had internalized Salmonella 
than B cells that had internalized Staphylococcus or control B cells without bacteria. 
As a control, T cells primed against Staphylococcus did proliferate in response to B 
cells that had internalized Staphylococcus, demonstrating that these B cells did 
present Staphylococcus Ags to CD4+ T cells (Fig. 5D, left panel). In addition, we 
restimulated Salmonella-primed T cells with PBMCs presenting tetanus toxoid Ags. 
This showed no response of the Salmonella-primed T cells, while tetanus toxoid-
primed T cells from the same donor proliferated after restimulation (Fig. 5D, right 
panel). 
Furthermore, we performed blocking assays to show that the T cell response 
depends on the MHC class II Ag presentation pathway with L243, an Ab that blocks 
the MHC class II-TCR interaction (Fig. 5E). The induction of T cell activation 
depended on presentation of Salmonella Ags via MHC class II (HLA-DR), as the T 
cells failed to respond after blocking of MHC class II with L243. 
The observation that fusion of MIICs with the phagosome occurs swiftly prompted 
us to examine whether this had consequences for Ag presentation. When we 
irradiated B cells immediately after incubation with anti-IgM coated Salmonella, no 
proliferation of B or T cells was observed after 6 days. B cells apparently need to be 
viable to process and present Salmonella Ags to T cells. To study the kinetics of Ag 
presentation, B cells were incubated with native or anti-IgM coated Salmonella and 
B cells were irradiated at several time points before incubation with T cells. After 5 





























cells did not induce T cell proliferation after irradiation. Anti-BCR coated Salmonella 
internalized by IgM+ B cells start to induce proliferation of T cells immediately (red 
line) and uncoated Salmonella internalized by BCR-reactive B cells 4 h after uptake 
of the Salmonella (blue line) (Fig. 5F). Ag presentation thus starts at times 
corresponding to the earliest phases of BCR-induced internalization and rapid fusion 
with the MIICs. Primary B cells rapidly present Ags of internalized Salmonella, even 




BCR-mediated bacterial uptake 
 Figure 5. BCR-mediated uptake of Salmonella induces Ag presentation by B cells. 
 (A) BCR-induced internalization results in proliferation of B cells and Ag-specific T cells. B cells (B) 
were either or not incubated with viable anti-BCR-coated (C) Salmonella in the presence or 
absence of autologous T cells (T), as indicated. Results are shown as percentage of maximal 
stimulation of T cells with anti-CD3 and -CD28 Abs. (B) The same experimental setup as in Fig. 4A 
was performed with uncoated (U) viable and dead Salmonellae. Data are from four independent 
experiments of different donors, error bars indicate SEM. B:T represents the ratio of different 
amounts of B cells added to a fixed amount of T cells. Experiments with uncoated and coated 
Salmonella were performed in parallel using the same donor. (C) B cells incubated with viable 
uncoated GFP-Salmonella were FACS-sorted as indicated and incubated for 6 days with T cells. 
White bar: B cells without bacteria, black bar: B cells before sorting, green bar: GFP-
Salmonella+LPS--sorted B cells, blue bar: GFP-Salmonella+LPS+-sorted B cells and grey bar: GFP-
Salmonella--sorted B cells. Data are from two independent experiments with cells from different 
donors, error bars indicate SEM. (D) Salmonella-primed or Staphylococcus-primed T cells were 
restimulated for 2 days with autologous B cells that were incubated with viable Salmonella or 
Staphylococcus or restimulated with PBMCs incubated with tetanus toxoid. Data are representative 
for three independent experiments with different donors, error bars indicate SEM. (E) T cells (T) 
were cultured with B cells (B) that had taken up uncoated (U) or anti-BCR-coated (C) Salmonella 
either or not in the presence of the MHC class II Ag presentation blocking Ab L243. (F) Ag 
presentation by B cells starts immediately after internalization of the Salmonella. B cells (B) were 
either or not incubated with uncoated (U) or anti-BCR-coated (C) Salmonella and irradiated with 60 
Gy at different time points before T cells (T) were added. Data are representative for four 



















BCR-mediated internalization induces IgM secretion 
To test if BCR-mediated internalization of Salmonella leads to differentiation of B 
cells into Ab-secreting cells, supernatants of B cells that internalized bacteria were 
tested for the presence of human IgM after culture. After 5 days incubation with 
viable uncoated bacteria, no strong induction of IgM secretion following BCR-
mediated internalization was detectable (Fig. 6A, left panel). When the Salmonella 
were coated with anti-IgM Abs, B cells produced four times more IgM than 
uncoated bacteria. Addition of T cells did not increase IgM production in the first 5 
days, indicating that IgM production resulted from a T cell-independent activation of 
B cells (Fig. 6A, left panel). T cell help did occur within 12 days, leading to a strong 
increase in IgM production (Fig. 6A, right panel). Thus, BCR-mediated 
internalization of Salmonella induces autonomous IgM secretion by B cells, whereas 
T cell help is required during the late stage of Ig secretion by B cells. IgG 
production of B cells incubated with Salmonella did not significantly surpass IgG 
production levels from B and T cells that were not incubated with Salmonella (data 
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not shown). This is in line with the observation that the B cells that take up 
Salmonella are IgM+ memory B cells. It also indicates that BCR-mediated 
internalization of Salmonella by the naive IgM+ B cell pool does not induce Ig class 
switching under our culture conditions. 
When B cells that internalize Salmonella through the BCR are activated, they might 
produce Salmonella-specific Abs. We incubated uncoated, viable GFP-Salmonella 
with primary B cells and FACS-sorted the GFP+ B cells. We cultured the sorted B 
cells on a monolayer of fibroblasts expressing human CD40L to provide 
costimulation. After 12 days, total human IgM as well as Salmonella-reactive Abs 
were quantified. B cells that internalized Salmonella produced more total IgM than 
B cells that did not take up Salmonella (Fig. 6B, upper left panel). The production of 
Salmonella-reactive Abs was measured using a whole-cell Salmonella ELISA. 
Strikingly, the sorted Salmonella-containing B cells produced significant amounts of 
anti-Salmonella IgM (Fig. 6B, lower left panel), unlike control B cells from the same 
donor. Correction of the anti-Salmonella reactive IgM for total IgM production by 
the B cells revealed that the sorted B cells produced significantly higher levels of 
anti-Salmonella IgM compared to control B cells (Fig. 6B, right panel). The 
production of significantly higher levels of anti-Salmonella IgM clearly shows the 
involvement of the BCR in internalization of Salmonellae. If the BCR would not be 
involved, but bacterial internalization and subsequent B cell activation would solely 
depend on TLR stimulation and/or co-stimulation, the B cells that had taken up 
Salmonella would not be able to produce Salmonella-specific IgM. Thus, BCR-
mediated internalization of Salmonella forms an efficient pathway to induce 




B cells may encounter Ags as free Ag or delivered by Dendritic cells (DCs) (36). 
DCs are equipped with both nondegradative and degradative Ag uptake pathways 
to facilitate Ag presentation to both B and T cells. Blood DCs can capture and 
transport particulate Ags such as invading bacteria to the spleen, where they 
promote differentiation of marginal zone B cells into IgM secreting plasma cells 
(37). We here show a pathway independent of DCs and macrophages. In contrast 
to the dogma that mammalian B cells lack the ability to ingest pathogens and are 
only involved in the adaptive phase of the immune response (38) or that entry of 
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Figure 6. BCR-mediated internalization induces IgM production and B cells with a BCR reactive 
for Salmonella Ags produce anti-Salmonella IgM.  
 (A) B cells (B) were either or not incubated with uncoated (U) or anti-BCR coated (C) Salmonella 
in the presence or absence of autologous T cells (T). After 5 (black bars, left panel) and 12 days 
(grey bars, right panel) total secreted human IgM was determined. (B) B cells either or not 
incubated with viable uncoated GFP-Salmonella were FACS sorted and cultured on a monolayer 
of irradiated, CD40L-expressing fibroblasts for 12 days and supernatant was analyzed for total 
IgM production and Salmonella-reactive IgM production. White bars represent B cells and black 
bars represent Salmonella-positive B cells. Anti-Salmonella IgM was divided on the total amount 
of IgM measured in the supernatants (right panel, P = 0.006). Data are representative for three 








Salmonella in B cells is a random process (39), primary B cells can internalize 
Salmonella via their specific BCR. So far, the general concept for Ag presentation of 
bacterial peptides by B cells was that B cells extract proteins from the surface of 
DCs or bacteria or bind shedded bacterial proteins (15). Indeed, this may occur for 
dead or lysed bacteria killed by Abs and complement or after antibiotic treatment. 
Our observation that recognition via the BCR of dead bacteria without 
internalization induces Ag presentation to T cells is in line with this concept. 
However, internalization of viable bacteria leads to superior CD4+ T cell activation 
and instantaneous generation of anti-Salmonella Abs by autonomous activation of 
the Salmonella-reactive B cells. 
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It has been proposed that Abs made by IgM memory B cells are the first-line 
defense mechanism against all infections and that Abs produced by IgM memory B 
cells are the only B cell defense against T-independent Ags (40). IgM+ memory B 
cells in peripheral blood represent circulating splenic marginal zone B cells in charge 
of T-independent responses (41). Since marginal zone B cells express a BCR of 
polyreactive nature (42), this could explain the relatively high numbers of CD27+ B 
cells that take up Salmonella. As for IgM+ memory B cells, a subset of mature naive 
B cells in peripheral blood are polyreactive (43). Combined, the primary B cells that 
we found to internalize Salmonella seem to represent naive and IgM+ memory B 
cells with a polyreactive BCR. 
How do these findings relate in the involvement of B cells in Salmonella infection? 
Studies in B cell-deficient mice show that B cells are necessary for efficient 
protection against both primary and secondary infection with Salmonella (44). 
Passive transfer of Salmonella-immune serum could not restore resistance of mice 
to Salmonella (45), demonstrating that high-affinity Ab production alone is not the 
only function of B cells in salmonellosis. Moreover, at the early stage of primary 
infection class-switched high-affinity Abs against Salmonella are not yet available 
and cannot explain the importance of B cells at this stage. Therefore polyreactive, 
IgM+ memory B cells may well be involved in protection against primary infection 
via BCR-mediated internalization of Salmonella and rapid generation of protecting 
Salmonella-reactive IgM Abs. B cell deficient Igh-6-/- mice have impaired Th1 T-cell 
responses from the early stage of Salmonella infection, showing that B cells play an 
essential role in the initiation of T cell-mediated protection as well (46). The 
importance of B cells in this line of immune defense may relate to their property to 
present Ags to T cells. It remained unclear how Ag presentation was achieved since 
processing and presentation of Ags by naive B cells was not observed. In this study, 
we provide a missing link in these observations by showing that the IgM+ B cells 
can internalize viable bacteria and very efficiently induce Th activation. However, 
IgM secretion can also be induced by BCR-mediated Salmonella uptake and 
activation alone, albeit less efficient than observed with additional CD4+ T cell help. 
The rapid secretion of IgM before B cells encounter CD4+ T cells represents a first 
line of specific immune responses to pathogens and may represent the remaining 
humoral response when CD4+ T cell help fails, as is the case in HIV patients. In 
conclusion, we demonstrate for the first time that bacterial uptake via the BCR by B 
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cells forms a highly efficient pathway to generate an immediate antimicrobial 
humoral immune response. 
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Supplemental figure S1. Blocking of the 
BCR with F(ab)2 fragments. 
 
 Primary B cells were pre-incubated with F(ab)2 
fragments of the anti-IgM antibody before 
incubation with anti-IgM coated Salmonellae. 








 Supplemental figure S2. BCR internalization 
before incubation with bacteria.  
Primary B cells were pre-incubated with an 
anti-IgM antibody followed by incubation with 
a goat-anti-mouse antibody to achieve partial 
BCR internalization before incubation with 
uncoated Salmonellae. Data are one 
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The bacterial pathogen Salmonella causes worldwide morbidity and mortality. A 
major route of host entry in the intestinal mucosa is via M cells, directly entering 
the B cell-rich Peyer’s Patches. Salmonella can be taken up by antigen-specific B 
cells in a B cell receptor (BCR)-dependent fashion. We studied the contribution of B 
cells to the pathogenicity of Salmonella typhimurium. Upon phagocytosis of 
Salmonella by primary human B cells, Salmonella survives intracellularly in a 
dormant state that is actively maintained by the B cell. Subsequently, Salmonella is 
excreted by B cells, allowing infection of other cell types and reinitation of 
replication. B cells may thus function as a transport vehicle for Salmonella. Indeed, 
adoptive transfer of Salmonella-specific B cells before oral infection of mice with 
Salmonella was required to disseminate Salmonella to the spleen. Salmonella-
specific B cells thus function as survival niche and reservoir to contribute to 
systemic dissemination of Salmonella and represent the first example of a pathogen 
that uses cells of the adaptive immune system for spreading of infection. 
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Introduction 
Salmonella enterica is a Gram-negative, enteric pathogen responsible for disease 
syndromes of significant morbidity and mortality (1). After oral uptake, the 
bacterium crosses the intestinal epithelium and enters the Peyer’s patches via 
specialized antigen-sampling M cells (2) or via luminal capture by dendritic cells (3, 
4). They are ultimately internalized by macrophages, dendritic cells, and 
neutrophils (5, 6). Entry into these cells is actively induced by the bacterium 
through an impressive array of effector proteins that orchestrate uptake by 
manipulating the host cellular machinery (7). Salmonella manipulate host cells 
upon infection in order to alter the actin cytoskeleton allowing phagosomal cup 
formation and entry of the relatively large pathogen into the host cell. Bacterial 
effector proteins are therefore introduced into the host cytosol through the 
Salmonella Type III Secretion System (TTSS). Salmonella can thus enter most cell 
types to form an intracellular vacuole called the Salmonella-containing vacuole 
(SCV). Here, another set of effectors is secreted into the host cytosol for vacuole 
maintenance and interference with the endosomal system to obtain nutrients and to 
prevent maturation and fusion with lysosomes (8, 9) by manipulating the Akt-
AS160-Rab14 cascade and PAK4 (10). Salmonella replicates in an expanding SCV 
(11, 12) and escapes detection by the immune system (13, 14). Although 
Salmonella replicates in the phagosome, it remains unclear how the bacteria are 
released from the infected cell. Obvious mechanisms would involve apoptosis or 
necrosis of the infected cell, but such is not established. 
When Salmonella has passed the intestinal epithelium, it spreads via mesenteric 
lymph nodes to liver, bone marrow and spleen where replication continues (15). 
How Salmonella reaches these organs is unclear. So far, dendritic cells, 
macrophages, neutrophils and CD18-expressing phagocytes have been implicated 
to be the target cells of Salmonella infection (4, 16). Similar to HIV (reviewed in 
(17)), dendritic cells may act as pathogen carriers for more systemic spreading of 
the infection. Macrophages, dendritic cells and neutrophils however, exhibit efficient 
bactericidal mechanisms (6, 18) that render these cells less favorite as vehicles for 
bacterial dissemination. Salmonella is able to enter and survive within human B cell 
lines (19, 20). In mice, infected B cells are able to present Salmonella antigens to 
CD4+ T cells (21). We recently showed that primary human B cells are able to 
internalize Salmonella after recognition by the B cell receptor (BCR) and 
subsequently present bacterial antigens to Salmonella-specific CD4+ T cells (22). 
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Here we show how primary antigen-specific B cells are used as transport vehicle for 
spreading within the host. We show that Salmonella utilizes the specificity of the 
immune system after uptake by antigen-specific B cells to survive intracellularly in 
a dormant state that is actively maintained by the B cell. Ultimately, Salmonella is 
excreted by the B cell followed by reinfection and replication in other cell types. 
Adoptive transfer of B cells with transgenic BCRs that specifically recognize hen egg 
lysozyme (HEL)-expressing Salmonella showed that Salmonella-specific B cells 
contribute to the in vivo dissemination of Salmonella in mice after oral 
administration of the bacteria. The antigen-specific B cells thus act as antigen-
specific reservoirs or transport vehicles to release Salmonella at distant sites for 
further infection. These data provide the first example of the use of the adaptive 
immune system by bacterial pathogens for spreading infection in a situation 
analogous to the involvement of dendritic cells in the spreading of HIV.  
 
Materials en methods 
Mice 
C57BL/6 mice (6–8 weeks old) were purchased from Harlan (Udine, Italy). BCR-HEL 
VDJ ki mice (a kind gift of Dr. J. Cyster, University of California, San Francisco) 
were bred under specific pathogen-free conditions at Charles River Laboratories. All 
experiments were performed in accordance with the guidelines established in the 
Principles of Laboratory Animal Care (directive 86/609/EEC).  
 
Evaluation of Salmonella spreading in vivo. 
CD43- naïve B cells were purified from spleens of BCR-HEL VDJ ki mice with CD43 
(Ly-48) Microbeads (Miltenyi Biotec, Bologna, Italy) according to the manufacturer’s 
instructions. 106-2X105 cells were injected intravenously into C57BL/6 mice (14 
mice per group) one day before oral infections. For survival experiments, mice 
received 105 CFUs of HEL surface-expressing S. typhimurium SL1344, and survival 
was monitored daily. For evaluation of splenic colonization, mice received 105 CFUs 
of bacteria. Sixteen hours after infection, spleens were collected and processed; a 
fixed number of cells was lysed with 0.5% sodium-deoxycholate and plated onto 
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Antibodies and bacterial strains 
mAb anti-human IgM (MH15, Sanquin, Amsterdam, The Netherlands) was mixed 
with rat anti-mouse IgG1 antibody (RM161.1, Sanquin) and mAb anti-S. 
typhimurium LPS (1E6, Biodesign International, Kennebunk, ME) to generate BCR-
LPS tetrameric antibody complexes. Fluorescent secondary antibodies and Texas 
Red-phalloidin were from Molecular Probes (Leiden, The Netherlands). GFP-S. 
typhimurium SL1344 has been described (23). The S. typhimurium strain 14028 
containing the lux operon of P. luminescens (luxCDABE) was a kind gift from S. 
Vesterlund (24) and K. Nealson. Exponentially grown bacteria were washed with 
PBS, incubated with BCR-LPS tetrameric antibody complexes for 30 min at RT, and 
washed twice to remove unbound antibodies. Surface HEL-expressing S. 
typhimurium SL1344 was generated by electroporating bacteria with a pVUB4 
vector (kindly provided by P. Cornelis, Flanders Institute for Biotechnology, 
Brussels, Belgium (25)) in which inactive HEL-encoding gene was cloned in frame 
with the one encoding for OprI protein from P. aeruginosa under the control of LacZ 
promoter. HEL expression was induced by the addition of 1 mmol/L isopropyl-L-
thio-B-D-galactopyranoside to exponentially growing bacteria (26). 
 
Lymphocyte isolation, infections and cell lines 
Isolation of human B cells from peripheral blood and culturing of the Ramos B cell 
line and NIH3T3 fibroblasts expressing human CD40L (3T3-CD40L) have been 
described (22). B lymphocytes with viable uncoated bacteria and Ramos cells with 
viable anti-IgM coated bacteria were incubated for 40 min at 37°C w/o antibiotics 
while tumbling. Next, cells were washed four times and cultured for 1h in media 
containing 100 µg/ml gentamycin (Invitrogen) to eliminate non-phagocytosed 
bacteria. Cells were cultured in RPMI 1640 medium with 5% FCS, p/s, 2 mM L-
Glutamine, 50 μM 2-mercaptoethanol, 20 μg/ml human apo-transferrin ((Sigma-
Aldrich) depleted for human IgG with prot-G sepharose) and 10 µg/ml Gentamycin. 
 
Live cell imaging 
Wide field microscopy was performed at 37ºC using 6-well plates (coated with Poly-
L Lysine) and a Zeiss Axiovert 200 M microscope equipped with a FluorArc 
fluorescence lamp, motorized scanning stage, 63x LD Achroplan objective; NA 0.75 
and climate chamber. Images were acquired using a Zeiss AxioCam MRm Rev.2 
CCD in combination with the manufacturer’s AxioVision software. All experiments 
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presented were repeated several times on different days, and results were 
consistent and reproducible. Further image processing was performed using the 
ImageJ software package. 
 
Intracellular survival and growth assays 
Human primary B cells were incubated in parallel experiments with either GFP- or 
Lux-expressing Salmonella with 2 bacteria per cell. The percentage of living cells 
and GFP levels were determined using a FACS Calibur (Becton Dickinson). 
Bioluminescence was measured for 5s in a luminometer (Berthold). Bacterial 
growth was determined by dividing the relative bioluminescence signal by the 
relative number of GFP+ living B cells, resulting in the amount of light produced per 
bacteria containing B cell. For induction of apoptosis, cells were treated with 0.1 µM 
Edelfosine (Biomol) (27). 
 
Bacterial excretion assay 
To visualize bacterial excretion, human primary B cells were incubated with 
uncoated GFP-Salmonella at 20 bacteria per cell, and followed using wide field 
microscopy in medium containing anti-LPS antibodies coupled to TexasRed. To 
quantify excretion, cells were stained with DAPI (Sigma-Aldrich) to exclude dead 
cells and anti-LPS coupled to APC and fixed with 3.7% formaldehyde before 
analysis using a LSR II (Becton Dickinson). For the increase in LPS levels, the initial 
level at time point 0 was set to 1. The percentage of excreted bacteria was 
calculated as the loss of GFP+/LPS- B cells compared to time point 0. To 
discriminate between bacterium and B cell-induced excretion, cells were cultured in 
medium containing 10µg/ml tetracycline to arrest intracellular bacteria 
(bacteriostatic capacity was verified using lux-Salmonella in Ramos cells).  
 
Statistical analysis 
Kaplan-Meier plots and long-rank tests were used to assess survival differences of 
adoptively transferred mice after virulent S. typhimurium infection. Statistic 
calculations were performed by JMP 5.1 software (SAS, Cary, NC). 
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Results and Discussion 
Primary human B cells form a survival niche for intracellular Salmonella 
Recent data indicated that B cells from early vertebrates act as efficient phagocytes 
in contrast to mammalian B cells that do not show phagocytic behavior (28). We 
demonstrated however, that human B cells have not lost this phagocytic capacity 
but will only phagocytose particles or pathogens when first recognized by the BCR 
(22). The BCR acts as an antigen-specific receptor for Salmonella, and BCR 
crosslinking likely cooperates with bacterial effector proteins to facilitate uptake in B 
cells. Other mammalian cells are infected by Salmonella without any further 
involvement of such specific receptors. Phagocytosed Salmonella grows in many cell 
types, and can only be efficiently destroyed in specialized cells like macrophages 
and neutrophils in a process requiring the nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase system (5). We previously noticed survival of 
Salmonella in B cells after BCR-mediated internalization and now studied the fate of 
these phagocytosed Salmonella in more detail.  
To study the fate of Salmonella typhimurium in B cells, time-lapse imaging of GFP-
Salmonella containing B cells was performed with wide-field microscopy to limit 
phototoxicity. After incubation with bacteria and extensive washing, we observed 
replication of GFP-Salmonella in the Ramos B cells (Fig. 1A, top panel and 
supplemental movie 1), whereas Salmonella did not multiply in primary B cells (Fig. 
1A, bottom panel and supplemental movie 2). To quantify these observations, we 
performed parallel experiments to compare GFP-Salmonella (detected by FACS 
analysis) with light producing lux-Salmonella (detected by luminometry). Light 
production by lux-Salmonella requires ATP and is thus a marker for bacterial 
viability (24). Figure 1B shows that anti-IgM coated GFP-Salmonella that have been 
phagocytosed by Ramos cells expanded intracellularly. Over a time course of 10h 
we observed a strong increase in lux activity (Fig. 1B, top left panel), while the 
number of GFP-Salmonella positive viable Ramos cells remained nearly constant 
(Fig. 1B, top right panel). The amount of light produced in GFP-Salmonella positive 
Ramos cells increased considerably (Fig. 1B, bottom left panel), indicating that the 
number of bacteria per Ramos cell increased over time. In accordance, the GFP 
signal per Ramos cell increased (Fig. 1B, bottom right panel). In contrast, lux 
activity sharply dropped over time when Salmonella was phagocytosed by primary 
































Salmonella as the fraction of GFP-Salmonella containing B cells declined equally fast 
(Fig. 1B, top right panel). In fact, the amount of light produced per living GFP-
Salmonella positive B cell remained constant during the course of the experiment 
(Fig. 1B, bottom left panel), showing that Salmonella remained viable in primary 
human B cells, albeit under conditions of inhibited proliferation. This confirms the 
wide-field microscopy data that showed that Salmonella does not replicate in 
primary B cells. Unlike specialized phagocytic immune cells like macrophages,  
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 Figure 1. Primary human B cells form a survival niche for intracellular Salmonella. 
(A) Widefield fluorescence microscopy of living Ramos and primary human B cells with phagocytosed 
GFP-expressing Salmonella. Bacteria were coated with anti-IgM mAbs to force BCR-specific recognition 
of the bacteria by the Ramos B cell line and to enhance the number of primary B cells that can 
phagocytose bacteria via their BCR. Depicted are GFP signals projected on the transmission image. 
Scalebar = 10µm. Number of bacteria in the visualized cell is given in the lower right corner. Lower left 
corner: time after Salmonella infection.  Images are frames from supplemental movie 1 and 2. (B) 
Analysis of Ramos and primary human B cells incubated with living anti-IgM coated lux-expressing (top 
left panel) or GFP-expressing (top right panel) Salmonella. The ratio of lux over GFP shows the amount 
of light produced per GFP-Salmonella positive B cell (bottom left panel), indicating intracellular 
Salmonella viability. The mean fluorescence of the GFP positive population, set arbitrarily at 1 at the 
beginning of the experiment, shows that the GFP signal increases in Ramos B cells, whereas it 
decreased in primary human B cells (bottom right panel). A representative example of three 
independent experiments is shown. (C) B cells were infected with anti-BCR coated GFP-expressing 
Salmonella before exposure to Edelfosine to induce apoptosis. Cells were imaged over a 14h period. 
Top panel: transmission image, bottom panel: GFP-signal. Scalebar = 10µm. Images are frames from 















neutrophils, or B cells from early vertebrates (28), human B cells are apparently 
inefficient in producing the microbicidal conditions that arerequired to eliminate 
Salmonella. We next investigated whether primary B cells actively suppress 
Salmonella growth. We selectively induced apoptosis of B cells (without affecting 
Salmonella) and measured Salmonella replication. Intracellular replication of 
Salmonella was no longer suppressed 2h after induction of apoptosis in primary B 
cells with the alkyl-lysophopholipid Edelfosine (27) (Fig. 1C and supplemental 
movie 3), demonstrating that growth arrest of Salmonella requires viable primary B 
cells. These data suggest that primary human B cells, unlike human B cell lines, 
actively suppress multiplication of intracellular Salmonella within the SCV.  
 
Salmonella is excreted by B cells and infects secondary host cells 
The number of primary B cells that had initially phagocytosed Salmonella dropped 
over time (Fig. 1B, top right panel), suggesting that Salmonella may be released. 
To visualize the fate of phagocytosed Salmonella in B cells, primary human B cells 
infected with GFP-Salmonella were co-cultured on a monolayer of CD40L-
expressing 3T3 cells and analyzed by time-lapse wide-field microscopy. In addition, 
CD40L will provide a pro-survival signal (29) enabling long term cell culture and 
imaging of primary B cells. Primary B cells that had phagocytosed GFP-Salmonella 


























3T3-CD40L monolayer (Fig. 2A and supplemental movie 4). At later time points, 
some GFP-Salmonella appeared to be exocytosed from the B cell. To visualize this, 
GFP-Salmonella infected primary B cells were cultured in the presence of a low 
concentration of Texas-Red labeled anti-LPS mAb in the medium. GFP-Salmonella 
will attract and concentrate this antibody upon exposure to the medium. Figure 2B 
shows a B cell with phagocytosed GFP-Salmonella that becomes accessible for anti-
LPS antibodies in the medium after 8 hr of culture (supplemental movie 5). 
Salmonella excretion from primary B cells was quantified using FACS by detecting 
GFP-Salmonella and LPS-positive B cells. Strong increase in cell surface exposed 
LPS on cells that were initially GFP-Salmonella positive and LPS negative was 
observed (Fig. 2C, left panel). This suggests that a large fraction of the 
phagocytosed Salmonella were exocytosed as in the example shown in Fig. 2B.  
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 Figure 2. Salmonella is actively excreted by B cells and capable of infecting secondary host cells. 
(A) Primary B cells having phagocytosed anti-BCR coated GFP-Salmonella on a monolayer of 3T3-
CD40L fibroblasts were imaged using widefield fluorescence microscopy. Depicted is the GFP signal 
projected on the transmission image with images taken every 30 min. Scalebar = 10µm. Arrows 
indicate the B cell, white arrow: B cells moves op top of the monolayer, black arrow: B cells moves 
below the monolayer. Images are frames from supplemental movie 4. (B) Primary B cells having 
phagocytosed anti-BCR coated GFP-Salmonella on a monolayer of 3T3-CD40L fibroblasts were imaged 
using widefield fluorescence microscopy in the presence of TexasRed labeled anti-LPS mAbs. Depicted 
are GFP and Texas-Red signals projected on the transmission image. Scalebar = 10µm. Images are 
frames from supplemental movie 5. (C) Quantification of Salmonella secretion from B cells. Primary B 
cells were incubated with live uncoated GFP-Salmonella. Cells were stained with antibodies against 
LPS, fixed and analyzed using FACS. Left panel: increase in cell surface exposed LPS from bacteria 
exposed at the cell surface after initial uptake by B cells. Middle panel: percentage of B cells having 
excreted Salmonella as calculated from the percentage of B cells containing GFP-Salmonella followed 
in time. Right panel: left and middle panels are projected to illustrate that both processes show 
similar kinetics. Error bars represent SD from three independent experiments. (D) Primary B cells 
were incubated with live uncoated GFP-expressing Salmonella and followed for the time points 
indicated. The fraction of living B cells is plotted to demonstrate that loss of GFP-Salmonella positive B 
















Accordingly, the population of GFP-Salmonella positive/LPS negative B cells 
declined over time inferring increase in excretion (Fig. 2C, middle panel) with 
kinetics that were identical to the acquired LPS signal over time (Fig. 2C, right 
panel). GFP-Salmonella infection of primary B cells did not affect B cell viability or 
induced apoptosis (Fig. 2D). Note that during the first phase of excretion 
Salmonella was released, but remained associated to the B cells, hence the 
increased staining with the anti-LPS antibodies in the first 10h. The bacterium was 
later released from the B cell, leveling off further LPS labeling. Loss of the GFP-
Salmonella signal from infected primary B cells increased over an 18h period in our 
experiments at which point more than 50% of the bacteria were released from B 
cells. Thus, a large proportion of phagocytosed Salmonella are secreted within 24 
hrs of human primary B cell infection.  
 
Excretion of Salmonella is a cell autonomous process 
Does Salmonella actively participate to the process of excretion from B cells? So 
far, we used the antibiotic gentamycin in our experiments to kill extracellular 
Salmonella and prevent their overgrowth, as gentamycin does not affect 
intracellular Salmonella replication (as seen in Fig. 1A). Unlike gentamycin, the 


















 Figure 3. Salmonella is actively excreted by B cells and capable of infecting secondary host cells 
(A) Left panel: the effect of antibiotics on the growth of lux-Salmonella in Ramos B cells. Right 
panel: the same FACS analysis as in 2C was performed in presence of either Gentamycin or 
Tetracycline to discriminate between host and bacteria mediated excretion. (B) The same FACS 
analysis as in Fig. 2C was performed in presence of either Gentamycin or Tetracycline to 
discriminate between host versus bacterial-mediated excretion. Increase in cell surface LPS levels 
is similar in the presence of Gentamycin and Tetracycline, indicating that viable Salmonella are 
not required for excretion. (C) Primary B cells having phagocytosed anti-IgM coated GFP-
Salmonella on a monolayer of 3T3-CD40L fibroblasts were imaged using widefield fluorescence 
microscopy for the times indicated. Imaging conditions are similar as in 2A. GFP-Salmonella is 
excreted from a primary B cell (white arrowhead), followed by infection of the 3T3-CD40L 
monolayer (outline of infected cell marked by a dashed line). Inset shows zoom-in on primary B 












These antibiotics inhibited lux-Salmonella growth in Ramos cells (Fig. 3A, left panel) 
and no viable Salmonella bacteria were recovered in plating assays of infected B 
cells, in contrast to exposure to gentamycin (data not shown). Salmonella secretion 
by primary B cells was measured in the presence of either gentamycin or 
tetracycline. Tetracycline did not affect excretion of GFP-Salmonella from primary B 
cells, which occurred equally efficient as in the presence of gentamycin (Fig. 3A, 
right panel), indicating that Salmonella viability is not required for excretion. 
Likewise, a similar increase in cell surface LPS levels was observed in the presence 
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of tetracycline as with gentamycin (Fig. 3B). While Salmonella participates in 
uptake after capture by the BCR (22), excretion does not require viable Salmonella.  
Can Salmonella then infect other cells following transport by B cells to distant sites? 
We co-cultured primary human B cells containing phagocytosed GFP-Salmonella on 
a monolayer of 3T3-CD40L and followed post-excretion events using time-lapse 
wide-field microscopy. Figure 3C shows an example of a phagocytosed GFP-
Salmonella that subsequently extruded from the primary B cell followed by infection 
of the fibroblast monolayer (supplemental movie 6). The released bacteria infected 
and replicated in the fibroblast monolayer, demonstrating that passage through 
primary B cell had not suppressed bacterial replication in an irreversible manner. 
These data suggest that Salmonella can use primary B cells as a reservoir or 
transport vehicle allowing it to escape immune attack and hitch-hike to distant 
locations.  
 
Salmonella-specific B cells mediate spreading in acute in vivo infection. 
Our observations imply that the availability of B cells with pathogen-specific BCRs 
would be advantageous for the spreading of infection as they may be used as 
Salmonella carriers. How Salmonella reaches the spleen is not clear. Possibly, 
Salmonella encounters specific B cells as they cross the intestinal epithelium via M 
cells directly located to gut-associated lymphoid tissue (GALT) sites where many B 
cells reside in Peyer’s patches. Among preferred distant sites of persistent infection 
are the spleen and lymph nodes. Salmonella has been isolated from splenic 
macrophages and splenic B cells of orogastrically infected mice (20). Salmonella 
was thought to reach these locations after transport by neutrophils (16), a notion 
incompatible with the efficient bactericidal capacity of neutrophils (5). Also 
macrophages and DCs have been implicated, but also these cells have bactericidal 
capacities, like neutrophils. The possibility that Salmonella uses antigen-specific 
primary B cells as transport vehicle to distant sites in the host has not been 
considered. To test this option in vivo, we adoptively transferred C57BL/6 mice with 
increasing amounts of CD43- naïve B cells carrying a BCR specific for the HEL 
antigen. One day after transfer, mice were infected with a sublethal dose of surface 
HEL-expressing Salmonella, and survival was monitored daily. Transfer of 2X105 
HEL-specific B cells increased C57BL/6 mortality after HEL-expressing Salmonella 
infection whereas 106 B cells protected (Fig. 4A). These results may be due to two 
opposite effects of the antigen-specific B cells; spreading of Salmonella and 
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production of antibodies against Salmonella, in which the balance of these activities 
determines survival of mice. To directly establish if HEL-specific B cells mediated 
systemic dissemination of HEL-expressing Salmonella, we investigated bacterial 
recovery from the spleen in the different experimental settings. Salmonella spread 
to the spleen only after adoptive transfer of antigen-specific B cells (Fig. 4B). Thus, 
















(A) Kaplan-Meier survival curves of C57BL/6 mice left untreated or adoptively transferred with 2X105, 
or 106 HEL-specific CD43- naïve B cells. Mice (n=14/group) were orally infected with surface HEL-
expressing Salmonella one day after transfer. Survival was monitored daily. (B) C57BL/6 mice were 
left untreated or adoptively transferred with 2X105 or 106 HEL-specific CD43- naïve B cells, as 
indicated. Mice were orally infected with surface HEL-expressing Salmonella one day after B cell 
transfer. Culturable splenic bacteria (CFU/105 cells) 16 hours after infection are shown (n=3/group). 







Our data show that Salmonella misuses the specificity of the adaptive immune 
system. Salmonella may hide from the early innate immune defenses in antigen-
specific B cells and may even create a sustained reservoir of infection by going 
through multiple rounds of uptake and excretion in B cell-rich areas like the Peyer’s 
patches and spleen. In addition, Salmonella may hitch-hike in B cells to facilitate 
systemic spreading of the infection. Previously, it was shown that cells of the innate 
system and erythrocytes can be used by pathogens for systemic spreading of 
infection within immunocompetent hosts, like HIV (DCs) (31) and P. falciparum 
(erythrocytes) (32). The adaptive immune system has evolved to protect against 
infection, while simultaneously generating immunological memory to ensure a rapid 
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immune response against reinfection. We now show that Salmonella has adapted to 
this by using antigen-specific B cells for immune evasion and spreading to distant 
sites within the host. This is the first example of the use of cells from the adaptive 
immune system by bacteria to enable their dissemination.  
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Phagocytosis of Salmonella by B cells generates an effective cytotoxic T 
cell response via cross-presentation of Salmonella-antigens 
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The eradication of facultative intracellular bacterial pathogens, like Salmonella 
typhi, requires the concerted action of both the humoral immune response and the 
cytotoxic CD8+ T cell response. Dendritic cells (DCs) are considered to orchestrate 
the cytotoxic CD8+ T cell response via cross-presentation of bacterial antigens onto 
MHC class I molecules. Cross-presentation of Salmonella by DCs however, is 
accompanied by the induction of apoptosis in the DCs. Besides antibody production, 
B cells are required to clear Salmonella infection for other unknown reasons. Here 
we show that Salmonella-specific B cells that phagocytose Salmonella upon BCR-
ligation are able to activate human CD8+ memory T cells via cross-presentation 
yielding a Salmonella-specific cytotoxic T cell response. Unlike the DCs, B cell-
mediated cross-presentation of Salmonella does not coincide with apoptosis. Thus, 
B cells are a viable alternative for DC in the activation of the cytotoxic effector arm 
and the generation of effective adaptive immunity against Salmonella reinfection. 
 74 
Cross-presentation of Salmonella-antigens by B cells 
Introduction 
Salmonella is a pathogenic bacterium that causes severe disease in mice and man. 
Salmonella typhi (Salmonella enterica serovar Typhi) causes invasive diseases in 
human, which has many features in common with Salmonella typhimurium in mice. 
The gastrointestinal tract is the major site of primary infection of the host and has 
to be passed before systemic infection can occur. One way to infect the host cells is 
via sampling of bacteria by DCs in the intestine. In vitro studies showed that DCs 
located in the lamina propria under the gut epithelium of the small bowel extend 
processes across the tight junctions between the epithelial cells and capture 
bacteria from the luminal side of the gut (1,2). The major route of infection 
however, is via microfold cells or M cells (3,4). The specialized antigen-sampling M 
cells are located in the dome region of the Peyer’s Patches and are efficient in 
transportation of macromolecules and microorganisms to the underlying immune 
cells (2,5). Like other Gram-negative bacteria, Salmonella uses specific virulence 
factors to invade other cell types, called the Type III Secretion System (TTSS). 
Many Salmonella virulence genes are clustered in Salmonella pathogenicity islands 
(SPIs). SPI-1 and SPI-2 encode TTSSs that mediate the injection of effector 
proteins into the host cell cytoplasm via sophisticated secretion devices (6). SPI-1 
is associated with invasion of intestinal epithelia and enhanced intestinal 
inflammation in the infected host (7,8). SPI-2 modulates intracellular trafficking 
and enables replication within a modified vacuolar compartment, called the 
Salmonella-containing vacuole (SCV) (9-11) and enhances inflammation during 
enteric phase (12,13). Salmonella activates the PKB/Akt1 pathway to prevent 
maturation of SCV into destructive phagolysosomes, thus manipulating the host for 
its own survival (14).  
After transcytosis by M cells, Salmonella reaches the subepithelial dome of the 
Peyer’s patches and encounters an extensive network of resident macrophages, 
DCs and great numbers of B cells (15,16). Instead of being immediately destroyed 
by these cells, Salmonella have evolved several mechanisms to survive in the harsh 
milieu of phagosomal compartments (17) and can be cytotoxic to macrophages by 
inducing apoptosis in vitro (18,19).  
Recently, we showed that recognition of Salmonella via the specific B cell receptor 
(BCR) on B cells results in internalization of Salmonella. Salmonella is able to 
survive intracellularly in primary B cells in a non-replicative state (20). Following 
uptake of Salmonella, B cells do not go into apoptosis, but differentiate and start to 
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produce Salmonella-specific antibodies. In addition, BCR-mediated phagocytosis of 
Salmonella by B cells leads to antigen presentation via MHC class II and subsequent 
CD4+ T cell activation, which in turn boosts antibody production by the infected B 
cell. 
Antibody transfer studies have shown that the requirement for B cells in the 
clearance of Salmonella does not solely depend on antibody formation (21). Which 
additional immune responses need B cell involvement remains unclear. For 
clearance of Salmonella, not only the humoral immune response is required, but 
also the activation of cytotoxic CD8+ T cells is needed to eliminate Salmonella-
infected cells. Recently, DCs have been shown to prime Salmonella-specific CD8+ 
memory T cells after direct uptake of bacteria or via suicide cross-presentation after 
uptake of S. typhi-infected human cells (22). As the generation of Salmonella 
antigens for MHC class II molecules is an efficient process in infected B cells, we 
tested whether BCR-mediated phagocytosis also leads to cross-presentation of 
Salmonella antigens via the MHC class I pathway of B cells and whether this elicits 
a cytotoxic T cell response against Salmonella-infected cells. 
Here we show that Salmonella-specific primary B cells that have internalized 
Salmonella do cross-present Salmonella antigens via MHC class I molecules in a 
proteasome-dependent manner. Subsequently, we demonstrate that cross-
presentation of Salmonella antigens by B cells activates Salmonella-specific CD8+ 
memory cells that acquire a cytotoxic phenotype and are efficient in the killing of 
Salmonella-infected cells. Thus, B cells are an unappreciated source of cells cross-
presenting bacterial antigens for T cell stimulation. 
 
Materials and methods 
Antibodies and fluorophores 
mAb anti-human IgM (MH15, Sanquin, Amsterdam, The Netherlands) was mixed 
with rat anti-mouse IgG1 antibody (RM161.1, Sanquin) and mAb anti-S. 
typhimurium LPS (1E6, Biodesign International, Kennebunk, ME) to generate BCR-
LPS tetrameric antibody complexes, used to coat bacteria as previously described 
(20). 
The following labeled anti-human mAbs were obtained from BD Biosciences (San 
Jose, CA): anti-IFN-γ-FITC, anti-CD27-PE, anti-CD107a-PE, anti-CD8-PerCP-Cy5.5, 
anti-CD4-APC, anti-CD45RO-PE, AnnexinV-APC and IgG1-PerCP-Cy5.5 isotype 
control. FITC-conjugated antibody IgG1, IgG2a and IgG2b, IgG1-PE and IgG-APC 
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isotype controls were obtained from DAKO (Glostrup, Denmark). Anti-CD45RA-FITC 
and anti-CD45RO-FITC were obtained from Sanquin and DAPI from Sigma-Aldrich 
(Steinheim, Germany). CFSE (Invitrogen, Paisley, UK) labeling was used in 
proliferation assays. 
 
Bacterial growth conditions 
GFP expressing-S. typhimurium SL1344 was described before (23). GFP-Salmonella 
defective in SPI-1 (invA mutant) or SPI-2 (ssrA mutant) were a kind gift of M. 
Rescigno (European Institute of Oncology, Milan, Italy). Staphylococcus aureus 
expressing GFP (RN4220 with pWVW189GFP) was kindly provided by S. A. J. Zaat 
(Academic Medical Center, Amsterdam, The Netherlands). All bacteria strains were 
grown overnight at 37ºC in Luria-Bertani (LB) broth with carbenicillin or 
chloramphenicol (Sigma-Aldrich, St Louis, MO) to maintain GFP expression while 
shaking, subcultured at a dilution of 1:33 in fresh LB medium and incubated while 
shaking at 37ºC for 3 to 4 hours to obtain exponentially growing bacteria. For 
coating, bacteria were washed twice with PBS and incubated with BCR-LPS 
tetrameric antibody complexes for 30 minutes at room temperature and washed 
twice with PBS to remove unbound antibodies. For experiments with dead 
Salmonella, bacteria were heat killed by incubation at 65°C for 15 minutes. 
 
Lymphocyte isolation and B lymphocyte infection with Salmonella 
Human PBMCs were isolated by centrifugation on a Ficoll-Hypaque gradient (Axis-
Shield PoC AS, Oslo, Norway) from a buffycoat obtained from healthy donors after 
informed consent (Sanquin). B and T cells were subsequently purified using anti-
CD19 and anti-CD4, anti-CD8 Dynabeads and DETACHaBEAD (Invitrogen), 
according to the manufacturer's instructions. 
B lymphocytes were incubated for 45 minutes at 37°C with Salmonella without 
antibiotics. Next, cells were washed to remove unbound bacteria four times and 
cultured for 1 hour in medium containing 100 µg/ml gentamycin (Invitrogen) to 
eliminate non-phagocytosed bacteria. Cells were washed and cultured in RPMI 1640 
medium w/o phenol red (Lonza, Basel, Switserland), supplemented with 5% FCS 
(Bodinco, Alkmaar, the Netherlands), 100 U/ml penicillin, 100 μg/ml streptomycin, 
2 mM L-Glutamine, 50 μM 2-ME, 20 μg/ml human apo-transferrin ((Sigma-Aldrich), 
depleted for human IgG with protein G sepharose (Amersham, Uppsala, Sweden)) 




1*105 B cells, or Salmonella-infected B cells were cultured with 5*104 CFSE-labeled 
T cells (CD8+ T cells alone or in 1:1 ratio with CD4+ T cells) for 6 days to activate 
and expand Salmonella-specific T cells. 50,000 events were acquired on a LSR II 
(BD) and analyzed with FACSDiva software (BD. To test plasma membrane 
markers, 1*105  B cells with 5*104 T cells were cultured for 6 days and after 
addition of 10 IU/ml IL-2 (Chiron, Emeryville) for another 6 days. All plasma 
membrane stainings were performed for 15 minutes at room temperature and 
washed after each incubation with PBS containing 0.1% BSA. 50,000 events were 
acquired on a LSR II (BD) and analyzed with FACSDiva software (BD). Lymphocytes 
were gated by forward and side scatter. Dead cells were excluded based on their 
positive reaction to DAPI staining. 
For some experiments, naïve T cells were sorted as CD8+CD45RA+CD45RO- (TN) 
and memory T cells as CD8+CD45RA-CD45RO+ (TMEM), and CD8+CD45RO+CD27- 
(TEM) and CD8+CD45RO+CD27+ (TCM) cells. Populations were >98% purified. 
 
Intracellular cytokine staining 
B cells and T cells were cultured for 12 days and cytokine production was measured 
by intracellular staining after restimulation with 0.1 µg/ml PMA, 1 µg/ml ionomycin 
and 10 µg/ml brefeldin A (Sigma-Aldrich) for 5 hours. Cells were washed twice with 
PBS, fixed with 1% formaldehyde (Merck, Darmstadt, Germany) for 15 minutes and 
after washing twice with PBS, permeabilized with 0.5% saponin (Calbiochem, CA) in 
PBS containing 1% BSA (Sigma-Aldrich) and incubated with fluorescent antibodies 
for 30 minutes at room temperature. 50,000 events were acquired on a LSR II (BD) 
and analyzed with FACSDiva software (BD). 
 
CD8+ degranulation assay 
CD8+ T cells were primed by 6 day incubation of 1*105 Salmonella-infected B cells 
with 2.5*105 CD4+ T cells and 2.5*105 CD8+ T cells. The dividing T cells 
(CD8+CFSElow) were FACS sorted after 6 days on a MoFlo Sorter (Dakocytomation, 
Glostrup, Denmark) and cultured with 50 IU/ml IL-2 for 6 more days. Next, isolated 
autologous B cells were thawed and infected with Salmonella. For proteasome 
inhibition, MG-132 (Sigma-Aldrich) was added at a concentration of 20 μM before 
incubation with bacteria. Salmonella-infected B cells were incubated in medium 
containing 10 µg/ml gentamycin for 15 hours at 37ºC to allow processing and 
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presentation of Salmonella antigens. Subsequently, the B cells were incubated at 
37ºC for 5 hours together with the primed Salmonella-specific CD8+ T cells in a 
ratio of 4:1, in the presence of anti-CD107a-PE labeled antibodies. Cells were 
washed twice with wash buffer (1 mM HEPES, 0.15 M NaCl, 5 mM KCl, 1.8 mM 
CaCl2, 1 M MgCl2, 0.1% BSA) and stained for CD8 and AnnexinV. After washing 
twice with washing buffer, DAPI was added and CD8+ T cells were analyzed for 
CD107a expression. 50,000 events were acquired on a LSR II (BD) and analyzed 
with FACSDiva software (BD). 
 
51Cr release assay 
Salmonella-specific CD8+ T cells were activated and FACS sorted as described and 
expanded with 50 U/ml IL-2. Autologous B cells were thawed and infected with 
Salmonella. After 15h, B cells were labeled with 51Cr (185MBq/ml; Perkin Elmer, 
Boston, MA) for 45 minutes at 37°C. After washing, the B cells were incubated in a 
96-wells U-bottom plate (Costar Corning Inc., NY) with primed CD8+ T cells in a 1:2 
ratio. Incubation in medium or in Triton X-100 (1% final concentration; Merck) was 
used to determine spontaneous and maximum 51Cr release, respectively. 51Cr 
release was measured in the supernatant using filters with a gamma counter 
(Cobra II, Canberra Packard, Mississauga, Canada). The percentage of specific cell 
lysis was calculated using the following formula: 
 
% specific lysis = [experimental release (cpm) – spontaneous release (cpm)] 




Statistical differences were determined by a paired Student’s t test, using GraphPad 
Prism (version 4.03, GraphPad Software, San Diego, CA) 
 
Results 
Salmonella-infected B cells initiate a CD8+ T cell response 
To study MHC class I antigen presentation by B cells, we used Salmonella 
typhimurium as a model for cross-presentation against facultative intracellular 
bacteria. Previously, we showed that about 4% of the B cells recognize Salmonella 
by their BCR, and subsequently initiate a CD4+ T cell response (20). To study T cell 
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responses in detail, we enhanced the uptake of Salmonella by B cells by coating 
Salmonella with a tetrameric antibody complex, consisting of anti-LPS antibodies 
and anti-IgM-BCR antibodies. As a result, all B cells expressing an IgM-BCR, 
recognize Salmonella and are able to phagocytose the bacterium via their BCR. This 
resulted in an uptake of Salmonella by 30% to 60% of the B cells (data not shown). 
Next, we investigated whether Salmonella-infected B cells were able to initiate 
proliferation of CD8+ T cells in addition to the Salmonella-specific CD4+ T cell 
response. Therefore we cultured B cells that had phagocytosed Salmonella with 
CFSE-labeled CD4+ and CD8+ T cells. As observed before, B cells that had 
phagocytosed Salmonella induced proliferation of the CD4+ T cells (20). 
Interestingly, a considerable amount of CD8+ T cells had proliferated as well (Fig. 
1A). To investigate the requirement of CD4+ T cell help for the proliferation of the 
CD8+ T cells Salmonella-infected B cells were cultured with CD8+ T cells in the 
absence of CD4+ T cells. This situation almost completely abolished proliferation of 
the CD8+ T cells (Fig. 1B and 1C). Thus, B cells infected by Salmonella act as 
antigen presenting cells and induce CD8+ T cell proliferation, but activation of CD8+ 
T cells requires the simultaneous activation of Salmonella-specific CD4+ T cells to 
enable T cell help. 
To exclude a role for the tetrameric antibody complex in cross-presentation, we 
analyzed the induction of a CD8+ T cell response by Salmonella-specific primary B 
cells that had taken up Salmonella via their specific BCR. Although the percentage 
of Salmonella-infected B cells was lower compared to B cells that had phagocyosed 
Salmonella via the tetrameric antibody complex, with appropriate CD4+ T cell help 
Salmonella-specific B cells also induce CD8+ T cell activation (Fig. 1D). 
 
Salmonella-infected B cells activate both the central memory and effector 
memory CD8+ compartment 
Do B cells elicit a naïve or a memory CD8+ cell response? To study this, we cultured 
the total CD8+ T cell population with or without Salmonella-infected B cells, in 
presence of CD4+ T cells for help, and determined the naïve (CD45RO-CD27+; TN), 
central memory (CD45RO+CD27+; TCM), effector memory (CD45RO+CD27-; TEM) or 
terminal effector (CD45RO-CD27-; TE) phenotype of the CD8+ T cells after prolonged 
culture. Upon 11 days of culture, purified CD8+ T cells show mainly a naïve 
phenotype. In contrast, following activation with Salmonella-infected B cells, the 
CD8+ population shifts towards the TEM phenotype (Fig. 2A). CD8+ T cells that are 
 80 





Figure 1. Salmonella-infected B cells induce CD8+ T cell proliferation with help of CD4+ T cells. 
(A) CFSE labeled CD8+ T cells were cultured alone (T), together with B cells (B + T) or together 
with B cells that had phagocytosed Salmonella (BSal + T), in presence of CD4
+ T cells. Proliferation 
was measured after 6 days. (B) CD8+ T cell proliferation was measured in absence of CD4+ T cells. 
(C) CD8+ proliferation (shown in A and B) of multiple independent experiments combined. 
Percentages are CD8+CFSElow cells, in the presence of CD4+ T cells (black bars) or not (open 
bars). The data are expressed as mean ± SEM, of twenty-two independent experiments of 
different donors and *** p < 0.001. D, CD8+ T cell proliferation was also measured after culture 
with B cells that had phagocytosed uncoated Salmonella (Bun-Sal) in presence of CD4
+ T cell help. 
The data are expressed as mean ± SEM, of five independent experiments of different donors, and 
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activated with Salmonella-infected B cells in the absence of help by CD4+ T cells, do 
not differentiate to a TEM phenotype (Fig. 2B). As these data indicate that 
Salmonella-infected B cells mainly induce a CD8+ memory response, we 


























































































Figure 2. Salmonella-infected B cells elicit a CD8+ memory response. 
 (A) CD4+ and CD8+ T cells were cultured alone (T), together with B cells (B + T) or with 
Salmonella-infected B cells (BSal + T). After 11 days, cells were stained for CD45RO and CD27 to 
discriminate between the different T cell populations: naïve (TN; CD45RA
+CD27+), central 
memory (TCM; CD45RO
+CD27+), effector memory (TEM; CD45RO
+CD27-) and terminal effector 
(TE; CD45RA
+CD27-) T cells. Gated CD8+ cells were analyzed. (B) Without CD4+ T cells, the 
differentiation of CD8+ T cells to effector memory is attenuated. Data are mean ± SEM from five 
independent experiments. (C) Salmonella-infected B cells activate proliferation of sorted 
CD8+CD45RO+ cells (TMEM), but not of purified CD8
+CD45RA+ cells (TN) in the presence of CD4
+ 
help. Data are mean ± SEM from three independent experiments. D, Salmonella-infected B cells 
activate proliferation of sorted CD8+CD45RO+CD27- (TEM) and CD8
+CD45RO+CD27+ (TCM) cells. 










we studied proliferation of sorted naïve (CD45RA+CD45RO-; TN) or memory 
(CD45RA-CD45RO+; TMEM) CD8+ T cells in response to Salmonella-infected B cells. 
Figure 2C shows that the naïve CD8+ population does not proliferate upon 
stimulation with Salmonella-infected B cells, whereas the memory CD8+ T cells 
proliferated vigorously. Sorting of TCM (CD45RO+CD27+) and TEM (CD45RO+CD27-) 
CD8+ T cells before coculture with Salmonella-infected B cells, showed that both TCM 
and TEM  can be activated by Salmonella-infected B cells. (Fig. 2D). Recent 
experiments in mice show that both TCM and TEM cells can arise from activation and 
proliferation of the TCM compartment, whereas TEM cells are more terminally 
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differentiated and therefore proliferate poorly and only give rise to TEM progeny 
(24). Indeed, expansion of the sorted TCM by Salmonella-infected B cells yielded 
offspring with both a TCM and a TEM phenotype, whereas TEM activation yielded 
mainly TEM progeny. Together, these data show that Salmonella-infected B cells 
activate a recall response of memory CD8+ T cells, yielding expansion of both the 
”memory stem cell” containing TCM compartment and the memory effector cell 
containing TEM compartments.  
 
Activated Salmonella-specific CTLs are able to kill Salmonella-infected cells 
Activation of cytotoxic CD8+ T cells by B cells is controversial. Earlier reports 
showed that B cells induce tolerance or anergy in CD8+ T cells. In contrast, we 
showed proliferation of CD8+ T cells upon B cell activation when B cells had 
phagocytosed Salmonella. Although this proliferation is unlikely to yield tolerance, 
proliferation itself does not guarantee that these B cells activate functional, 
cytotoxic CD8+ T cells. CD8+ T cells kill intracellular pathogens either via secretion 
of IFN-γ or via direct killing of the infected target cell (25). To investigate if 
Salmonella-containing B cells induce a functional CD8+ T cell response, the IFN-γ 
secretion of CD8+ T cells was measured using an intracellular IFN-γ staining. This 
showed that, after culture with Salmonella-infected B cells, the number of CD8+ T 
cells producing IFN-γ is increased to more than 65% (Fig. 3A and 3B). Thus, cross-
presentation of Salmonella antigens by B cells induces not only proliferation of the 
CD8+ T cells but also renders the cells functional in that it initiates IFN-γ secretion.  
As these data demonstrate that B cells that had taken up Salmonella are able to 
functionally activate CD8+ T cells, the question remained if the activated CD8+ T 
cells were Salmonella-specific and whether CD8+ T cells can acquire a cytotoxic 
phenotype through B cell-mediated activation. First, we investigated if the CD8+ 
degranulate their cytotoxic granules upon recognition of Salmonella-infected target 
cells. For this we analyzed expression of the marker CD107a, which is expressed at 
the plasma membrane of CD8+ T cells upon degranulation. Anti-IgM-coated 
Salmonella-infected B cells were cultured together with CFSE labeled CD4+ and 
CD8+ T cells and the proliferating Salmonella-primed CD8+ T cells were sorted after 
6 days. After expansion with IL-2 for another 6 days, the CD8+ T cells were re-
exposed to autologous, Salmonella-infected B cells and CD107a expression was 
measured. Upon re-exposure to Salmonella-infected B cells, the Salmonella-primed 
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Since the proliferating CD8+ T cells did not show degranulation when re-exposed to 
autologous, non-infected B cells, the CD8+ T cells specifically degranulated upon 
recognition of Salmonella-infected cells (Fig. 3C). To confirm our results without 
anti-IgM coating of the bacteria, we also primed CD8+ T cells with Salmonella-
specific B cells that had phagocytosed uncoated Salmonella via the Salmonella-
specific BCR. These primed CD8+ T cells degranulated specifically upon recognition 
of autologous B cells infected with uncoated Salmonella, of which a relative small 
percentage (5%, data not shown) contained Salmonella-infected antigen-specific B 
cells (Fig. 3D; middle bar). In addition, the Salmonella-primed CD8+ T cells very 
efficiently degranulated upon contact with autologous B cells of which a higher 
percentage (26%, data not shown) of cells had been infected with anti-IgM coated 
Salmonella (Fig. 3D; right bar). 
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 Figure 3. Salmonella infected B cells induce Salmonella-specific CD8+ T cells to secrete IFN-γ 
and are cytotoxic.  
(A) CD4+ and CD8+ T cells were cultured alone (T), with B cells (B + T) or with Salmonella-
infected B cells (BSal + T). After 11 days, CD8
+ T cells were analyzed for IFN-γ production by 
intracellular FACS staining. A representative experiment of five independent experiments using 
cells from different healthy donors is shown. (B) Salmonella-infected B cells induce IFN-γ-
expression by CD8+ T cells compared to non-infected B cells. Data are the mean ± SEM from five 
independent experiments of different donors and ** p < 0.01. (C) CD8+ T cells were primed with 
Salmonella-infected B cells and the proliferating CD8+ T cells were sorted after 6 days. Sorted 
CD8+ T cells were restimulated with autologous B cells that had either or not phagocytosed anti-
IgM-coated Salmonella. Salmonella-specific degranulation was measured by CD107a expression 
at the plasma membrane CD8+ T cells. Data are means ± SEM of five independent experiments 
of different donors, and ** p < 0.01. (D) Proliferating CD8+ T cells primed with B cells that had 
phagocytosed uncoated Salmonella were sorted and CD107a expression was measured upon re-
encounter of B cells (T + B), B cells infected with uncoated (T + Bun-Sal) or anti-IgM-coated 
Salmonella (T + BSal). Data are of one experiment. E, Sorted Salmonella-primed CD8
+ T cells 
(see C) specifically kill Salmonella-infected B cells as measured by 51Cr release of autologous B 
cells that were either or not infected with Salmonella. Data are expressed as mean ± SEM, of six 
independent experiments of different donors, and ** p < 0.01. F, Sorted Salmonella-primed 
CD8+ T cells (see C) do not kill Staphylococcus-infected B cells as measured by 51Cr release of 
autologous B cells that were either infected with Salmonella or with Staphylococcus. The data are 


















Finally, we investigated if degranulation of the Salmonella-specific CD8+ T cells also 
leads to death of the Salmonella-infected cells to determine the true cytotoxic 
potential of the lytic granules. CFSE labeled CD8+ T cells were primed by incubation 
with Salmonella-infected B cells and proliferating CD8+ cells were sorted and 
expanded with IL-2 for 6 days. Re-exposure of the Salmonella-primed T cells to 
Salmonella-infected, 51Cr-labeled autologous B cells demonstrated that the primed 
CD8+ T cells were able to kill Salmonella-infected B cells but not non-infected B 
cells (Fig. 3E). In addition, the Salmonella-primed CD8+ T cells were not able to kill 
B cells that had phagocytosed Staphyloccocus via BCR ligation (Fig. 3F), 
demonstrating that the CD8+ cells are indeed Salmonella-specific and do not 
recognize autologous B cells that are activated via BCR-mediated uptake of other 
bacteria. Thus, activation of CD8+ T cells by B cells cross-presenting Salmonella 
antigens induces a cytotoxic phenotype in the CD8+ T cells that specifically 




Cross-presentation of Salmonella antigens is partly proteasome dependent 
We showed that after phagocytosis of Salmonella, B cells are able to cross-present 
antigens to CD8+ T cells and thereby initiate a Salmonella-specific cytotoxic T cell 
response. The mechanism of cross-presentation of Salmonella antigens by B cells is 
unknown. One possible mechanism is that after phagocytosis, antigens are 
translocated from the Salmonella-containing vacuole (SCV) into the cytoplasm of B 
cells. Next, the antigens are degraded in the cytoplasm by proteasomes into small 
peptides, which are presented via the classical MHC class I antigen presentation 
route. To investigate this mechanism of cross-presentation, we used a chemical 
compound that specifically blocks the proteasome (MG-132). To study the effect of 
cross-presentation when blocking the proteasome, we used the CD107a 
degranulation assay. Re-exposure of Salmonella-primed CD8+ T cell to autologous, 
Salmonella-infected B cells showed that by blocking of the proteasome, a 
Salmonella-infected B cell is much less efficient in inducing CD8+ T cell 
degranulation when proteasomes are inhibited (Fig. 4). This observation implies 
that the proteasome is somehow involved in cross-presentation of Salmonella 
antigens by B cells. How the proteasome is involved is unclear as proteasome 
inhibition has many secondary effects on the ubiquitin cycle, the modification of 





































Figure 4. Proteasome inhibition of Salmonella-infected B 




 Salmonella-specific CD8+ T cells were sorted and co-cultured 
with B cells (T + B) or with Salmonella-infected B cells (T + 
BSal). Treatment of B cells with proteasome inhibitor MG-132 
(20 µM) leads to a decrease in degranulation of the 
Salmonella-specific CD8+ T cells (T + B[MG-132]Sal), as 








B cells do not cross-present heat-killed Salmonella 
Salmonella survives inside a cell via expression of the TTSS that create an 
intracellular environment that neutralizes the destructive forces of  the host cell 
(27). The TTSS components SPI-1 and SPI-2 play a role in this neutralization by 
exporting proteins into the host cell. Because of the capacity of Salmonella to 
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invade cells and to control its maintenance inside the cell via SPI-1 and SPI-2, it is 
possible that Salmonella might directly play a role in the cross-presentation by B 
cells. To determine the role of SPI-1 and SPI-2 in cross-presentation of Salmonella 
by B cells, we analysed CD8+ T cells proliferation via co-culture with CD4+ T cells 
and B cells that had phagocytosed wild type Salmonella, or Salmonella with a 
mutation in SPI-1 (invA-) or SPI-2 (ssrA-). Both Salmonella mutants were still able 
to elicit a CD8+ T cell response, albeit at lower percentages of T cell proliferation 
compared to wild type Salmonella (Fig. 5A). Thus SPI-1 and SPI-2 each contribute 
to cross-presentation of Salmonella antigens by B cells, but are not essential. 
By creating an environment in which Salmonella itself cannot be killed, it is possible 
that the intracellular survival plays a role in the efficacy of cross-presentation of 
Salmonella antigens by B cells. To study the contribution of Salmonella on the 
efficacy of cross-presentation of Salmonella antigens, we compared the efficiency of 
living and dead Salmonella to induce CD8+ T cell activation. Living and heat-killed 
Salmonella were coated with the LPS-BCR tetrameric antibody complexes to ensure 
similar levels of bacterial phagocytosis by B cells (data not shown). B cells that 
have phagocytosed dead Salmonella less initiate CD8+ T cell proliferation (Fig. 5B), 
indicating that Salmonella contributes to the process of cross-presentation in B 
cells.  
However, another part of the response continued with dead Salmonella. To confirm 
that Salmonella antigens of dead bacteria are inefficiently cross-presented to CD8+ 
T cells by B cells, we primed CD8+ T cells with B cells infected with living or heat-
killed Salmonella, sorted and expanded the primed T cells followed by re-exposure 
to autologous B cells that had not phagocytosed Salmonella, or had phagocytosed 
either living or dead Salmonella. Cross-presentation of Salmonella antigen was 
measured by the extent of degranulation of the primed T cells using CD107a 
expression.  
CD8+ T cells that had been primed by B cells infected with living Salmonella 
efficiently degranulated upon recognition of autologous B cells that had 
phagocytosed living Salmonella (upregulation of CD107a to 60%), whereas the cells 
did not degranulate upon contact with B cells that had phagocytosed dead 
Salmonella (Fig. 5C; left panel). This indicates either that B cells present different 
Salmonella antigens to CD8+ T cells from live or dead bacteria or that B cells cannot 
cross-present Salmonella antigens when the intracellular bacterium is not alive. 
Furthermore, CD8+ T cells that had been primed with B cells that had taken up  
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Figure 5. Induction of the cytotoxic T cell response against Salmonella by B cells requires uptake 
of living Salmonella. 
 
 
(A) CD8+ T cells were labeled with CFSE and cultured with B cells that had phagocytosed either 
wild type Salmonella (WT), mutant for SPI-1 (invA-) or SPI-2 (ssrA-). Proliferation was measured 
after 6 days. Data shown are proliferation of CD8+ cells relative to wild type proliferation and are of 
two different donors; error bars are SEM. (B) CD8+ T cells were labeled with CFSE and cultured 
with B cells (T + B), or with B cells that have internalized either living Salmonella (T + BSal) of heat 
killed Salmonella (T + BSal-hk). Proliferation was measured after 6 days. C, Salmonella-specific T 
cells that were primed with B cells that had either internalized living (left panel) or dead Salmonella 
(right panel) were sorted and restimulated with B cells (T + B), B cells that had internalized living 
Salmonella (T + BSal) or dead Salmonella (T + BSal-hk). Degranulation was analyzed as CD107a 
expression by CD8+ T cells. D, CD8+ T cell mediated kill was measured as the release of 51Cr by B 
cells. Data are expressed as mean ± SEM, from four (live Salmonella primed) or two (dead 











dead Salmonella showed poor degranulation to B cells that had taken up either live 
or heat-killed Salmonella (Fig. 5C; right panel), demonstrating that B cells indeed 
do not induce a cytotoxic CD8+ T cell response via cross-presentation of Salmonella 
antigens from dead intracellular bacteria. This observation was confirmed by 
studying elimination of Salmonella-infected B cells by 51Cr-release (Fig. 5D). 
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Together, these results show that B cells are not able to cross-present antigens of 
dead Salmonella and that Salmonella contributes to the activation of a Salmonella-
specific cytotoxic CD8+ memory response. 
 
Discussion 
Studies in B-cell-deficient mice showed that protective immunity to Salmonella 
strongly depends on B cells (28). This dependency does not only result from 
antibody generation, as passive transfer of Salmonella-immune serum cannot 
transfer resistance to Salmonella (29). In addition, B cells are involved in the 
generation of a profound CD4+ and CD8+ T cell response after Salmonella infection 
(21), but the precise role of B cells remained unclear. We previously showed that 
human antigen-specific B cells that have internalized Salmonella via their BCR are 
able to induce a Salmonella-specific CD4+ T cell response (20). The data described 
here may explain the role of B cells in immune response against Salmonella 
infection other than antibody formation. In contrast to other data, in which uptake 
of Salmonella does not lead to antigen cross-presentation via MHC class I in mouse 
B cell lines (30), we now demonstrate that Salmonella-specific human B cells that 
have phagocytosed Salmonella via their BCR are capable to induce a strong recall 
response of cytotoxic CD8+ T cells after cross-presentation of Salmonella antigens. 
We previously showed that in the human Ramos B cell line, Salmonella is not only 
capable to survive, but also to replicates intracellularly. In contrast, in primary 
human B cells Salmonella survives, but is unable to replicate inside the B cell (20). 
The incapability to replicate in primary human B cells may play a role in cross-
presentation and activation of CD8+ T cells. A recent report shows that the most 
functional CD8+ T cell responses are induced against Salmonella that do not 
replicate intracellularly (31). These observations may explain our finding why 
Salmonella-specific primary B cells are efficient in cross-presentation of Salmonella 
antigens from the non-replicating bacteria and activate Salmonella-specific CD8+ 
cells that show a functional cytotoxic T cell response. Thus, inhibition of Salmonella 
replication by primary human B cells may be beneficial for cross-presentation to 
CD8+ T cells.  
After internalization by the B cell, Salmonella survives in the SCV. For cross-
presentation, Salmonella-antigens should be loaded onto MHC class I. The TTSS of 
Salmonella could play a role in delivery of antigens in the cytosol by injecting 
proteins directly into the cytosol (32). These proteins can be degraded by the 
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proteasome and after transportation into the ER, loaded onto MHC class I 
molecules. We demonstrated that SPI-1 and SPI-2 contribute to cross-presentation, 
but both are not required separately. It is therefore likely that antigens excreted in 
the host cytosol by SPI-1 and SPI-2 are both used for antigen processing to MHC 
class I. In addition, we showed that B cells were not able to cross-present 
Salmonella-specific antigens of heat killed Salmonella. Thus, Salmonella itself 
appears to be involved in the generation of an effective cytotoxic CD8+ T cell 
response against the bacteria, a phenomenon that points to the occurrence of co-
evolution of bacterial immune evasion and the generation of effective anti-bacterial 
immunity.  
Cross-presentation of Salmonella antigens by B cells leads to activation of a CD8+ 
cytotoxic T cell response, but help of CD4+ T cells is required. The exact kind of 
CD4+ T cells help could be via cell-cell contact or cytokine mediated and is presently 
under investigation.  
Various reports have described that B cells play a role in the expansion of 
Salmonella-specific T cells, but how specific T cell responses are induced is not 
understood. This has been attributed to the fact that antigen-specific B cells are 
probably the main B cell population with an antigen presenting function in 
Salmonella infection and that the frequency of antigen-specific B cells is elevated 
during a secondary infection (reviewed in (33)). Indeed, our data concur with these 
observations as we show that the antigen-specific B cells are the cells that are 
responsible for efficient cross-presentation of Salmonella antigens. In addition, our 
data provide an additional explanation why B cells are mainly involved in the recall 
response; Salmonella-infected B cells do not prime naïve CD8+ T cells, but are very 
efficient in inducing a potent recall response of cytotoxic CD8+ memory T cells. This 
implies that other APCs (e.g. DCs) are still needed to prime naïve CD8+ T cells. In 
secondary infections however, DCs can induce CD8+ proliferation via direct infection 
or via suicide cross-presentation upon ingestion of infected apoptotic cells (22), but 
also B cells are very efficient in generating an anti-Salmonella cytotoxic CD8+ 
responses. In addition, DC were shown to mainly activate the TEM compartment 
(22), whereas Salmonella-infected B cells activate both the TCM and TEM 
compartment. This ensures not only the direct terminal differentiation of effector 
memory cells, but also the expansion of the Salmonella-specific CD8+ memory T 
cell compartment, which may both amplify the anti-Salmonella immune response 
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and simultaneously ensure generation of anti-Salmonella memory for further 
reinfections.  
In summary, we propose a model on the role of B cells in the generation of the 
humoral and cellular immune response against Salmonella. After infection, 
Salmonella enters the body via DCs that activate CD4+ and CD8+ T cells or via M 
cells after which it encounters B cells, which are situated in the Peyer’s Patches, 
directly under the M cells. Salmonella-specific B cells internalize Salmonella via 
their BCR and are activated. Next, internalization of Salmonella leads to 
presentation of Salmonella antigens MHC class II molecules and activates 
Salmonella-specific CD4+ T-helper cells that stimulate Salmonella-infected B cells to 
secrete Salmonella-specific antibodies (20), either locally or upon arrival or the 
infected B cells in the mesenteric lymph node. Upon re-infection, infection of 
Salmonella-specific memory B cells by Salmonella ensures rapid antibody 
production but also mediates a strong cytotoxic CD8+ recall response to eliminate 
infected cells. The Salmonella-specific CD4+ response that aided antibody 
production in early stages of the immune response is now also required for the 
reactivation of the cytotoxic T cell response against Salmonella in later stages of 
the immune response or upon reinfection. Thus, uptake of Salmonella by antigen-
specific B cells may generate a survival niche for Salmonella, but at the same time 
strongly contributes to the generation of effective anti-Salmonella immunity at 
multiple levels of the adaptive immune response. The combined attack of 
pathogens by various members of the adaptive immune system will allow efficient 
eradiation of the infection.  
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Effective antitumor responses need the activation of CD4+ T cells. MHC class II 
antigen presentation requires the release of class II-associated invariant chain 
peptide (CLIP) from the antigen-binding site. In antigen-presenting cells, human 
leukocyte antigen DM (HLA-DM; abbreviated DM in this article) catalyzes CLIP 
dissociation. In B cells, HLA-DO (DO) down-modulates DM function. Cell surface 
CLIP:HLA-DR (DR) ratio correlates to DO:DM ratio and the efficacy of antigen 
presentation. We examined 111 blood and bone marrow samples of patients with 
newly diagnosed acute myeloid leukemia (AML) for the expression of CLIP, DR, DM, 
and DO by flow cytometry. Patients with DR+/CLIP– blasts had a significant longer 
disease-free survival than patients with DR+/CLIP+ blasts. DO, until now believed 
to be restricted to lymphoid cells, could be demonstrated at protein level as well as 
by reverse transcription-PCR. DO:DM ratio correlated to CLIP:DR ratio, suggesting 
that, unlike in other antigen-presenting cells of the nonlymphoid cell type, both DO 
and DM mediate regulation of CLIP expression in AML blasts. We hypothesize that 
DR+/CLIP– AML blasts are able to present leukemia-specific antigens to CD4+ T 
helper cells initiating an effective and long-lasting antitumor response resulting in a 
prolonged disease-free survival.  
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Introduction 
The role of MHC class II molecules presenting tumor antigens to CD4+ T helper 
cells in antitumor responses is well established (1). The major MHC class II 
molecule, DR, consists of an α and β chain that, after translocation to the 
endoplasmic reticulum, form a complex with the invariant chain (Ii) (2). Ii serves as 
a chaperone for newly synthesized class II molecules and prevents the binding of 
undesired antigen in the endoplasmic reticulum. The Ii is cleaved in the 
endosomal/lysosomal pathway until only a small remnant, called class II-associated 
invariant chain peptide (CLIP), remains associated with the antigen-binding groove 
(3). Release of CLIP is necessary for replacement with antigens, a process 
catalyzed by DM, a nonclassical MHC class II molecule (4). In mice lacking DM, 
CLIP is not released from the antigen-binding site and severely injures antigen 
presentation (5). In B cells and thymic epithelial cells, DO, another nonclassical 
MHC class II molecule, associates with DM. DO down-modulates the catalytic 
activity of DM in a pH-dependent manner, thus altering the repertoire of presented 
antigens (6). By expression of different levels of DM and DO, B cells regulate the 
antigen presentation capacity of their MHC class II molecules (7). High cell surface 
expression of CLIP correlates with a high DO:DM ratio and can be viewed as an 
indicator for low effectiveness of antigen presentation (8). 
In MHC class II negative tumors, the activation of CD4+ T cells relies on 
presentation of tumor antigens by professional antigen-presenting cells (APCs). 
MHC class II transfection studies in mice have shown that, upon expression of MHC 
class II molecules, tumor cells can present their tumor antigens directly to CD4+ T 
cells, thus bypassing the need for professional APCs (9). Moreover, simultaneous Ii 
suppression by antisense therapy revealed that these cells present endogenous 
tumor antigens and can mount a tumor-specific immune response (10). DR+/Ii– 
tumor cells, which are believed to present an optimal range of endogenous tumor 
antigens, are the predominant APC in vivo and have been demonstrated to be 
potent vaccines for tumor-bearing mice (11). Moreover, as recently described (12), 
human DR+/Ii–/CD80+-transfected tumor cell lines were demonstrated to elicit 
tumor-specific T-cell responses.  
In AML, acquired mutations of the hematopoietic stem cells block differentiation. 
The result is accumulation of immature cells in the bone marrow and peripheral 
blood, often accompanied by suppression of the normal blood cells. With 
chemotherapy and stem cell transplantation, 70% of patients achieve complete 
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remission, but approximately one half of these patients relapse (13). Although AML 
blasts generally express MHC class II molecules and costimulatory molecules (14), 
they must have escaped the initial immune response in acute disease status. We 
hypothesize that in the situation of minimal tumor burden, i.e., after achieving 
complete remission, AML blasts with a functional MHC class II complex could evoke 
effective immunosurveillance. In this study, we report that CLIP expression could 
be detected on AML blasts. Furthermore, we found a strong correlation between a 
high level of CLIP-positive AML blasts and a shortened disease-free survival. Also, 
the regulation of CLIP dissociation was studied. Strikingly, DO expression, until now 
demonstrated only in lymphoid cells (15), was demonstrated in AML blasts. This 
indicates that, in these myeloid cells, both DO and DM contribute to the efficacy of 
CLIP-antigenic peptide exchange.  
 
Materials and methods 
Patients 
After informed consent, blood and bone marrow samples were collected from 111 
patients with previously untreated AML between 1992 and 2003. Patients were 
classified according to the French-American-British (FAB) classification (13). 
Patients with promyelocytic leukemia (FAB-M3), whose leukemic blasts were DR 
negative, were excluded. Patients received remission induction and consolidation 
therapy according to HOVON (Dutch-Belgian Hematology-Oncology Cooperative 
Group) protocols. Cytogenetic risk group was defined as favorable [t(8;21), or 
inversion (16)], standard (neither favorable nor adverse), or adverse [complex 
karyotype, –5 or –7, deletion(5q), abnormality 3q or 11q] (13). Human leukocyte 
antigen (HLA) allotype was diagnosed with a serological microcytotoxic assay 
(Sanquin Research at CLB, Amsterdam). Disease-free survival was defined as the 
time period between achievement of complete remission and the moment of 
relapse or the last date of follow-up in nonrelapsed patients. Patient characteristics 
are shown in Table 1 and reflect a representative AML patient group.  
 
Mononuclear Cell Isolation 
Bone marrow mononuclear cells and peripheral blood mononuclear cells, withdrawn 
before the start of therapy, were collected through density-gradient centrifugation 
(Ficoll-PaquePLUS, Amersham Biosciences). Samples were analyzed immediately or 
cryopreserved in liquid nitrogen until analysis. For mRNA detection, cryopreserved 
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samples were thawed and the CD45dim/CD19-/7AAD-population (representing 
living myeloid leukemic, non-B cells) was isolated by sorting [FACS Vantage, Becton 
Dickinson (BD)]. Purity was always >99%.  
 
Antibodies and Flow Cytometry Analysis 
The following mouse antibodies were used: FITC-labeled anti-HLA-ABC (Dako), 
anti-DR (BD), CD86 (BD), anti-DO (BD PharMingen), CD22 (BD); phycoerythrin-
labeled anti-DM (BD PharMingen), CD19 (Dako), CD20 (BD), CD14 (BD); peridinin 
chlorophyll protein-labeled CD45 (Coulter); allophycocyanin-labeled CD34 (BD); 
and 7-AAD (Via-Probe, BD PharMingen). CerCLIP.1 was kindly provided by P. 
Cresswell (Howard Hughes Medical Institute, Yale University School of Medicine, 
New Haven, CT; ref. 4). Mononuclear cell fractions were preincubated with 10% 
human gammaglobulin (6 mg/ml; Sanquin, Amsterdam), followed by incubation 
with directly labeled antibodies. For CLIP detection, cells were incubated with 
CerCLIP and subsequently with phycoerythrin-conjugated rabbit-antimouse 
immunoglobulin (Dako). A mixture of nonrelevant mouse antibodies of different 
isotypes was added to avoid aspecific binding of subsequently directly labeled 
antibodies. For intracellular staining with DO or DM antibodies, cells were, after 
plasma membrane staining, fixed with PBS-1% paraformaldehyde and 
permeabilized with PBS-0.05% saponine. All of the incubations were performed at 
room temperature during 15 min for extracellular and 30 min for intracellular 
staining. Cells were washed after every incubation step with PBS-0.1% BSA-0.05% 
sodiumazide and analyzed on a FACSCalibur (BD). 25,000 living cells on a forward 
scatter were analyzed using CellQuest software (BD). Blasts were defined as 
CD45dim/SSClow. Mean fluorescence intensity index (MFI) was defined by the 
following formula:  
 
Mean fluorescence (total population) - Mean fluorescence (isotype control) 
Mean fluorescence (isotype control) 
 
The capability of eliciting effective antitumor immune responses is likely to depend 
on the total number of DR molecules that are not occupied by CLIP. To take both 
the number of DR- and CLIP-positive cells, as well as the amount of DR and CLIP 
molecules per cell, into consideration, we defined CLIP expression in respect to 




MFI  CLIP 
Relative CLIP amount =      x 
Percentage CLIP+ cells 
MFI  DR Percentage DR+ cells  
Real-Time Reverse Transcription-PCR 
Six samples of leukemic myeloid blasts with different DO and DM protein expression 
were selected with the purpose of correlating protein expression with mRNA 
expression. Sorted cells (see above) were lysed in peqGOLD Trifast (PeQlab, 
Erlangen, Germany). GlycoBlue (Ambion, Austin, TX) was added as a carrier, and 
total RNA was extracted according to the manufacturer’s instructions. First-strand 
cDNA was reverse transcribed using random hexamers [pd(N)6; Amersham 
Biosciences, Piscataway, NJ] and a SuperScript II, RNase H-reverse transcriptase 
kit (Invitrogen, Breda, the Netherlands). Gene expression was measured in the ABI 
PRISM 7000 sequence detection system (Applied Biosystems, Foster City, CA). 
Selection and specificity of the primers (B&G Biotech, Freiburg, Germany) have 
been described previously (16). The sequences of the primers are as follows: DO , 
forward 5'-GAGCCATCAACGTGCCTC-3', reverse 5'-AGTGACAGTTTGGCCGTTG-3'; DOβ, 
forward 5'-GGAGAAAGATGCTGAGTGGC-3', reverse 5'-AGGGAGCAGAACAGCTCTTG-3'; and 
DMβ, forward 5'- CCAGCCCAATGGAGACTG-3', reverse 5'- CAGCCCAGGTGTCCAGTC-3'. As 
endogenous control, primers specific for human 18S rRNA were used, forward 5'-
CGGCTACCACATCCAAGGAA-3' and reverse 5'-GCTGGAATTACCGCGGCT-3'. Relative 
quantitation of gene expression was determined using the comparative threshold 
cycle method as suggested by the manufacturers. All of the results were normalized 
with respect to the internal control 18S rRNA and are expressed relative to CD19-
positive B cells from healthy donors. We used the T2 cell line as a negative control, 




Statistical analyses were conducted with a SPSS 9.0 software program. To analyze 
associations between variables, Spearman’s correlation coefficient was used. 
Differences between patient characteristics were analyzed with the Mann-Whitney U 
and the 2 test. For survival data, Kaplan-Meier curves were constructed and 
compared by the log-rank test. To explore the simultaneous effect of several 
variables on disease-free survival, the Cox regression model was used. Relative 
CLIP amount was log transformed, yielding a normally distributed variable. 
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Results 
Flow Cytometry Studies 
We analyzed the cell surface expression of HLA-ABC, DR, CLIP, CD80, CD86, and 
CD40 expression on 111 samples of patients with AML. In line with previous 
observations (14), we found a consistently high percentage of cells expressing HLA-
ABC, a low percentage expressing CD80, and a variable percentage expressing DR, 
CD86, and CD40. The percentage of cells with CLIP expression was variable (Table 
1). All of the samples allowed clear analysis of these markers (Fig. 1). Double 




Figure 1. Example of CLIP, 
DR, DO and DM expression 
on myeloid leukemic blasts 
(gate R2: CD45dim/SSClow) 
with appropriate isotype 
controls (gated on 99% of 
the population).  
Double labeling of CLIP and 
DR was not possible due to 





CLIP expression did not differ between peripheral blood and bone marrow samples, 
nor did it change after freezing and thawing (n = 4; data not shown). CLIP 
expression did not vary significantly among several FAB classes. Because cell 
surface expression of CLIP on blood and bone marrow cells was described only on 
mature B cells and monocytes (7), we investigated the cross-lineage expression of 
CD19, CD20, and CD22 (as B-cell markers) and CD14 (monocytoid marker) on AML 
blasts. No correlation between relative CLIP amount and these markers was 
observed (neither for MFI nor for percentage; P = 0.37, 0.32, 0.56, 0.28, and 0.53, 
0.27, 0.81, 0.21, respectively). Finally, we tested whether differences in CLIP 
expression were a reflection of DR allotype. We did not observe however, any 
relationship between DR allotype and CLIP expression (n = 19; data not shown) as 
was suggested previously (18).  
 
Correlation of Relative CLIP Expression with Clinical Data 
To test the hypothesis that a functional MHC II complex (DR+/CLIP–) would result 
in higher antigen-presenting capacity and, hence, a survival benefit, we excluded 
11 DR- patients. We observed no differences in relative CLIP amount between 
patients that achieved complete remission and those that did not (P = 0.15). In 
AML patients, most relapses occur within 2 years. Therefore, we compared the 
relative CLIP amount between patients who survived at least 24 months after 
complete remission and those who suffered relapse within this period. Significantly 
lower relative CLIP amount was observed in patients with prolonged remission 
compared with that in patients who relapsed before 24 months (P = 0.04). In 
clinical practice, the percentage of positive cells of different markers is used to 
determine the phenotype of leukemic blasts. AML patients without relapse had a 
maximum level of 33% CLIP-positive AML blasts. A cutoff level of 35% resulted in 
strongly deviating Kaplan-Meier curves (P = 0.015) that clearly demonstrated the 
survival advantage for DR+/CLIP– patients (Fig. 2). To exclude good- and poor-risk 
patients based on cytogenetic risk profile, a similar Kaplan-Meier curve including 
only patients with an intermediate cytogenetic risk profile was constructed. The P 
value was slightly increased (0.08) because of the smaller group size (Fig. 2).  
Because the relative CLIP amount was not related to the capability of patients to 
achieve complete remission, the cytogenetic risk profile, which is currently the best 
predictive variable for outcome for AML patients, remained a stronger predictor for  
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Table 1. Patients’ characteristics and flow cytrometric expression of different markers (percentage 
of positive cells) on myeloid blasts of total group and different subgroups (DR- defined as <10% of 









patients  with 
DR+/CLIP+ blasts
Number of patients 111 11 78 22
Male/female 56/55 5/6 39/39 11/11
Age at diagnosis, y, mean (range) 52  (16-79) 46 (23-77) 52 (16-77) 52 (22-79)
WBC at diagnosis (range) 67 (1-300) 73 (1-300) 70 (1-282) 58 (1-246)
follow-up in months, mean (range) 21 (0.03-113) 21 (0.46-58) 23 (0.03-113) 14 (0.7-80)
complete remission rate, number (%) 85 (75) 9 (82) 59 ( 76) 15 (68)
DFS, mean (95% CI) * 41 (30-53) 32 (16-50) 48 (34-62) 11 (5-18)
Fab classification. number (%)
     AML M0 6 (5) 2 (18) 2 (3) 2 (10)
     AML M1 17 (15) 5 (46) 8 (10) 4 (18)
     AML M2 21 (19) 3 (27) 15 (19) 3 (14)
     AML M4 29 (26) 0 25 (32) 4 (18)
     AML M5 29 (26) 0 20 (26) 9 (41)
     AML M6 4 (4) 1 (9) 3 (4) 0
     RAEB-t 4 (4) 0 4 (5) 0
     Not classified 1 (1) 0 1 (1) 0
Cytogenetic risk group, number  (%)
    Favorable 9 (8) 0 9 (11.5) 0
    Standard 65 (59) 8 (73) 45 (58) 12 (55)
    Adverse 17 (9) 2 (18) 11(14) 4 (18)
    No metaphasis 14 (13) 0 11 (14) 3 (13.5)
    Not done 6 (5) 1 (9) 2 (2.5) 3 (13.5)
CD40 (%) † 25.7 2 28.8 26.6
CD80 (%) 1.3 0.6 1.6 0.8
CD86 (%) ‡ 22.4 4.4 24.2 25.5
MHC class I (%) 98.8 98 98.6 99.6
MHC class II (%) 66.2 1.18 70.7 83
CLIP (%) 19.8 4.1 12.3 54.5
HLA-DM (%) § 55.6 0.62 61.1 59.5
HLA-DO (%) 16.5 26.5 15.3 16.4
A. Clinical characteristics of patients






















Abbreviations: WBC, white blood cell count; CR, complete remission; DFS, disease-free survival; CI, 
confidence interval, RAEB-t, refractory anemia with excess blasts in transformation. 
 
 
* Significant differences were seen in DFS between DR+/CLIP+ and DR+/CLIP- patients (P = 0.015, 
log-rank). Differences in other characteristics were not significant. 
 
† Significant differences were seen in CD40 expression between DR+ and DR- patients, (P = 0.001, 
Mann-Whitney U test). Differences in other characteristics were not significant. 
 
 
‡ Significant differences were seen in CD86 expression between DR+ and DR- patients, (P = 0.003, 
Mann-Whitney U test). Differences in other characteristics were not significant. 
 
 
§ Significant differences were seen in HLA-DM expression between DR+ and DR- patients,  








overall survival than did the relative CLIP amount (P = 0.06 versus P = 0.08, Cox 
regression). However, after achievement of complete remission, when the immune 
surveillance is supposed to control disease status, relative CLIP amount was a 
better predictor than cytogenetic risk profile (P = 0.06 versus P = 0.36, Cox 
regression) for the duration of the disease-free survival.  
Antigen presentation in the absence of adequate costimulatory signals leads to 
anergy. DR+/CLIP– blasts do express costimulatory molecules like CD86 and CD40. 
DR+ cells showed significantly higher expression levels of CD86 and CD40 as 
compared with DR– cells (P = 0.003 and 0.001, respectively), apparently above the 
minimal threshold required for effective costimulation.  
 All patients


















Patients with intermediate cytogenetic risk profile


























 Figure 2. Kaplan-Meier analyses for disease-free survival. 
 Left panel, All patients, significant differences were seen between DR+/CLIP- and DR+/CLIP+ 
(cutoff 35% of cells CLIP positive), P = 0.015 (log-rank). Right panel, including only patients 




Regulation of CLIP Expression Level by HLA-DO 
To elucidate the mechanism underlying the regulation of CLIP expression in AML 
blasts, we analyzed 89 samples for intracellular DO and DM expression by flow 
cytometry (Fig. 1). Surprisingly, DO was readily detectable in myeloid blasts. In B 
cells, the intracellular DO:DM ratio correlates with the cell surface CLIP:DR ratio. In 
AML blasts, we also could demonstrate a correlation [Fig. 3, left panel ; P = 0.001, 
correlation coefficient (R) = 0.46], indicating a functional role of DO and DM for cell 
surface CLIP expression in AML blasts similar to that in B cells. In B cells, reduced 
DO:DM ratio levels could not be explained by similar changes in transcriptional 
regulation (8). We assessed six samples of blasts with different DO and DM protein 
expression levels for DOα, DOβ, and DMβ that were readily detectable (Fig. 3, right 
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panel). As in B cells, however, a significant correlation between transcription level 











 Figure 3. Left panel: ratio of percentage of CLIP+ to percentage of DR+ cells (CLIP:DR ratio) 
correlated to the ratio of DO+ to percentage of DM+ cells (DO:DM ratio) (Spearman, P < 
0.001, r = 0.46, 10 log values yielding normal values). Right panel: relative gene expression 
levels of DOα, DOβ and DMβ of negative (T2/B27) and positive (B cells) control and 3 






Aberrant MHC class I antigen presentation can function as a mechanism of tumor 
immune escape. The importance of antigen presentation via the MHC class II 
pathway for establishing effective antitumor immunity via proper CD4+ helper 
activation is still an emerging topic of research. Here, we report that AML blasts 
consistently express high levels of MHC class I molecules, whereas MHC class II is 
variably expressed. Moreover, we show for the first time that differences in class II 
antigen presentation are associated with the clinical outcome of disease in humans. 
The immune system as surveillant in AML is not likely to play a role at the moment 
of diagnosis (when an enormous tumor burden exists), but rather during the period 
of minimal residual disease (when the patient has achieved complete remission). 
Indeed, we demonstrated in this study that the level of relative CLIP amount does 
not influence the probability of patients to achieve complete remission but that 
patients in complete remission with a high percentage DR+/CLIP– AML blasts have 
a significantly better disease-free survival rate compared with patients with 
DR+/CLIP+ blasts. Our finding strongly indicates that, analogous to mouse MHC 
class II+/Ii–tumor cells, the release of CLIP from the DR-binding site, and 
subsequent presentation of a broad panel of tumor antigens to CD4+ helper cells, is 
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a prerequisite for an effective and long-lasting antitumor response. Because of the 
lack of effective methods for identifying MHC class II-restricted tumor antigens in 
small samples of patient material, proof of this hypothesis will be difficult, but 
functional studies to demonstrate the higher immunogenicity of DR+/CLIP– blasts 
are currently being undertaken in our laboratory. 
At first sight, our finding seems to contradict the fact that the patients with the 
FAB-M3 subtype, which is DR negative, have a better prognosis than patients with 
the other subtypes. However, FAB-M3 blasts present a highly immunogenic fusion 
protein (PML-RAR ), via their MHC class I molecule or via professional APCs, to the 
immune system (19). 
Until now, expression of DO as a coregulator of antigen-presenting capacity was 
observed only in B cells that have acquired B-cell receptor expression. B cells 
regulate their antigen-presenting capacity during differentiation by differing levels 
of DO, compared with less varying DM expression (8). Loss of DO favors more 
efficient peptide loading on removal of CLIP. We were also able to demonstrate the 
presence of DO in myeloid blasts and to relate a low DO:DM ratio to a low cell 
surface CLIP:DR ratio. As in B cells, the absence of relationship between mRNA and 
protein levels of DO, which could be due to protein degradation (20), is an issue 
that needs further investigation.  
We conclude that cell surface CLIP expression on AML blasts seems to be regulated 
by the balance of both DO and DM and shows a striking correlation with disease-
free survival, pointing to the active involvement of the MHC class II presentation 
pathway. Ineffective MHC class II antigen presentation seems to be an immune 
escape mechanism of AML blasts that offers opportunities for developing 
immunotherapy for AML patients based on manipulation of the MHC class II 
antigen-processing pathway.  
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In human B cells, effective MHC class II-antigen presentation depends not only on 
MHC class II, but also on the Invariant chain (CD74 or Ii), HLA-DM (DM) and HLA-
DO (DO), the chaperones regulating the antigen loading process of MHC class II 
molecules. We analyzed immediate ex vivo expression of HLA-DR (DR), Ii, DM and 
DO in B cell chronic lymphocytic leukemia (B-CLL). Real-time RT-PCR demonstrated 
a highly significant upregulation of DRA, CD74, DMB, DOA and DOB mRNA in 
purified malignant cells compared to B cells from healthy donors. The increased 
mRNA levels were not translated into enhanced protein levels but could reflect 
aberrant transcriptional regulation. Indeed, upregulation of DRA, DMB, DOA and 
DOB mRNA correlated with enhanced expression of class II transactivator (CIITA). 
In-depth analysis of the various CIITA transcripts demonstrated a significant 
increased activity of the IFN-γ-inducible promoter CIITA-PIV in B-CLL. Comparison 
of the aberrant mRNA levels with clinical outcome identified DOA mRNA as a 
prognostic indicator for survival. Multivariate analysis revealed that the prognostic 
value DOA mRNA was independent from the mutational status of the IGHV genes. 
Thus, aberrant transcription of DOA forms a novel and additional prognostic 
indicator for survival in B-CLL. 
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Introduction 
B-cell chronic lymphocytic leukemia (B-CLL) is the most common form of leukemia 
in adults in the Western world. A highly variable clinical course is typical for the 
disease is, with survival rates varying between a few months and two decades (1). 
B-CLL is characterized by a progressive accumulation of a malignant B cell 
population that fails to undergo apoptosis. Apparently, the immune system is 
unable to deal with this abnormal cell population. Indeed, B-CLL is characterized by 
striking immune incompetence in which not only the number but also the function 
of the B and T cells is impaired (2). 
MHC class II molecules play a pivotal role in the induction and regulation of an 
antigen-specific immune response. MHC class II antigen presentation activates 
antigen-specific CD4+ T cells. The biosynthesis pathway of MHC class II is now 
understood in detail. MHC class II molecules bind exogenous antigens generated in 
the endosomal/lysosomal pathway. After synthesis, the MHC class II molecule is 
directed into this pathway by associating to the invariant chain (CD74 or Ii) (3). 
During transport to the lysosomal-like MHC class II-containing compartments 
(MIICs), where the majority of antigen loading occurs, CD74 is proteolytically 
removed, leaving only a small fragment [class II-associated invariant chain 
peptides (CLIP)] in the MHC class II peptide binding groove (4). Release of CLIP is 
facilitated by the specialized chaperone human leukocyte antigen (HLA) HLA-DM 
(DM), a MHC class II-like molecule. DM catalyses the natural process of peptide 
dissociation from MHC class II (5), thereby releasing both CLIP and other low 
affinity binding peptides. Consequently, DM acts as a peptide editor, favouring 
presentation of stable binding antigens (6-9). HLA-DO (DO), a heterodimer 
composed of a DOα and DOβ chain, is selectively expressed in B cells and regulates 
the action of DM in a pH-dependent manner. We and others reported that DO 
reduced MHC class II-mediated presentation of antigenic peptides in general and 
modulated the antigenic peptide repertoire by facilitating presentation of certain 
antigenic peptides, while suppressing others (10-13). DO therefore both limits and 
skews the class II-presented antigenic peptide repertoire in B cells. The balance 
between DO and DM expression thus seems to be a key factor in controlling antigen 
presentation in B cells, which may explain why in healthy B cells DO and DM 
expression are tightly regulated at various levels (14). 
Transcription of MHC class II, DM and DO is regulated by a master regulator, 
termed the class II transactivator (CIITA) (15, 16). CIITA is transcriptionally 
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controlled by four distinct promoters, each transcribing a unique first exon and 
yielding a unique CIITA transcript (17). A physiological role for CIITA-PII is 
questioned as transcripts originating from this promoter are rare. The promoters I, 
III and IV are differentially used in different cell types and in response to 
inflammatory stimuli. CIITA-PI is constitutively active in myeloid dendritic cells 
(DCs) and CIITA-PIII constitutively in B cells, plasmacytoid DCs, monocytes and 
activated T cells (18). CIITA-PIV has been shown to be the promoter predominantly 
involved in IFN-γ-inducible CIITA expression (19, 20). In healthy B cells 
transcription of the MHC class II genes is tightly regulated by CIITA, but 
dysregulation has been observed in tumors (21-23).  
The purpose of this study was to perform an overall, in depth investigation of 
transcription and translation of the genes involved in MHC class II antigen 
presentation in a small, but very well-defined B-CLL cohort and to determine 
whether transcriptional aberrancies occurred and if so, whether they correlated to 
clinical outcome.  
 
Materials and methods 
Patients and healthy volunteers 
Peripheral blood samples from 21 B-CLL patients were obtained after informed 
consent according to the declaration of Helsinki and samples were anonymized 
before analysis. Patients were diagnosed and staged based on standard 
morphologic and immunophenotypic criteria (24). Patient characteristics are shown 
in Table 1. Cytogenetic data are not available because this was not routinely 
performed at the time of sample collection. Out of the 21 patients, 15 had not 
received chemotherapy at the time of sample acquisition and six patients had 
received prior treatment. Patients that had received treatment were equally 
distributed between the groups with mutated and unmutated IGHV genes. Buffy-
coats from healthy donors were obtained from the Sanquin blood supply foundation 
(Sanquin, Amsterdam, The Netherlands). 
 
Purification of primary B cells 
Peripheral blood mononuclear cells (PBMCs) were isolated by centrifugation on a 
Ficoll-Hypaque gradient (Pharmacia, Uppsala, Sweden) and B cells were purified 
using anti-CD19 Dynabeads and DETACHaBEAD (Dynal, Oslo, Norway), according 
to the manufacturer's instructions. The cell purity and viability was >99% as 
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determined by FACS analysis (data not shown). Purified primary B cells were 
pelleted, snap frozen and stored at -80C until further use. For purification of 
malignant leukaemic cells from B-CLL blood samples, mononuclear cells were 
stained with fluorescein isothiocyanate (FITC)-conjugated anti-CD19 
(Dakocytomation, Heverlee, Belgium) and phyoerythrin (PE)-conjugated anti-CD5 
(Dakocytomation). The CD5+CD19+ population was purified by FACS sorting using a 
MoFlo Sorter (Dakocytomation), pelleted, snap frozen and stored at -80C until 
further use. Purity was >99% as determined by FACS analysis (data not shown). 
 
Real-time PCR 
CD5+CD19+ cells were lysed in peqGOLD Trifast (PeQlab, Erlangen, Germany). 
GlycoBlue (Ambion, Austin, TX) was added as a carrier and total RNA was extracted 
according to the manufacturer’s instructions. First strand cDNA was reverse 
transcribed using random hexamers (pd(N)6, Amersham Biosciences, Piscataway, 
NJ) and a SuperScript II, RNase H-reverse transcriptase kit (Invitrogen, Breda, The 
Netherlands). Gene expression was measured in the ABI PRISM 7000 sequence 
detection system (Applied Biosystems, Foster City, CA). Primers were selected to 
span exon-intron junctions to prevent amplification of genomic DNA. Primer sets 
(sense sequence, antisense sequence and transcript size, respectively) for the 
following genes were used: 
HLA-DRA (5'-CATGGGCTATCAAAGAAGAAC-3', 5'-CTTGAGCCTCAAAGCTGGC-3', 180 bp) 
HLA-DMB (5'-CCAGCCCAATGGAGACTG-3', 5'-CAGCCCAGGTGTCCAGTC-3', 136 bp) 
HLA-DOA (5'-GAGCCATCAACGTGCCTC-3', 5'-AGTGACAGTTTGGCCGTTG-3', 146 bp) 
HLA-DOB (5'-GGAGAAAGATGCTGAGTGGC-3', 5'-GCTCTTGAGACCTCATTACC-3', 133 bp) 
CD74 (5'-CACCTGCTCCAGAATGCTG-3', 5'-CAGTTCCAGTGACTCTTTCG-3', 210 bp) 
Total CIITA (5'-AACCCTCAATCTGTCCCAG-3', 5'-TGTACTGGACGTCCATCAC-3', 191 bp) 
For specific CIITA promoter transcripts, primer pairs analogous to Hornell et al. were used 
(25): 
CIITA-PI (5'-GGAGACCTGGATTTGGCCC-3', 5'-GAAGCTCCAGGTAGCCACCTTCTA-3', 145 bp) 
CIITA-PIII (5'-GGGGAAGCTGAGGGCACG-3', 5'-GAAGCTCCAGGTAGCCACCTTCTA-3', 182 bp) 
CIITA-PIV (5'-GCGGCCCCAGAGCTGG-3', 5'-GAAGCTCCAGGTAGCCACCTTCTA-3', 125 bp). 
As endogenous control, primers specific for human 18S rRNA were used (5'-
CGGCTACCACATCCAAGGAA-3', 5'-GCTGGAATTACCGCGGCT-3', 187 bp). Product 
specificity of each primer set was verified by agarose gel electrophoresis and by 
dissociation curve analysis. PCR products were further confirmed by sequence 
analysis. Transcript levels and relative gene expression of mRNA were determined 
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as described by Pfaffl (26). All results were normalized for starting template with 
respect to the internal control, and were expressed relative to the expression levels 
found in one of the CD19+ B cells from a healthy donor. 
 
SDS-PAGE and Western blot analyses 
The DR-specific monoclonal antibody (mAb) 1B5 (27), DM-specific mAb 5C1 
(28), the previously described DO polyclonal Ab (10) and the anti-actin mAb Ab-1 
(Oncogene Research Products, Boston. MA) were used for Western blot analyses. 
Cells were lysed in 1% Nonidet P-40 (NP-40) lysis buffer [50 mM Tris/HCl (pH 8.0), 
150 mM NaCl, 5 mM EDTA and protease inhibitors] for 30 minutes at 4°C and 
centrifuged for 30 minutes at 10,000 x g at 4°C. The protein content of the cell 
lysates was quantified using the BCA protein assay (Pierce, Rockford, IL). For 
Western blot analysis, equal amounts of proteins were boiled for 5 minutes in 
reducing Laemmli sample buffer and separated by SDS-PAGE on 12% 
polyacrylamide gels and transferred onto polyvinylidene difluoride (PVDF) 
membranes (Immobilon P, Millipore Corp., Bedford, USA) in 25 mM Tris, 192 mM 
Glycine, 20% methanol, pH 8.3. Membranes were blocked in 5% skimmed milk in 
phosphate-buffered saline (PBS). Ab binding (in 5 % skimmed milk in PBS) was 
detected by incubation with secondary horseradish peroxidase-conjugated rabbit 
anti-mouse or swine anti-rabbit immunoglobulin Abs (Dakocytomation), followed by 
enhanced chemiluminescence detection (Amersham). Washes were performed 
using 0,1% Triton X-100 in PBS. For semi-quantitative analysis of the Western 
blots, subsaturated autoradiograms were scanned and the signals analyzed using 
TINA 2.09 software (Raytest, Staubenhardt, Germany). The relative expression 
levels were correlated to the cellular actin levels, measured as a reference in each 
sample on the blots. 
 
Determination of mutation status 
The mutational status of the immunoglobulin heavy chain variable (IGHV) genes of 
20 patients was determined as described (29). Patient 16 had no material available 
for IGHV analysis. In brief, IGHV transcripts were amplified using a mixture of 
forward primers located in the FR1 regions of the IGHV gene families IGHV1 to 
IGHV6 or alternatively in the FR3 region of IGHV1 to IGHV6 in combination with 
one of the FAM-labelled reverse primers located in the Cμ, Cδ, Cα or Cγ regions. 
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Less than or equal to 2% difference from the most homologous germ line gene was 
considered to be mutated.  
 
Statistical methods 
Statistical analyses were conducted with the SPSS 15.0 software program. 
Differences between groups were analyzed with the 2-sided Mann-Whitney U test. 
For correlations, the Spearman non-parametric correlation test was used. 
Multivariate analysis was performed using the Cox's proportional-hazards model. P 
< 0.05 were considered statistically significant.  
Survival time after sampling was measured from the time of sampling until death, 
or until the end of follow-up. Survival curves were constructed using the Kaplan-
Meier method. Differences between curves were analysed using the Log-rank test. 
The optimal cut-off value for DOA transcription levels in this patient cohort was 
determined using two methods: (i) the Log-rank test, by testing the prognostic 
value for each possible cut-off point (3.1, 3.2, 3.3 etc); and (ii) Cox regression 
analysis, including all cut-off points as continuous variables. Both methods gave 
identical results.  
 Table 1. Characteristics of the B-CLL patients included in our analyses. 
1 F 76 217 - 20.2 0 A MUT
2 F 61 95 - 21.4 0 A MUT
3 F 77 6 - 22.6 0 A UM
4 M 73 118 - 24.1 0 A MUT
5 F 75 115 - 39.4 0 A MUT
6 F 66 150 - 43.5 0 A MUT
7 M 63 165 - 72.8 0 A MUT
8 F 57 11 - 7.7 I A MUT
9 F 41 14 - 38.6 I A MUT
10 M 59 88 - 58.4 I A MUT
11 M 54 19 Chlo 13.4 0 A UM
12 F 62 41 - 94.2 0 A UM
13 M 57 79 Pred 7.2 I A UM
14 M 57 80 - 41.0 I B UM
15 M 62 98 Chlo 62.5 I B UM
16 M 55 33 - 17.0 III C ND
17 M 45 105 Chlo 84.3 III C MUT
18 M 59 46 Pred 7.0 IV C MUT
19 M 77 25 Chlo 7.1 IV C MUT
20 M 61 125 - 9.0 IV C MUT
21 M 74 108 - 52.6 IV C MUT

























All variables indicated were assessed at time of sampling.  
 Chlo, chlorambucil; Pred, prednisone. Rai and Binet refer to current standard clinical staging 




Transcriptional upregulation of the MHC class II components in B-CLL 
To avoid patient selection biases, PBMCs were collected from a random cohort of 21 
B-CLL patients, either receiving therapy or not (Table I). In purified CD5+CD19+, 
malignant B-CLL cells and mature, resting CD19+ B cells from healthy donors, we 
analyzed immediate ex vivo gene expression of DRA, CD74, DMB and both chains of 
the DO molecule, as unlike the DR and DM chains (16), DOA and DOB are not 
completely co-regulated (15, 30). Gene expression in eight samples of six 
independent healthy donors showed little variation in expression of DRA (0.67 
(mean)±[0.37] [SD]), CD74 (0.58±[0.27]) DMB (0.79±[0.44]), DOA (0.84±[0.36]) 
and DOB (1.02 ±[0.42]) (Fig. 1), demonstrating that HLA-DR, CD74 and both class 
II chaperones are tightly regulated in B cells from healthy volunteers. Transcription 
of HLA-DR, CD74, DM and DO was markedly elevated in the malignant B-CLL cells. 
Overall, the patients showed a highly significant upregulation of the mRNA levels of 
DRA (1.49±[0.83]; P=0.022), CD74 (1.11±[0.39]; P=0.001), DMB (1.81±[0.72]; 





Figure 1. Transcriptional upregu-
lation of DRA, DMB, CD74, DOA 
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the CD5+CD19+ cells from B-CLL 
patients. Results are normalized to 
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Downmodulation of DR, DM and DO protein expression in B-CLL 
Expression of the components of the MHC class II pathway is not only regulated at 
the transcriptional level, but also at the post-transcriptional and translational level 
(14). Thus, the anomalous transcriptional upregulation of DR, DM and DO in B-CLL 
is not necessarily reflected at the protein level. We analyzed the total protein 
expression of DR, DM and DO using SDS-PAGE and semi-quantitative Western 
blotting. Unlike in healthy B cells, a highly variable expression pattern of DR, DM 
and DO was observed in the malignant B-CLL population (Fig. 2A). Subsequent 
semi-quantitative analysis demonstrated that in B cells obtained from healthy 
donors (n=3), DM and DO expression was almost invariable (1.01[0.03] and 
1.00[0.03] respectively), with minor DR variation (1.13[0.21]). Surprisingly, B-
CLL cells did not express more DR (0.73±[0.04]), DM (0.75±[0.18]) and DO 
(0.56±[0.37]) protein compared to control B cells (Fig. 2B), in contrast to the 
significant upregulation of mRNA. DM protein is even significantly lower in B-CLL 
patients as compared to healthy controls.  
 
Increased transcription of the MHC class II genes is correlated with 
enhanced transcription of total CIITA in B-CLL 
Since CIITA is the master regulator of MHC class II transcription, we measured total 
CIITA mRNA levels in B cells from healthy donors and B-CLL patients. B-CLL 
patients had significant more CIITA mRNA than B cells from controls (P < 0.001) 
(Fig. 3A). The enhanced mRNA levels of DRA, DMB, DOA and DOB correlated to the 
CIITA mRNA levels (R = 0.486, P = 0.026; R = 0.530, P = 0.013; R = 0.621, P = 
0.003; R = 0.614, P = 0.003 respectively), suggesting that enhanced transcription 
of these MHC class II genes is mediated by enhanced CIITA expression. As 
expected, CD74 mRNA expression did not correlate with CIITA expression since 
CD74 transcription involves other factors as well (31). 
 
CIITA-PIV expression is increased in B-CLL 
CIITA is a complex regulated gene, with three promoters known to display distinct 
cell type- and cytokine-specific responses (32). Transcription initiated by each of 
the CIITA promoters leads to synthesis of distinct CIITA mRNAs containing 
alternative first exons spliced to a shared second exon. To identify which 
promoter(s) of CIITA was responsible for this upregulation of CIITA, we used 
























Figure 2. Variable and deviant protein expression of DR, DM and DO in B-CLL.   
(A) Western blot analysis of total cell lysates of purified, malignant B-CLL cells and B cells from 
healthy donors immediately after isolation. A representative healthy control is shown on the right. 
Equal amounts of cellular proteins were analyzed (2 µg for DR, 5 µg for DM and 15 µg for DO) as 
demonstrated by the comparable amounts of actin in each sample. Molecular marker sizes are 
indicated on the left (kDa). (B) Semi-quantitative Western blot analysis of the relative DR, DM and 
DO expression in healthy B cells versus malignant B cells from B-CLL patients. Subsaturated 
autoradiograms were scanned and signals were quantified by densitometric analysis. The values 
for DR, DM and DO expression were correlated to actin in each sample and subsequently 









No messenger from CIITA-PI was found in B cells or B-CLL cells (data not shown). 
Transcription of CIITA-PIII mRNA was observed both in B cells from healthy donors 
and B-CLL patients with no significant difference between these two groups (Fig. 
3B, left panel). In line with a previous report, only low levels of IFN-γ-inducible 
CIITA-PIV mRNA were found in B cells from healthy controls  (33). In B-CLL 
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however, the activity of the CIITA-PIV promoter was strongly and significantly 
enhanced (P < 0.001; Fig. 3B, right panel). Thus, transcription of CIITA in B-CLL is 
controlled by the co-ordinated activity of the B cell-lineage-specific promoter PIII 














Figure 3. Transcriptional upregulation of CIITA in B-CLL.   
Comparison of relative mRNA levels between CD19+ B cells from healthy volunteers (= CTRL) 
and the CD5+CD19+ cells from B-CLL patients. Results are normalized to the internal control 18S 




Prognostic value of DOA mRNA expression 
Now that we uncovered transcriptional aberrancies in the MHC II genes in B-CLL, 
we analyzed if differences in mRNA levels for the respective MHC II components 
showed a correlation with clinical outcome. Variables included were DRA, DMB, 
CD74, DOA and DOB, with only DOA mRNA levels showing a significant difference 
between surviving and non-surviving patients (Fig. 4A). If patients were divided 
into a group with DOA mRNA levels < 3.4 and ≥ 3.4 (the threshold with the most 
discriminative power in this patient cohort), DOA mRNA levels ≥ 3.4 defined a 
subgroup of patients with an unfavourable prognosis: six out of eight patients with 
DOA mRNA levels ≥ 3.4 died during follow-up as compared to four out of 12 
patients with DOA mRNA levels < 3.4 (Log-rank test; P = 0.031, Fig. 4B). When 
entered as continuous variables using Cox regression analysis, a similar result was 



















Figure 4. DOA mRNA expression has prognostic power in B-CLL.  
(A) Comparison of DOA mRNA levels between surviving and non-surviving B-CLL patients. (B) 
Comparison of survival time after sampling in B-CLL according to DOA mRNA expression levels and 




To date, the mutational status of the IGHV genes has been considered the best 
prognostic marker for survival in B-CLL and indeed we confirmed this in our cohort 
(P = 0.001). When DOA mRNA levels and IGHV mutational status were entered as 
categorical variable in the Cox's proportional-hazards model for multivariate 
analysis, both indices remained independent prognostic markers. Thus, these data 
indicate that aberrant DOA mRNA expression is a novel and additional prognostic 
indicator for survival in B-CLL, with the potential to be a risk stratifier in B-CLL 
patients with mutated IGHV. 
 
Discussion 
A plethora of factors has been identified that may play a role in tumor immune 
evasion. Some of these directly affect tumor recognition by CD8+ effector CTLs, 
such as deficiencies in components of the MHC class I antigen processing pathway 
(34-37). Also, in B-CLL, MHC class I has been suggested to play a role in tumor 
immune evasion  (38). Over the last years it has become clear that the 
establishment of an effective CD4+ T cell response via MHC class II antigen 
 120 
Enhanced MHC-II transcription in CLL 
presentation is required for both the induction and maintenance of anti-tumor CD8+ 
CTL responses (39). Indeed, loss of MHC class II expression has been observed in 
diffuse large B cell lymphomas with fewer tumor-infiltrating CD8+ T cells in MHC 
class II-negative tumors (40, 41). 
Here, we identified transcriptional aberrancies in the genes of the MHC class II 
antigen processing machinery in B-CLL. In B-CLL, the DRA, CD74, DMB, DOA and 
DOB were transcribed at higher levels than in healthy controls. We demonstrated 
that the transcriptional upregulation of the MHC II genes was not translated in 
increased protein levels. Therefore, the observed transcriptional aberrancies in B-
CLL may not result in a form of immune evasion. Instead, it is more likely to point 
to an aberrant regulation of transcription. Indeed, upregulation of the 
transcriptional master regulator CIITA correlated to transcriptional upregulation of 
the MHC II genes. We demonstrated that CIITA transcription in leukaemic B cells is 
the resultant of both PIII and PIV promoter activity. Currently, it remains unclear 
why CIITA-PIV is active in B-CLL. CIITA-PIV is responsive to inflammatory stimuli. 
It has been shown in B-CLL that several serum cytokine levels are elevated in B-
CLL (42-45) and that both CD4+ and CD8+ T cells express significantly more IFN-γ 
and IL-4 than in healthy controls (46, 47). Thus, activation of CIITA-PIV may be 
the resultant of the aberrant immunological environment in B-CLL. 
Correlation of the identified transcriptional aberrancies with clinical outcome showed 
that the level of DOA mRNA predicts patient survival in B-CLL with high DOA mRNA 
levels correlating with poor survival time after sampling and low DOA mRNA 
correlating to good survival time after sampling. The finding that mRNA levels of 
DRA, CD74, DMB and DOB are not predictive indicates that transcription of DOA is 
not fully coregulated with the transcription of the other MHC class II genes. To 
validate the predictive power of DOA mRNA, we are currently expanding our cohort 
of B-CLL patients. The identification of DOA mRNA as a prognostic marker in our 
patient group is remarkable with potential clinical implication.  
IGHV mutational status is the best stage-independent prognostic marker for B-CLL, 
but IGHV gene analysis is expensive and laborious and therefore unsuitable for 
standard diagnostic purposes. DOA mRNA analysis would be an additional diagnostic 
marker and can be readily applied in routine diagnostic purposes. Since novel 
therapies in the form of therapeutic antibodies or purine analogues can now induce 
complete remission, alternative prognostic markers become increasingly important. 
Even more so, the early identification of asymptomatic patients likely to progress is 
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of great clinical importance as these patients are eligible for early treatment 
protocols. Indeed, recently other prognostic markers have been identified, with only 
CLLU1 (48) adding prognostic value independent of IGHV mutational status, but 
only in patients younger than 70 years. Here we present DOA mRNA as a novel, 
IGHV mutational status-independent prognostic marker for clinical outcome in B-CLL 
in a cohort of only 21 patients. By investigating the expression of the components of 
the MHC class II pathway at the transcriptional and protein level in a well defined B-
CLL cohort with clinical follow-up, we defined a novel factor that is predictive for 
clinical outcome. Validation of this marker in a larger cohort of patients will show if 
DOA mRNA can be used for further tailoring therapy in B-CLL patients. 
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In patients with B-CLL, the immune dysfunction of T cells towards malignant B cells 
may contribute to the pathobiology of B-CLL. TCR-dependent 
oligoclonal/monoclonal expansion of the CD4+ T cells however points to antigen-
dependent T cell activation. For this reason, we investigated the role of MHC class 
II antigen presentation in B-CLL. Using flow cytometry, we analyzed the expression 
levels of HLA-DR, CLIP, HLA-DM and HLA-DO of B cells from 17 B-cell chronic 
lymphocytic leukemia patients and 10 healthy donors. In addition we analyzed the 
T cell compartment of patients by expression of CD45RO, CD27, HLA-DR and CD38 
and correlated these results to the MHC class II antigen loading pathway results. B-
CLL cells showed ubiquitous expression of MHC class II that did not vary from 
healthy controls. B-CLL cells however showed disturbed expression of HLA-DM and 
HLA-DO, the editors of the MHC class II antigenic peptide repertoire. The perturbed 
DM/DO balance altered the peptide repertoire, as it was related to reduced 
expression of the self-peptide CLIP at the plasma membrane. The T cell 
compartment in B-CLL patients was significantly decreased in naïve CD4+ and CD8+ 
subsets in favor of increased activated effector populations. The percentage of 
activated T cells inversely correlated with CLIP expression, pointing to improved 
antigen presentation. Our data show that in B-CLL a relative increase in HLA-DM 
and a concomitant change in the MHC class II peptide repertoire of the malignant B 
cells is related to ongoing T cell activation. Altered MHC class II antigen 




Enhanced immune activation in B-CLL 
Introduction 
A successful anti-tumor T cell response is achieved by the two effector arms of the 
immune system. CD8+ cytotoxic T lymphocytes (CTLs) ensure specific elimination of 
tumor cells upon recognition of MHC class I-antigen (Ag) complexes and CD4+ T 
helper cells generate the required T cell help upon activation by MHC class II-Ag 
complexes (1). The absence of T cell help can lead to abortive induction of CTL 
responses and subsequent tolerance (2). Moreover, T cell help is required for the 
maintenance of CTL responses, which is essential in diseases like cancer (3, 4). 
Indeed, CD4+ T cell inclusion in adoptive T cell transfer studies improved tumor 
clearance by the CD8+ T cells (5, 6) and aberrant MHC class II Ag presentation in 
acute myeloid leukemia was related to poor prognosis (7).  
B-cell chronic lymphocytic leukemia (B-CLL) is the most common form of leukemia 
in adults in the Western world. Typical for the disease is the highly variable clinical 
course, with survival rates that vary between a few months and two decades (8). 
B-CLL is characterized by a progressive accumulation of malignant B cells that fail 
to undergo apoptosis. Notably, B-CLL is characterized by striking immune 
incompetence and T cell expansion combined with T cell dysfunction (9). It is 
unclear whether this T cell expansion is indicative for attempted but unsuccessful 
tumor clearance or contributes in another way to the disease, for instance by 
creating an environment that supports survival of neoplastic cells (10). Antigen-
independent mechanisms have been implicated in the T cell expansion in B-CLL 
(reviewed in (11)). The TCR-dependent oligoclonal/monoclonal expansion of CD4+ 
T cells in B-CLL however, points to an antigen-driven process. How malignant B 
cells present antigens via MHC class II molecules to CD4+ T cells and whether this 
may be an explanation for observed T cell expansion in B-CLL is so far unclear. 
MHC class II molecules bind exogenous Ags generated in the endosomal/lysosomal 
pathway. After synthesis, the MHC class II molecule is directed into this pathway by 
associating to the invariant chain (Ii) (12). During transport to the lysosomal-like 
MIIC compartments where the majority of Ag loading occurs, the Ii is proteolytically 
removed, leaving only a small fragment (class II-associated invariant chain 
peptides (CLIP)) in the class II peptide binding groove (13). Release of CLIP is 
facilitated by the specialized chaperone HLA-DM (DM). DM catalyses the natural 
process of peptide dissociation (14). DM thus releases both CLIP and other 
nonstable binding peptides. Consequently, DM acts as a peptide editor, favoring 
presentation of stable binding Ags (15-19). HLA-DO (DO), a heterodimer of DOα 
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and DOβ, is expressed in B cells and regulates the action of DM in a pH dependent 
manner. We and others reported that DO reduces MHC class II-mediated 
presentation of antigenic peptides in general and modulates the antigenic peptide 
repertoire by facilitating presentation of particular Ags, while suppressing others. 
DO therefore both limits and skews the class II-associated antigenic peptide 
repertoire in B cells (20-22). The relative expression of DO and DM (or the number 
of DM molecules in association with DO) thus controls Ag presentation in B cells. 
Not surprisingly, DO and DM expression are very consistent and tightly regulated at 
different cellular levels in healthy B cells (23) and B cell differentiation status (24). 
Aberrant expression of DM and/or DO could lead to an altered MHC class II peptide 
repertoire. This shift in antigen presentation may lead to altered T helper cell 
activation and subsequent help to CD8+ CTLs.  
We recently showed that increased transcription of HLA-DOA mRNA is correlated 
with shorter survival of B-CLL patients (25). To determine the role of MHC class II-
mediated antigen presentation in B-CLL at the protein level, we set out to 
determine whether anomalies in the MHC class II Ag presentation pathway occurred 
in patients suffering from B-CLL and whether this is related to the observed 
expansion of T cell subsets in this disease. Here we show that the relative 
expression of DO compared to DM is affected in malignant B-CLL cells, improving 
dissociation of the self-peptide CLIP in MHC class II molecules. This change in the 
MHC class II peptide repertoire is strongly correlated to a shift from the naïve T cell 
compartment towards the activated effector T cell compartment.  
 
Materials and methods 
Patients and healthy volunteers 
Peripheral blood samples from 17 B-CLL patients were obtained after informed 
consent according to the Declaration of Helsinki and samples were anonymized 
before analysis. Patients were diagnosed and staged based on standard 
morphologic and immunophenotypic criteria (26). Cytogenetic data are not 
available since this was not routinely performed at the time of sample collection. 
Out of the 17 patients, 14 had not received chemotherapy at the time of sample 
acquisition and 3 had received prior treatment with chlorambucil. Ten buffy-coats 
from healthy donors were obtained from the Sanquin Blood Supply Foundation 
(Sanquin, Amsterdam, The Netherlands). 
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Isolation of peripheral blood mononuclear cells 
Heparinized blood was diluted in PBS and layered on a Ficoll-Hypaque density 
gradient (Axis-Shield PoC AS, Oslo, Norway). PBMCs were collected from the 
interphase and washed twice with RPMI 1640 medium w/o phenol red, 
supplemented with 5% FCS (Bodinco, Alkmaar, the Netherlands), 100 U/ml 
penicillin, 100 μg/ml streptomycin, 2 mM L-Glutamine, 50 μM 2-mercaptoethanol 
and 20 μg/ml human apo-transferrin ((Sigma-Aldrich, Munich, Germany), depleted 
for human IgG with protein G sepharose (Amersham, Uppsala, Sweden)). Cells 
were cryopreserved and stored in liquid nitrogen until analysis. 
 
Antibodies and Flow Cytometry Analysis 
Rapidly thawed mononuclear cell fractions were preincubated with 10% human 
gammaglobulin (6 mg/ml, Sanquin) and incubated with different combinations of 
directly labeled antibodies. The following mouse monoclonal antibodies were used: 
FITC-labeled anti-HLA-DR (BD Biosciences (BD), San Jose, CA, clone L243), anti-
HLA-ABC (BD), anti-HLA-DO (BD), -CD8 (BD), -CD45RO (Sanquin), -CD80 (BD); 
Phycoerythrin-labeled anti-HLA-DM, -CD4, -CD27, -CD38, -CD86 (all BD); Peridinin 
chlorophyll protein-Cy5.5-labeled anti-CD8 and -CD19 (both BD) and 
Allophycocyanin-labeled anti-CD4 and -CD5 (both BD). For CLIP detection, cells 
were incubated with the Cerclip.1 mAb (kindly provided by P. Cresswell)17 and 
subsequently stained with PE-conjugated rabbit-anti-mouse immunoglobulin 
(Dakocytomation, Heverlee, Belgium). A mixture of non-relevant mouse Abs of 
different isotypes was added to prevent non specific binding of subsequently added 
directly labeled fluorescent Abs. All plasma membrane stainings were performed at 
room temperature for 15 minutes. For intracellular staining of HLA-DM and HLA-DO, 
cells were fixed and permeabilized with a Fix & Perm kit (Caltag Laboratories, 
Burlingame, CA) and subsequently incubated with antibodies for 20 min at room 
temperature. After each incubation, cells were washed twice with PBS containing 
0.1% bovine serum albumin and 100,000 events were acquired by a FACS Calibur 
(BD). Lymphocytes were gated by forward and side scatter and analyzed using 
CellQuest software (BD). B-CLL cells were defined as CD5+CD19+.  
Median fluorescence intensity (MFI) index was defined by the formula: 
median fluorescence intensity (total population)– median fluorescence intensity (isotype control) 




Determination of anti-CMV serology and mutation status 
Anti-CMV IgM and IgG was determined by ELISA in plasma samples of 13 patients 
at the Department of Virus Serology at Sanquin Diagnostics Division, from 4 
patients plasma was not available. Determination of the mutational status of the 
immunoglobulin heavy chain variable (IGHV) genes of 20 patients was determined 
as described (25).  
 
Statistical methods 
Statistical analyses were conducted with the SPSS 15.0 software program. 
Differences between groups were analyzed with the 2-sided Mann-Whitney U test. 
For correlations, the Spearman nonparametric correlation test was used. P values 
less than 0.05 were considered statistically significant. 
 
 Table 1. Patients' characteristics and expression of different markers on B-CLL cells 
 Clinical characteristics of patients
Gender 9 Male / 8 Female
Age at time of sample, years, mean 64 (41-78)






Mutational status of the IGHV  genes 12 mutated, 4 unmutated, 1 ND
CMV serology 5 seronegative, 8 seropositive, 4 ND
Flow cytometric analysis of B-CLL
Leucocyte count at time of sample, 42 (7-94)
CD4/CD8 ratio (%, mean (range)) 1.3 (0.4-2.5)
CD40 (median FI (range)) 6.4 (4.1-9.4)
CD80 (median FI (range)) 3.4 (0-5.5)
CD86 (median FI (range)) 13.8 (6.3-50.0)













 Abbreviations: ND, not determined; FI, fluorescence intensity 
 
Results 
B-cell chronic lymphocytic leukemia cells express less CLIP in their peptide 
binding groove 
We analyzed cell surface expression of DR and CLIP on the B cells of 17 samples of 
a random group of B-CLL patients (Table 1) and 10 healthy volunteers by flow 
cytometry. Expression of MHC class I (HLA-ABC) was not different between healthy 
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volunteers and B-CLL patients (data not shown). We also found no difference in DR 
expression on the B cells between control and B-CLL cells (Fig. 1A). B-CLL patients 
however, have significantly less CLIP (P<0.001) associated to DR (Fig. 1B). The 
amount of DR molecules still associated to the self-peptide CLIP is indicative for the 
efficacy of the MHC class II peptide loading process. To analyze the relative 
occupancy of plasma membrane expressed DR with the self-peptide CLIP, the CLIP 
level on B cells was related to the DR level. This showed a reduced expression of 
CLIP associated to DR at the plasma membrane (CLIP/DR) in B-CLL patients 
compared with healthy controls (P<0.001) (Fig. 1C). Thus, in B-CLL a relative 
larger proportion of the DR molecules is available for MHC class II mediated antigen 





























































 Figure 1. Decreased relative CLIP occupancy of DR in B-CLL. 
(A) and (B) Representative flow-cytometric examples of HLA-DR and CLIP expression (left panels, 
numbers indicate the median index). DR expression is not significantly different between patients 
and healthy controls, CLIP expression is significantly decreased (P < 0.001) (right panels). (C) The 
relative CLIP amount in the MHC class II peptide binding groove (CLIP/DR) is significantly 











Figure 2. Aberrant expression of DM and DO in B-CLL. 
(A) Representative flow-cytometric examples of intracellular HLA-DM and HLA-DO expression. (B) 
Both DM (upper left panel) and DO (upper right panel) are significantly decreased (both P < 0.001) 
in B-CLL patients. The relative expression of DM and DO (bottom panel) is increased (P < 0.001). 
Controls are represented by squares and B-CLL patients by triangles. (C) Relative CLIP occupancy 
of DR (CLIP/DR) correlated with the overexpression of DM (DM/DO) (R = -0.592, P = 0.001; 10 log 























































































Reduced DM and DO expression in B-cell chronic lymphocytic leukemia 
cells 
Antigen binding to newly synthesized MHC class II molecules is modulated by the 
expression of the peptide editors DM and DO. A high expression of DM compared to 
DO favors exchange of CLIP for antigenic peptides (20). Since DR molecules 
expressed reduced CLIP levels in B-CLL, we investigated the intracellular expression 
levels of DM and DO. Representative examples are shown in Figure 2A. The relative 
expression levels of DM and DO in B-CLL were markedly different from healthy 
controls, with both DM and DO being significantly reduced (P<0.001 for both) (Fig. 
2B, upper panels). When DM was compared to DO, a relative overexpression of DM 
 134 
Enhanced immune activation in B-CLL 
was observed in B-CLL (P<0.001) (Fig. 2B, bottom panel). This correlated with the 
efficiency of CLIP removal from DR (CLIP/DR) (R= -0.592, P=0.001) (Fig. 2C). Both 
relative overexpression of DM and the relative CLIP occupancy of DR did not 
correlate to B-CLL mutational status (as measured by IGHV gene analysis), CMV 
status, costimulatory markers (CD40, CD80 and CD86), Rai stage of disease or 
treatment regimen (data not shown). Collectively, these data show differential 
expression of the MHC class II peptide editors in B-CLL in combination with a 
reduced expression of CLIP in plasma membrane deposited DR.  
 
Expansion of CD4+ and CD8+ effector T cell compartments in B-cell chronic 
lymphocytic leukemia 
How does the altered CLIP expression on B-CLL cells relate to differences in CD4+ T 
cell differentiation between CLL patients and healthy controls? In line with previous 
observations (9), the CD4+/CD8+ ratio in B-CLL patients was lower compared to 
healthy controls (Table 1). No correlation was observed between the relative CLIP 
occupancy of DR and the CD4+/CD8+ ratio. We analyzed the peripheral T cells for 
the CD4+CD45RO-CD27+ naïve T cells, CD4+CD45RO+CD27+ central memory T cells 
and the CD4+CD45RO+CD27- memory effector cells. Representative examples are 
shown in Figure 3A. Patients with B-CLL showed a lower percentage of naïve CD4+ 
T cells compared to healthy controls (P=0.009) (Fig. 3B, upper left panel), an 
unvaried central memory CD4+ T cell compartment (Fig. 3B, upper right panel) and 
an expansion of the memory effector CD4+ T cell compartment (P=0.001) (Fig. 3B, 
bottom panel). This points to ongoing activation of CD4+ T cells in B-CLL.  
We analyzed the percentages of CD8+CD45RO-CD27+ naïve T cells, 
CD8+CD45RO+CD27+ central memory T cells, CD8+CD45RO+CD27- memory effector 
T cells and CD8+CD45RO-CD27- cytotoxic effector T cells. Representative examples 
are shown in Figure 3C. Patients with B-CLL showed a lower the percentage of 
naïve CD8+ T cells (P<0.001) (Fig. 3D, upper left panel) and no difference in CD8+ 
central memory T cells (Fig. 3D, upper right panel). The percentage of CD8+ 
memory effector T cells was increased (P=0.001) (Fig. 3D, bottom left panel), as 
well as the CD8+ cytotoxic effector T cells (P=0.003) (Fig. 3D, bottom right panel). 
Because the increase in cytotoxic effector T cells in B-CLL patients has been related 
to CMV infection (27), we tested patients for CMV infection. In our patient cohort, 
no significant difference in CD8+ T cell populations was observed between CMV 























































































































































































Enhanced immune activation in B-CLL 
 Figure 3. Expansion of effector type CD4+ and CD8+ T cells in B-CLL. 
(A) Representative flow-cytometric examples of CD45RO and CD27 expression on CD4 gated cells. 
Percentages of cells in each quadrant are given. (B) The naïve CD4+ T cell compartment (upper 
left panel) is significantly decreased (P = 0.009) in B-CLL patients. The CD4+ central memory T 
cells (upper right panel) are not significantly different between patients and healthy controls and 
the CD4+ memory effector subset (bottom panel) is significantly increased (P = 0.001). Controls 
are represented by squares and B-CLL patients by triangles. (C) Representative flow-cytometric 
examples of CD45RO and CD27 expression on CD8 gated cells. Percentages of cells in each 
quadrant are given. (D) The naïve CD8+ T cell compartment (upper left panel) is significantly 
decreased (P < 0.001) in B-CLL patients. The CD8+ central memory T cells (upper right panel) are 
not significantly different between patients and healthy controls. The CD8+ memory effector 
subset (bottom left panel) is significantly increased (P = 0.001) as well as the CD8+ cytotoxic 
effector subset (bottom right panel) (P = 0.003). Controls are represented by squares and B-CLL 













CD4+ T cells provide help to the effector function of CD8+ T cells. Is there a 
relationship between the expanded CD4+ effector and CD8+ compartments in B-
CLL? Indeed, the expansion of the CD4+ memory effector T cell compartment 
correlated with the observed expansions in CD8+ compartment in B-CLL, with the 
strongest correlation between the CD4+ memory effector and CD8+ memory 
effector compartments (Table 2).  
 
 
Table 2. Correlations between the CD4+ memory effector and CD8+ T cell compartments 
 
CD4+CD45RO+CD27- memor
CD8+CD45RO-CD27+ naive R = -0.835, P <0.001
CD8+CD45RO+CD27- memory R = 0.881, P <0.001






Increased T cell activation in B-cell chronic lymphocytic leukemia 
As a marker for ongoing T lymphocyte activation, we analyzed the expression of 
HLA-DR and CD38 on T cells. Representative examples are shown in Figure 4A. 
Patients with B-CLL showed increased levels of CD4+HLA-DR+CD38+ T cells and 
CD8+HLA-DR+CD38+ T cells compared to healthy controls (both P<0.001) (Fig. 4B). 
The percentage of activated CD4+ T cells showed a positive correlation with the 
percentage of activated CD8+ T cells (R=0.846, P<0.001) (Fig. 4C). Thus, patients 






Figure 4. Increase in subsets 
of activated T cells correlates 
with the relative CLIP 





cytometric examples of HLA-
DR and CD38 expression on 
CD4 (upper panels) and CD8 
(lower panels) gated cells. 
Percentages of cells in each 
quadrant are given. (B) Both in 
the CD4+ (left panel) and CD8+ 
(right panel) T cell 
compartment more of the T 
cells have an activated 
phenotype (both P < 0.001). 
(C) The percentage of 
activated CD4+ T cells 
correlated with the percentage 
of activated CD8+ T cells (R = 
0.846, P < 0.001). (D) Relative 
CLIP occupancy of DR 
(CLIP/DR) correlated with the 
percentage of CD4+ activated T 
cells (R = -0.750, P < 0.001) 
and to a lesser extend CLIP/DR 
correlated with the percentage 
of CD8+ activated T cells (R = -

































































log % HLA-DR+CD38+ cells
























































































































Enhanced immune activation in B-CLL 
Correlation of the T cell parameters with the parameters involved in antigen 
presentation in our samples demonstrated a strong negative correlation between 
the relative CLIP levels associated to DR and the percentage of activated CD4+ T 
cells (R=-0.750, P<0.001 ) (Fig. 4D, left panel). To a lesser extent, the relative 
CLIP expression correlated to the percentage of activated CD8+ T cells (R=-0.617, 
P=0.001) (Fig. 4D, right panel).  
Thus, in B-CLL a lower occupancy of the MHC class II peptide binding groove with 




Deficiencies in components of the MHC class I Ag processing pathway have been 
shown in a variety of human cancers (28, 29), and some studies have correlated 
these deficiencies with tumor progression (30, 31). Here we identify aberrancies in 
the MHC class II Ag processing machinery in B-CLL and demonstrate that this is 
accompanied with increased T cell activation in B-CLL patients. B-CLL cells always 
express DR and the class II chaperones DM and DO. Thus, tumor immune escape 
due to genetic silencing of the MHC class II genes does not seem to occur in B-CLL. 
This in contrast to poor prognosis correlated to the overall loss of MHC class II 
expression in diffuse large B cell lymphomas (32, 33).  
It is under debate whether B-CLL disease is a homogenous entity. Based on the 
mutational status of the immunoglobulin heavy-chain variable-region (IGHV) genes, 
B-CLL cases can be divided into two subgroups, resembling either a resting or a 
germinal center-experienced phenotype. DO expression is reported to vary during B 
cell development (24, 34), but in our cohort we could not demonstrate a difference 
in DO expression between patients with mutated and unmutated IGHV genes.  
In B-CLL patients the presence of T cells with an anti-tumor specificity declines 
during disease progression (35). A lower CD4/CD8 ratio is observed in patients with 
progressive disease together with a concomitant Th1 to Th2 shift, which is 
detrimental for an effective anti-tumor response. These observations point to 
perturbed MHC class II-mediated CD4+ and CD8+ activation in B-CLL. Since the 
malignant B cells are poor APCs and DR cell surface expression is not altered, Dazzi 
and colleagues described that poor Ag presentation is due to a low B7 molecule 
expression (36). Although reduced expression of the costimulatory markers CD80 
and CD86 is an established phenomenon in B-CLL (and confirmed in this study, see 
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Table 1), we now show that additional aberrancies in antigen presentation are 
present in the MHC class II antigen loading pathway itself. In order to get stable 
binding peptides in the peptide binding groove of a class II molecule, DR associates 
with DM which results in the release of CLIP and the preferential binding of Ags with 
an optimal binding motif to the class II backbone. In normal B cells about 50% of 
DM is associated to DO which then fails to properly support MHC class II peptide 
loading (24), whereas the other 50% is free for peptide editing of the class II Ag 
repertoire. The expression of DM in B-CLL shows that CLIP on newly synthesized 
class II molecules can be exchanged with antigenic peptides through the editing 
function of DM. The result that DM is relatively higher expressed than DO in B-CLL 
implies that more free DM is available for the generation of MHC class II complexes 
with antigens after removal of CLIP. Indeed, a decreased level of CLIP associated to 
DR at the plasma membrane in B-CLL patients is observed. Thus, the peptide 
repertoire presented by MHC class II molecules is modulated by DM and DO in 
healthy controls as well as in B-CLL patients. In addition, the composition of the 
MHC class II peptide repertoire is different in B-CLL compared to healthy controls. 
The amount of CLIP associated to DR apparently varies between different types of 
leukemias. In acute myeloid leukemia we recently observed a relative 
overexpression of MHC class II complexes still containing CLIP at the plasma 
membrane in patients with poor prognosis (7). For acute myeloid leukemia, CLIP 
may constitute a form of tumor immunoediting or tumor immune escape. In B-CLL, 
reduced CLIP levels may serve another function. There is ample evidence that in B-
CLL aggressive and non-aggressive forms arise due to the intrinsic properties of the 
B-CLL cells themselves and therefore the relative contribution of failed immune 
surveillance is under debate. The strong clinical manifestations of immune 
dysfunction and the expanded circulating T cell compartment have lead to the 
hypothesis that T cells may be involved in the pathobiology of B-CLL through the 
creation of a “leukemia-supportive” environment (37). Still, the mechanisms 
underlying the onset and sustainment of the expansion of these T cell populations 
in B-CLL were poorly defined. Our observations suggest that altered MHC class II 
antigen presentation by the malignant B cells may be involved; T cells of B-CLL 
patients are more differentiated towards effector and immune activated T cells and 
these findings correlate with parameters of improved MHC class II antigen 
presentation (a reduced CLIP expression and a relative overexpression of DM). In 
spite of the lack of strong costimulation, this correlation suggests that T cell 
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activation is still antigen-driven, in line with the observation that T cell expansion in 
B-CLL is oligoclonal or monoclonal (38). Whether initiation of T cell activation and 
maintenance of T cell activation are both antigen-driven remains to be established, 
but the observed correlations propose a contribution of MHC class II antigen 
presentation at certain stages in the pathobiology of B-CLL. A perturbed MHC class 
II antigen presentation pathway in B-CLL may thus be a new factor in the immune 
dysfunction and pathobiology of B-CLL. 
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MHC class II antigen presentation plays a pivotal role in human health and disease. 
One the one hand antigen presentation via MHC class II molecules activates CD4+ 
T cells to produce cytokines and express CD40L to stimulate B cells to produce 
antibodies. In this thesis we studied the importance of MHC class II antigen 
presentation by B cells and the antibody response in bacterial infection. On the 
other hand, after MHC class II antigen presentation the activated CD4+ T cells give 
help to CD8+ T cells. The activated CD8+ T cells can now exercise their cytotoxic 
activities to eliminate defective/transformed or infected cells. Disruption of MHC 
class II antigen presentation could play a role in the immune evasion of cancer 
cells; therefore we investigated the MHC class II antigen presentation pathway in 
leukemia. The importance of MHC class II antigen presentation becomes clear in 
patients that have a deficiency in MHC class II antigen presentation. This rare 
primary immunodeficiency disease, called Bare Lymphocyte Syndrome type II 
(BLSII), is characterized by the absence of expression of MHC class II proteins (1). 
The MHC class II genes themselves are unaltered in these patients, but their 
expression is abolished by mutations in transcription factor genes that initiate 
transcription of MHC class II genes. The result is that patients have a severe defect 
in both cellular and humoral immunity and exhibit an extreme vulnerability to 
infections. Infections start within the first year of life, there is a dramatic 
progression of various types of infectious complications and patients generally die 
before the age of 10. This demonstrates that a defect in MHC class II antigen 
presentation can only poorly be compensated for by the other players of the innate 
and acquired immune system.  
 
Phagocytosis of bacteria by B cells 
Classically, professional phagocytes include neutrophils, monocytes, macrophages, 
dendritic cells (DCs), and mast cells. Professional phagocytes have receptors on 
their surfaces that can detect harmful objects that are not normally found in the 
body, such as pathogenic bacteria. Phagocytes are therefore crucial in fighting 
infections, as well as in maintenance of health in tissues by removing dead and 
dying cells that have reached the end of their life-span. Hallmarks for phagocytosis 
are the internalization of large particles (typically >500 nm in diameter), with 
reorganization of the actin cytoskeleton and pseudopodia extension (the formation 
of a phagocytic cup). The dogma is that B cells lack phagocytic capacities, but 
recently it was shown that B cells from early vertebrae (teleost fish and 
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amphibians) are potent phagocytes (2). The authors suggested that the phagocytic 
capacity of B cells was already present in a common ancestor at the time of the 
phylogenetic split of teleosts from amphibians, but that mammalian B cells seemed 
to have lost that innate immune capacity. Indeed, although human B cell lines had 
been described to present particulate Ags in the context of MHC class II (3, 4) and 
to extract Ag from a non-internalizable surface (5), human primary B cells were 
thought not to be able of phagocytosing large particles because they have little 
space in the cytoplasm and a relatively large nucleus. 
Since human primary B cells are not considered as phagocytic cells, how do they 
acquire antigens from bacteria? The dogma is that B cells capture antigen from 
follicular dendritic cells (FDCs) in lymphoid follicles of the spleen, lymph nodes 
(LNs) and mucosal lymphoid tissues (6). Another way could be via normal DCs, 
which have been shown to recycle internalized antigens to their cell surface and 
present these in an unprocessed form to B cells (7). Recently, subcapsular sinus 
macrophages have been identified in LNs as an important site of B cell encounter 
with particulate antigen (8-10). Since B cells have been shown to extract antigens 
from a non-internalizable surface, antigen extraction from the surface of other cells 
could be a way to internalize bacterial antigens. Alternatively, bacteria may 
translocate to regional LNs (11) or to B cell areas in the spleen and mucosa-
associated lymphoid tissue (MALT), where B cells may directly extract antigens 
from the bacteria themselves. In Chapter 2 the human B cell line Ramos is used in 
combination with anti-IgM coated beads to show that human B cell lines are indeed 
very capable phagocytic cells when triggered via the B cell receptor (BCR). Ramos 
cells completely internalize anti-IgM coated beads but irrelevant coated beads are 
not internalized. As a more physiological model system we used the bacterium 
Salmonella. In contrast to the current dogma, we demonstrated that also naïve and 
memory primary B cells are able to phagocytose whole, living Salmonella. Further 
analysis showed that this occurs via the BCR and that phagocytosis via the BCR 
results in activation of the B cell and secretion of immunoglobulins. The antibodies 
produced by B cells that have internalized Salmonella are reactive to Salmonella, 
again showing involvement of the BCR. The relatively high percentage of circulating 
B cells that recognize Salmonella via their BCR can be explained by the expression 
of a polyreactive BCR (also reactive to other bacteria) by CD27+ circulating 
marginal zone B cells (12). As for IgM+ memory B cells, also a subset of mature 
naïve B cells in peripheral blood express a BCR of polyreactive nature (13). Next to 
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antibody production, we showed in Chapter 2 that phagocytosis of Salmonella also 
leads to rapid antigen presentation via MHC class II molecules to CD4+ T cells. In 
turn, activated CD4+ T cells give help to B cells, as antibody secretion is enhanced 
after incubation B cells that have internalized Salmonella and CD4+ T cells. The 
activation of CD4+ T cells is bacteria-specific, as we showed that T cells primed 
against Staphylococcus do not respond upon restimulation with B cells that have 
phagocytosed Salmonella.  
 
The B cell as transport vehicle for Salmonella  
Since Salmonella is a facultative intracellular bacterium, the question arises what 
the fate is of Salmonella once inside the B cell. Chapter 3 describes the possible 
role of B cells in the dissemination of Salmonella after oral ingestion. We showed 
that (unlike macrophages, neutrophils and to a lesser extent DCs (14, 15)) B cells 
are not able to kill Salmonella after uptake via the BCR. However, replication of 
Salmonella is repressed in living B cells, but in apoptotic B cells Salmonella starts to 
multiplicate again. We noticed release of viable bacteria from B cells hours after 
phagocytosis and these excreted bacteria could reinfect other cells in vitro. To 
evaluate the role of B cells as transporters of Salmonella in vivo, we performed 
experiments in mice. These experiments showed that adoptive transfer of 
Salmonella-specific B cells in wild-type mice enhanced mortality after oral 
administration of a sub-lethal dose of Salmonella. Moreover, Salmonella were found 
in the spleen of mice that had received Salmonella-specific B cells and not in the 
spleen of mice that had not received Salmonella-specific B cells.  
 
Cross-presentation of Salmonella antigens by B cells 
B cells belong to the group of “professional antigen presenting cells” mainly 
because of their very efficient way of internalizing antigen. Other members are DCs 
and macrophages, which like B cells, display fragments of antigens via MHC class II 
molecules on their cell surface. Next to presentation via MHC class II molecules, 
DCs are able to cross-present exogenous antigens via MHC class I molecules to 
CD8+ T cells (16). In Chapter 4 we showed that B cells are also able to cross-
present Salmonella antigens and activate CD8+ T cells. Not surprisingly, this 
activation of CD8+ T cells is dependent on CD4+ T cell help, as culturing of B cells 
that had phagocytosed Salmonella with only CD8+ T cells did not result in activation 
of the CD8+ T cells. Upon activation, CD4+ T cells produce IL-2 and adding IL-2 
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together with CD8+ T cells restored the activation of CD8+ T cells by B cells. 
Activation and proliferation alone is not sufficient to eliminate infected cells, CD8+ T 
cells need to degranulate upon encountering an infected cell. We performed 
cytotoxicity assays to show that Salmonella-primed CD8+ T cells degranulate 
(measured by CD107a expression on the surface of CD8+ T cells) and are truly 
killing infected cells (measured by release of 51Chromium from the cytoplasm of 
infected B cells). In addition we showed in Chapter 4 that the CD8+ T cell response 
induced by infected B cells is a memory response, since naïve CD8+ T cells could 
not be primed by B cells. This in contrast to the CD4+ T cell response, in which both 
naïve and memory CD4+ T cells were activated by B cells that had phagocytosed 
Salmonella (unpublished results).  
 
The role of B cells in Salmonella infection 
After oral uptake, Salmonella crosses the intestinal epithelium and enters the 
Peyer’s patches via specialized antigen-sampling M cells (17) or luminal capture by 
DCs (18, 19). After entry in the Peyer’s patches, Salmonella immediately meets 
with B cells that can phagocytose the bacteria and activate CD4+ T helper cells and 
secrete anti-Salmonella antibodies. B cells are necessary for efficient protection 
against both primary and secondary infection with Salmonella (20) and generation 
of high-affinity antibodies is not the only function of B cells in salmonellosis, since 
passive transfer of Salmonella-immune serum could not restore immunity of mice 
to Salmonella (21). B cell deficient mice have impaired Th1 T-cell responses from 
the early stage of Salmonella infection, showing that B cells play an essential role in 
the initiation of T-cell-mediated protection (22). Human B cells are able to prime 
naïve CD4+ T cell and also activate memory CD4+ cells, but are not able to kill 
Salmonella and disseminate the bacterium through the body. However, B cells that 
have taken up Salmonella are able to activate memory CD8+ T cells that 
subsequently kill infected cells. During primary infection, other antigen presenting 
cells (e.g. DCs) are still needed for priming of naïve CD8+ T cells. Salmonella thus 
uses the immune system of the host for survival and dissemination through the 
body via antigen-specific B cells, but the evolving immune system generates anti-
Salmonella antibodies and activated CD4+ T helper and CD8+ CTLs. This is an 
example of interaction between bacteria and host, which seems to be difficult to 




Dead bacteria are also recognized by the BCR, but not phagocytosed. In Chapter 2 
we showed that although not completely taken up, antigens from dead bacteria are 
still presented by B cells to CD4+ T cells and activate the latter. In this way, B cells 
can be activated by CD4+ T cells to differentiate into antibody secreting plasma cells 
yielding an effective immune response for subsequent infections. Chapter 4 shows 
that B cells do not cross-present antigens from dead bacteria to CD8+ T cells, 
indicating that Salmonella itself contributes to cross-presentation of its own 
antigens. Living Salmonella injects proteins into the cytosol of the host cell via its 
TTSS to ensure its intracellular survival. Inevitably, these proteins will be degraded 
by the proteasome. Peptides can then be shuffled into the ER, loaded onto newly 
synthesized MHC class I molecules and presented to CD8+ T cells. Dead Salmonella 
have no functional TTSS anymore which may explain the lack of cross-presentation 
of dead bacteria. The finding that B cells that harbor dead Salmonella do not 
activate Salmonella-specific CTLs may fit with the concept that this is also 
immunologically unneeded; in this situation the cells do not form a niche for 
Salmonella survival and spreading, thus their immediate clearance may be less 
important for survival of the host.  
 
MHC class II antigen presentation in leukemia 
Professional APCs take up apoptotic cells and debris to initiate a CD4+ T cell 
response. Dying tumor cells can also be taken up, but sometimes the APC does not 
succeed in generating an effective immune response against the tumor cells, since 
the cancer is not always cleared. However, many tumors of the hematological 
system express MHC class II molecules on the cell surface. Apparently, MHC class 
II antigen presentation by these tumor cells did not succeed in the generation of an 
effective immune response which might be the result of aberrancies in the MHC 
class II antigen presentation pathway. We have studied the MHC class II antigen 
presentation pathway in the myeloid leukemia AML and in more detail in the 
lymphoid leukemia B-CLL.  
In Chapter 5 we showed that the self-peptide CLIP was expressed by MHC class II 
positive AML blasts. Patients with HLA-DR+/CLIP- blasts had a significant longer 
disease-free survival than patients with HLA-DR+/CLIP+ blasts, indicating that the 
expression of CLIP on the blasts could be a measure for immune escape by the 
leukemic cells. Exploring the MHC class II antigen presentation pathway, we found 
that HLA-DO and HLA-DM (the peptide editors of the MHC class II antigen 
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presentation pathway) were readily detectable in AML blasts both on the mRNA and 
protein level. The relative expression of DO and DM correlated with the efficiency of 
antigen loading on DR molecules: the more DO relative to DM, the more CLIP 
relative to DR. Together this led to the hypothesis that HLA-DR+/CLIP- blasts are 
able to present leukemia-specific antigens to CD4+ T cells, priming an effective 
antitumor response that results in a prolonged disease-free survival. Strategies to 
down-modulate CLIP expression on leukemic blasts are being explored to provoke 
an effective anti-tumor response in AML. Retroviral transduction of specific Ii 
siRNAs in two human myeloid leukemic cell lines shows a reduced expression of 
CLIP relative to DR (van Luijn et al., submitted). Despite the reduced levels of DR 
at the cell surface (as a secondary consequence of knocking-down Ii), both cell 
lines strongly enhance activation of allogeneic CD4+ T cells. However, the induction 
of tumor-specific CD4+ T cells (and subsequent help by the induction of tumor-
specific CD8+ T cells) by AML cells transduced with Ii siRNAs is not demonstrated 
yet. Other strategies could target DM and/or DO, the peptide editors. Unpublished 
data of our group show that when exposing B cells in vitro to dexamethasone, a 
strong increase in the amount of DM was observed, with no change in DR or DO 
protein levels. More DM relative to DO could enhance peptide loading of MHC class 
II molecules, without affecting the total amount of DR molecules available for 
antigen presentation. 
 
The HLA-DOA mRNA expression level predicts prognosis in B-CLL 
Next to the myeloid leukemia AML, we studied the MHC class II antigen 
presentation pathway in the lymphoid leukemia B-CLL. In Chapter 6 we showed 
that expression of DRA, DMB, DOA and DOB, but also Ii is highly aberrant on the 
mRNA level. Since transcription of these genes is regulated (DOB and Ii partly) by 
CIITA, we analyzed mRNA levels of total CIITA and the lymphoid-specific promoters 
PIII and PIV. Total CIITA mRNA was significantly enhanced in comparison with 
mRNA levels in B cells from healthy controls. mRNA from CIITA-PIII was detected 
in all samples, but showed no difference with controls. The mRNA levels from the 
IFN-γ-inducible promoter CIITA-PIV were however significantly enhanced, 
indicating that transcription of CIITA in B-CLL is controlled by the coordinated 
activity of the B cell-lineage-specific promoter PIII and the IFN-γ-inducible 
promoter PIV. Increased transcription does not always lead to increased translation 
and enhanced protein levels, as we showed in Chapter 6. Analysis of protein 
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expression by semi-quantitative Western blotting showed no increase in protein 
expression by B-CLL cells compared with B cells from healthy controls. DM protein 
expression was even significantly lower in B-CLL patients.  
We investigated the mechanism underlying the discrepancy between the observed 
transcriptional upregulation and the unvaried or downmodulated total protein levels 
of DR in the malignant B-CLL cells. We performed pulse chase analysis of DR in the 
B cells of three healthy donors and four B-CLL patients exhibiting various levels of 
transcriptional upregulation of DRA. A similar half-life was observed for DR in the 
malignant B-CLL cells and the healthy B cells, as in all cases approximately 90% of 
the newly synthesized DR pool was still present 24 hrs after biosynthesis. 
Moreover, the maturation of the DR complex and degradation rate of the class II-
associated Ii was comparable between healthy B cells and malignant B-CLL cells 
(unpublished results). Thus, unexpectedly, the malignant B-CLL cells demonstrated 
a comparable biosynthesis rate of DR as the healthy B cells, in spite of their up to 3 
fold higher mRNA levels. Recently it was shown that mesenchymal stem cells show 
increased levels of CIITA-PIV in response to IFN-γ, but that this is not reflected in 
an increase of HLA-DR protein due to cytoplasmic retention of the CIITA transcript 
(23). Since we also found upregulation of transcripts downstream of CIITA, it is not 
likely that CIITA-PIV is retained in the cytoplasm. Whether cytoplasmic retention of 
DRA transcripts could be an explanation for the normal or decreased levels of DR 
protein remains to be investigated. These data nicely illustrate that evaluating 
mRNA levels does not necessarily reflect expression levels of functional proteins.  
In addition we analyzed whether the increased mRNA levels of the MHC II 
components showed a correlation with clinical outcome. Only DOA mRNA levels 
were significantly different when we compared survival after sampling between 
patients. If patients were divided into a group with DOA mRNA levels < 3.4 and ≥ 
3.4, DOA mRNA levels ≥ 3.4 defined a subgroup of patients with an unfavorable 
prognosis: 6 out of 8 patients with DOA mRNA levels ≥ 3.4 died during follow-up as 
compared to 4 out of 12 patients with DOA mRNA levels < 3.4.  
As the change in transcription of the DO genes is not reflected by their protein 
levels, the question arises why DOA mRNA correlates with clinical outcome. It has 
been shown in B-CLL that several serum cytokine levels are elevated (24-26) and 
that both CD4+ and CD8+ T cells express significantly more IFN-γ and IL-4 than in 
healthy controls (27, 28). These pro-inflammatory cytokines can initiate 
transcription of CIITA-PIV, which is elevated in B-CLL. Thus, overexpression of DOA 
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mRNA might be the resultant of the aberrant immunological environment in B-CLL 
but can predict survival in B-CLL. This needs to be validated in a larger cohort of B-
CLL patients and preferably in samples from the time of diagnosis.  
 
Altered MHC class II antigen presentation is reflected in expansion of the 
activated T cell compartment in B-CLL 
In Chapter 7 we quantitatively showed that actually both DM and DO are 
expressed lower at the protein level in B-CLL in comparison with healthy controls. 
Although we did not examine the biosynthesis rate of DM and DO, less expression 
of protein would suggest a difference in turnover of DM and DO protein in B-CLL 
patients compared to healthy controls. This is an interesting topic that deserves 
further research. However, the relative expression of DM over DO was significantly 
higher in B-CLL patients. Expression of DR at the plasma membrane did not differ, 
but CLIP levels were significantly lower in B-CLL patients. The correlation between 
the relative higher expression of DM and the reduced expression of the self-peptide 
CLIP suggests that variation in DM levels changed the peptide repertoire presented 
by DR molecules as it correlated to a reduced expression of the self-peptide CLIP. 
We next analyzed the differentiation and activation status of the T cell 
compartment. Chapter 7 shows that the T cell compartment in B-CLL patients was 
significantly decreased in naïve CD4+ and CD8+ subsets in favor of increased 
activated effector populations. The percentage of activated T cells inversely 
correlated with CLIP expression, pointing to improved antigen presentation. Altered 
MHC class II antigen presentation may thus be a new factor in the immune 
dysfunction and pathobiology of B-CLL. 
 
New therapies against B cell malignancies comprise the use of monoclonal 
antibodies, especially against CD20 and CD52. The effector mechanism of anti-
CD20 and anti-CD52 antibodies is mainly based on complement-dependent cellular 
cytotoxicity (CDCC) and antibody-dependent cellular cytotoxicity (ADCC) (29, 30). 
Treatment with these monoclonal antibodies seems promising, but in case of high B 
cell burden, exhaustion of the body’s effector mechanisms may lead to substantial 
decreases of the immunotherapeutic efficacy.  
The data in this thesis may form a new approach for therapy of B cell cancers. All 
chronic B cell leukemia’s and B cell lymphoma’s express IgM and/or IgD at the cell 
surface (31). Since we have shown that targeting particles to the IgM-type BCR will 
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lead to internalization and recently the same was demonstrated for IgD (32), 
targeting microparticles with anti-cancer agents to the constant region of the BCR 
would be an option. This approach may especially be attractive in the case of 
mantle cell lymphoma, which express high levels of IgM and/or IgD and in which 
patients have the poorest prognosis of all B cell cancers (33).  
Anti-cancer agents packed in microparticles are less harmful for the host and 
targeted to the constant region of the BCR this will bring the drugs directly inside 
the cancer cells. High drug concentrations can be reached in the target cells, 
without harming other cells in the body. Thus, this strategy, may reduce the 
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In de mens speelt MHC klasse II antigeen presentatie een tweezijdige rol bij ziekte 
en gezondheid. Aan de ene kant activeert antigeen presentatie via MHC klasse II 
moleculen CD4+ T cellen om cytokines te produceren en CD40L tot expressie te 
brengen zodat B cellen gestimuleerd worden om antistoffen te produceren. In dit 
proefschrift hebben we de rol van MHC klasse II antigeen presentatie door B cellen 
bestudeerd in de antistof respons bij bacteriële infecties. Aan de andere kant geven 
na MHC klasse II antigeen presentatie de geactiveerde CD4+ T cellen hulp aan CD8+ 
T cellen. De geactiveerde CD8+ T cellen kunnen nu hun cytotoxische activiteiten 
uitvoeren om defecte/getransformeerde of geïnfecteerde cellen te elimineren. 
Verstoring van MHC klasse II antigeen presentatie zou een rol kunnen spelen bij 
het ontduiken van het immuunsysteem door kankercellen, daarom hebben wij de 
MHC klasse II antigeen presentatie route bestudeerd bij leukemie. Het belang van 
MHC klasse II antigeen presentatie wordt duidelijk in patiënten met een defect in 
MHC klasse II antigeen presentatie. Deze zeldzame primaire immuundeficiëntie 
ziekte, genaamd Bare Lymphocyte Syndrome type II (BLSII), wordt gekenmerkt 
door de afwezigheid van MHC klasse II eiwit expressie. De MHC klasse II genen zelf 
zijn onveranderd in deze patiënten, maar hun expressie is verstoord door mutaties 
in transcriptiefactor genen die de transcriptie van MHC klasse II genen initiëren. 
Het resultaat is dat patiënten een ernstig defect hebben in zowel de cellulaire als 
humorale immuniteit en een extreme gevoeligheid voor infecties laten zien. 
Infecties beginnen in het eerste levensjaar, er is een dramatische progressie van 
verschillende soorten infectieuze complicaties en patiënten sterven doorgaans voor 
de leeftijd van 10 jaar. Dit laat zien dat een defect in MHC klasse II antigeen 
presentatie slecht gecompenseerd kan worden door de andere onderdelen van het 
aangeboren en verworven immuunsysteem. 
 
Fagocytose van bacteriën door B cellen 
Klassiek gezien omvatten professionele fagocyten de neutrofielen, monocyten, 
macrofagen, dendritische cellen (DCs) en mast cellen. Professionele fagocyten 
hebben receptoren op hun oppervlak die schadelijke objecten kunnen detecteren 
die normaal niet in het lichaam gevonden worden, zoals pathogene bacteriën. 
Fagocyten zijn daarom cruciaal bij het bestrijden van infecties en in het behouden 
van de gezondheid van weefsels door het verwijderen van dode en stervende cellen 
die het einde van hun levensduur bereikt hebben.  
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Kenmerken van fagocytose zijn de internalisatie van grote partikels (meestal > 500 
nm in diameter) met reorganisatie van het actine cytoskelet en de extensie van 
pseudopodia (vorming van een fagocytische cup). Het dogma is dat B cellen geen 
fagocytische capaciteiten hebben, maar recent is aangetoond dat B cellen van zeer 
vroege gewervelden (teleost vissen en amfibieën) potente fagocyten zijn. De 
auteurs suggereerden dat de fagocytische capaciteit van B cellen al aanwezig was 
in een gezamenlijke voorouder op het moment van de fylogenetische splitsing van 
teleosten en amfibieen, maar dat B cellen van zoogdieren deze aangeboren 
immuun capaciteit verloren lijken te hebben. Inderdaad, hoewel beschreven is dat 
humane B cellijnen antigenen gebonden aan deeltjes presenteren in de context van 
MHC klasse II en antigenen van een niet-internaliseerbaar oppervlak kunnen 
onttrekken, werden primaire B cellen niet gedacht in staat te zijn om grote partikels 
te fagocyteren omdat zij weinig ruimte hebben in het cytoplasma en een relatief 
grote kern. 
Aangezien humane primaire B cellen niet als fagocytische cel gezien worden, hoe 
verkrijgen zij dan antigenen van bacteriën? Het dogma is dat B cellen antigeen 
verkrijgen van folliculaire dendritische cellen (FDCs) in lymfoïde follikels van de 
milt, lymfe knopen (LNs) en mucosale lymfoïde weefsels. Een andere manier zou 
via normale DCs kunnen zijn, waarvan is aangetoond dat ze geïnternaliseerde 
antigenen recyclen naar hun cel oppervlak en deze in onaangepaste vorm aan B 
cellen presenteren. Recent zijn subcapsulaire macrofagen geïdentificeerd in LNs als 
belangrijke plaats waar B cellen aan deeltjes gebonden antigenen tegen komen. 
Aangezien aangetoond is dat B cellen antigenen kunnen oppikken van een niet-
internaliseerbaar oppervlak, zou het vangen van antigeen van het oppervlak van 
andere cellen een manier kunnen zijn om bacteriële antigenen te internaliseren. 
Een alternatief is dat bacteriën naar regionale LNs zouden kunnen verplaatsen of 
naar B cel gebieden in de milt en mucosa-geassocieerd lymfoïd weefsel (MALT), 
waar B cellen direct antigenen van de bacteriën zelf zouden kunnen oppikken. In 
Hoofdstuk 2 is de humane B cellijn Ramos gebruikt in combinatie met anti-IgM 
gecoate beads om aan te tonen dat humane B cellijnen inderdaad zeer capabele 
fagocytische cellen zijn als de beads via de B cel receptor (BCR) herkend worden. 
Ramos cellen internaliseren anti-IgM gecoate beads compleet, maar irrelevant 
gecoate beads worden niet geïnternaliseerd. Als een meer fysiologisch model 
hebben we de Salmonella bacterie gebruikt. In tegenstelling tot het huidige dogma, 
hebben we laten zien dat ook naïeve en memory primaire B cellen in staat zijn hele, 
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levende Salmonella te fagocyteren. Verder onderzoek liet zien dat dit via de BCR 
plaats vindt en dat fagocytose via de BCR resulteert in activatie van de B cel en 
secretie van immuunglobulinen. De antistoffen die geproduceerd worden door B 
cellen die Salmonella hebben geïnternaliseerd zijn reactief tegen Salmonella, dat 
wederom betrokkenheid van de BCR aantoont. Het relatief hoge percentage 
circulerende B cellen dat Salmonella herkent via de BCR kan verklaard worden door 
de expressie van een polyreactieve BCR (ook reactief tegen andere bacteriën) op 
CD27+ circulerende marginale zone B cellen. Net als IgM+ memory B cellen, is er 
ook een subset van mature naïeve B cellen in perifeer bloed die een polyreactieve 
BCR tot expressie brengen. Naast antistof productie, hebben we in Hoofdstuk 2 
laten zien dat fagocytose van Salmonella ook leidt tot snelle antigeen presentatie 
via MHC klasse II moleculen aan CD4+ T cellen. De activatie van CD4+ T cellen is 
bacterie-specifiek, aangezien we hebben aangetoond dat T cellen die opgewekt zijn 
tegen Staphylococcus niet reageren op restimulatie met B cellen die Salmonella 
hebben gefagocyteerd.  
 
De B cel als transportmiddel voor Salmonella 
Aangezien Salmonella een facultatief intracellulaire bacterie is, rijst de vraag wat 
het lot is van Salmonella eenmaal binnen in de B cel. Hoofdstuk 3 beschrijft de 
mogelijke rol van B cellen in de verspreiding van Salmonella na orale infectie. We 
hebben laten zien dat (anders dan macrofagen, neutrofielen en in mindere mate 
DCs) B cellen niet in staat zijn om Salmonella te doden na opname via de BCR. De 
replicatie van Salmonella wordt echter onderdrukt in levende B cellen, terwijl in 
apoptotische B cellen Salmonella weer begint te vermenigvuldigen. We hebben 
gezien dat uren na fagocytose levende bacteriën uit B cellen vrij kwamen en dat 
deze uitgescheiden bacteriën in vitro opnieuw andere cellen konden ïnfecteren. Om 
de rol van B cellen als verspreider van Salmonella in vivo te bestuderen, hebben we 
experimenten gedaan in muizen. Deze experimenten hebben laten zien dat 
adoptieve overdracht van Salmonella-specifieke B cellen in wild-type muizen de 
mortaliteit significant verhoogt na orale toediening van een sub-lethale dosis 
Salmonella. Bovendien werden verhoogde aantallen Salmonella bacteriën gevonden 






Cross-presentatie van Salmonella antigenen door B cellen  
B cellen behoren vooral tot de groep van “professionele antigeen presenterende 
cellen” om hun zeer efficiënte manier van internaliseren van antigeen. Andere leden 
zijn DCs en macrofagen, die net als B cellen fragmenten van antigenen tonen via 
MHC klasse II moleculen op hun cel oppervlak. Naast presentatie via MHC klasse II 
moleculen, zijn DCs in staat om exogene antigenen te cross-presenteren via MHC 
klasse I moleculen aan CD8+ T cellen. In Hoofdstuk 4 hebben we aangetoond dat 
B cellen ook in staat zijn om Salmonella antigenen te cross-presenteren en CD8+ T 
cellen te activeren. Niet verbazingwekkend is dat deze activatie van CD8+ T cellen 
afhankelijk is van CD4+ T cel hulp, aangezien het incuberen van B cellen die 
Salmonella hadden gefagocyteerd met alleen CD8+ T cellen niet resulteerde in 
activatie van de CD8+ T cellen. Na activatie wordt IL-2 geproduceerd door CD4+ T 
cellen en het toevoegen van IL-2 samen met CD8+ T cellen herstelde de activatie 
van CD8+ T cellen door B cellen. Alleen activatie en proliferatie is niet voldoende om 
geïnfecteerde cellen te elimineren, CD8+ T cellen moeten ook degranuleren na 
interactie met een geïnfecteerde cel. We hebben cytotoxiciteits proeven gedaan om 
te laten zien dat Salmonella geprimede CD8+ T cellen degranuleren (gemeten door 
CD107a expressie op het oppervlak van CD8+ T cellen) en werkelijk geïnfecteerde 
cellen doden (gemeten door het vrijkomen van 51Chroom uit het cytoplasma van 
geïnfecteerde B cellen). Ook hebben we in Hoofdstuk 4 laten zien dat de CD8+ T 
cel respons geïnduceerd door geïnfecteerde B cellen een memory respons is, 
aangezien naïeve CD8+ T cellen niet geprimed konden worden door B cellen. Dit in 
tegenstelling tot de CD4+ T cel respons, waarin zowel naïeve als memory CD4+ T 
cellen werden geactiveerd door B cellen die Salmonella hadden gefagocyteerd 
(ongepubliceerde resultaten). 
 
De rol van B cellen in Salmonella infectie 
Na orale opname doorkruist Salmonella het darmepitheel en treedt het de Peyer’s 
patches binnen via gespecialiseerde antigeen-sampling M cellen of opname door 
DCs aan de luminale zijde van de darm. Na het binnentreden in de Peyer’s patches, 
komt Salmonella direct B cellen tegen die de bacteriën kunnen fagocyteren, CD4+ T 
cellen activeren en anti-Salmonella antistoffen uitscheiden. B cellen zijn nodig voor 
efficiënte bescherming tegen zowel primaire als secondaire infecties door 
Salmonella en vorming van antistoffen met hoge affiniteit is niet de enige functie 
van B cellen in salmonellosis, aangezien passieve overdracht van Salmonella-
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immuun serum de immuniteit van muizen tegen Salmonella niet kan 
bewerkstelligen. B cel deficiënte muizen hebben een verstoorde Th1 T cel response 
in het vroege begin van een Salmonella infectie, wat laat zien dat B cellen een 
essentiële rol spelen in het initiëren van T cel gemediëerde bescherming. Humane B 
cellen kunnen naïeve CD4+ T cellen primen en ook memory CD4+ cellen activeren, 
maar zijn niet in staat om Salmonella te doden en dus verspreiden B cellen de 
bacterie door het lichaam. Desalniettemin, B cellen die Salmonella hebben 
opgenomen kunnen memory CD8+ T cellen activeren die vervolgens de 
geïnfecteerde cellen doden. Tijdens een primaire infectie zijn nog steeds andere 
APCs (zoals DCs) nodig voor het activeren van naïeve CD8+ T cellen. Salmonella 
gebruikt dus het immuunsysteem van de gastheer om te overleven en zich te 
verspreiden door het lichaam via antigeen-specifieke B cellen, maar het zich 
ontwikkelende immuunsysteem maakt anti-Salmonella antistoffen en activeert 
CD4+ T helper en CD8+ CTLs. Dit is een voorbeeld van interactie tussen bacterie en 
gastheer welke voor de mens moeilijk in balans te houden lijkt en de 
pathogeniciteit van Salmonella zou kunnen verklaren. 
 
Dode bacteriën worden ook herkend via de BCR, maar niet gefagocyteerd door B 
cellen. In Hoofdstuk 2 hebben we aangetoond dat, hoewel ze niet helemaal 
opgenomen worden, antigenen van dode bacteriën door B cellen gepresenteerd 
worden aan CD4+ T cellen en dat de CD4+ T cellen ook geactiveerd worden. Op 
deze manier kunnen B cellen door CD4+ T cellen geactiveerd worden om te 
differentiëren in antistof producerende plasma cellen, wat resulteert in een 
effectieve immuunrespons tegen volgende infecties. Hoofdstuk 4 laat zien dat B 
cellen geen antigenen van dode bacteriën presenteren aan CD8+ T cellen, wat 
aantoont dat Salmonella zelf bijdraagt aan de cross-presentatie van zijn eigen 
antigenen. Levende Salmonella injecteert eiwitten in het cytosol van de gastheercel 
via zijn Type 3 secretie systeem (TTSS) om zijn intracellulaire overleving veilig te 
stellen. Deze eiwitten worden onoverkomelijk gedegradeerd door het proteasoom. 
Peptides kunnen dan getransporteerd worden naar het endoplasmatisch reticulum 
(ER), op nieuw gesynthetiseerde MHC klasse I moleculen geladen worden en 
gepresenteerd aan CD8+ T cellen. Dode Salmonella hebben geen functioneel TTSS 
meer, wat zou kunnen verklaren waarom dode bacteriën niet gecrosspresenteerd 
worden. De bevinding dat B cellen die dode Salmonella bij zich dragen geen 
Salmonella-specifieke CTLs activeren zou kunnen kloppen met het idee dat dit 
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immunologisch gezien ook niet nodig is; in deze situatie vormen de cellen geen 
niche voor Salmonella overleving en verspreiding, dus hun onmiddellijke opruiming 
zou minder belangrijk kunnen zijn voor de gastheer.  
 
MHC klasse II antigeen presentatie in leukemie 
Professionele APCs nemen apoptotische cellen en puin op om een CD4+ T cell 
respons te initiëren. Stervende tumorcellen kunnen ook opgenomen worden, maar 
soms slaagt de APC er niet in om een effectieve immuunrespons te genereren tegen 
de tumorcellen, aangezien de kanker niet altijd wordt opgeruimd. Desalniettemin 
brengen veel tumoren van het hematologisch systeem MHC klasse II tot expressie 
op hun cel oppervlak. Blijkbaar is de MHC klasse II antigeen presentatie door deze 
tumorcellen er niet in geslaagd om een effectieve immuunrespons te genereren wat 
het resultaat zou kunnen zijn van afwijkingen in de MHC klasse II antigeen 
presentatie route. Wij hebben de MHC klasse II antigeen presentatie route 
bestudeerd in de myeloïde leukemie AML en in meer detail in de lymfoïde leukemie 
B-CLL. 
In Hoofdstuk 5 hebben we laten zien dat het zelf-peptide CLIP tot expressie werd 
gebracht in AML blasten die MHC klasse II tot expressie brachten. Patiënten met 
HLA-DR+/CLIP- blasten hadden een significant langere ziekte-vrije overleving dan 
patiënten met HLA-DR+/CLIP+ blasten. Dit laat zien dat de expressie van CLIP op de 
blasten een maat zou kunnen zijn voor ontsnapping aan het immuunsysteem door 
de leukemie cellen. Tijdens het onderzoek naar de MHC klasse II antigeen 
presentatie route, vonden we dat in AML blasten HLA-DO en HLA-DM (de peptide 
editors van de MHC klasse II antigeen presentatie route) duidelijk detecteerbaar 
waren op zowel mRNA als eiwit niveau. De relatieve expressie van DO en DM 
correleerde met de efficiëntie van antigeen belading op DR moleculen: hoe meer 
DO relatief aan DM, hoe meer CLIP relatief aan DR. Samen leidde dit tot de 
hypothese dat HLA-DR+/CLIP- blasten in staat zijn om leukemie-specifieke 
antigenen aan CD4+ T cellen te presenteren. Dit zou een effectieve anti-tumor 
respons teweeg brengen die in een verlengde ziektevrije overleving resulteert. 
Strategieën om CLIP expressie omlaag te brengen op leukemische blasten worden 
onderzocht om een effectieve anti-tumor respons op te wekken in AML. Retrovirale 
transductie van specifiek Ii siRNAs in twee humane myeloïde leukemische cellijnen 
laat een gereduceerde expressie van CLIP zien relatief aan DR (van Luijn et al., 
submitted). Ondanks de verlaagde hoeveelheden DR op het celoppervlak (als 
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secondaire consequentie van de verlaging van Ii), verhogen beide cellijnen sterk de 
activatie van allogene CD4+ T cellen. Echter, de inductie van tumor specifieke CD4+ 
T cellen (en daaropvolgende hulp voor de inductie van tumor specifieke CD8+ T 
cellen) in AML blasten getransduceerd met Ii siRNAs is nog niet aangetoond. Andere 
strategieën zouden DM en/of DO, de peptide editors, kunnen aanpakken. 
Ongepubliceerde data van onze groep laten zien dat wanneer B cellen in vitro 
worden blootgesteld aan dexamethason, een sterke toename van DM eiwit wordt 
gezien, zonder veranderde DR of DO eiwit hoeveelheden. Meer DM relatief aan DO 
zou peptide belading van MHC klasse II moleculen kunnen verbeteren, zonder de 
totale hoeveelheid DR moleculen die beschikbaar zijn voor antigeen presentatie te 
beïnvloeden.  
 
Het HLA-DOA mRNA expressie niveau voorspelt prognose in B-CLL 
Naast de myeloïde leukemie AML, hebben we de MHC klasse II antigeen presentatie 
route bestudeerd in de lymfoïde leukemie B-CLL. In Hoofdstuk 6 hebben we laten 
zien dat in B-CLL de expressie van DRA, DMB, DOA en DOB maar ook Ii sterk 
afwijkend is op mRNA niveau in vergelijking met B cellen van gezonde controles. 
Aangezien transcriptie van deze genen gereguleerd wordt (DOB en Ii deels) door 
CIITA, hebben we mRNA levels bestudeerd van totaal CIITA en de lymfoïd-
specifieke promoters PIII en PIV. Totaal CIITA mRNA was significant verhoogd in 
vergelijking met mRNA levels in B cellen van gezonde controles. mRNA van CIITA-
PIII werd in alle monsters gedetecteerd, maar liet geen verschil zien met controles. 
De mRNA levels van de IFN-γ-induceerbare promoter CIITA-PIV waren echter 
significant verhoogd, wat laat zien dat transcriptie van CIITA in B-CLL gecontroleerd 
wordt door de gecoördineerde activiteit van de B cel-specifieke promoter PIII en de 
IFN-γ-induceerbare promoter PIV. Verhoogde transcriptie leidt niet altijd tot 
verhoogde translatie en verhoogde eiwit levels, zoals we hebben laten zien in 
Hoofdstuk 6. Analyse van eiwitexpressie met semi-kwantitatieve Western blot liet 
geen toename zien in eiwit expressie door B-CLL cellen vergeleken met B cellen van 
gezonde controles. DM eiwit expressie was zelfs significant lager in B-CLL 
patiënten.  
We hebben het mechanisme bestudeerd onderliggend aan het verschil tussen de 
geobserveerde transcriptionele opregulatie en de onveranderde of 
gedownreguleerde totale eiwit levels van DR in de maligne B-CLL cellen. We hebben 
pulse chase analyse gedaan in B cellen van drie gezonde donoren en vier B-CLL 
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patiënten met verschillende niveaus van transcriptionele opregulatie van DRA. Voor 
DR zagen we een vergelijkbare halfwaardetijd in de maligne B-CLL cellen en de 
gezonde B cellen, aangezien in alle gevallen ongeveer 90% van de nieuw 
gesynthetiseerde DR moleculen 24 uur na biosynthese nog steeds aanwezig was. 
Bovendien was de maturatie van het DR complex en de degradatie snelheid van het 
klasse II-geassocieerde Ii vergelijkbaar tussen gezonde B cellen en maligne B-CLL 
cellen (ongepubliceerde resultaten). Onverwachts laten de maligne B-CLL cellen 
een vergelijkbare biosynthese snelheid van DR zien als de gezonde B cellen, 
ondanks hun tot drievoudige hogere mRNA levels. Recent is aangetoond dat 
mesenchymale stamcellen in respons op IFN-γ verhoogde levels van CIITA-PIV 
hebben, maar dat dit niet tot uiting komt in een verhoging van HLA-DR eiwit als 
gevolg van cytoplasmatische retentie van het CTIIA transcript. Aangezien wij ook 
opregulatie hebben gevonden van transcripten downstream van CIITA is het niet 
waarschijnlijk dat CIITA-PIV in het cytoplasma vast gehouden wordt. Of 
cytoplasmatische retentie van DRA transcripten een verklaring zou kunnen zijn voor 
de normale of verlaagde DR eiwit levels moet nog onderzocht worden. Deze data 
laten zien dat het bestuderen van mRNA levels niet noodzakelijkerwijs een 
afspiegeling is van de expressie levels van functionele eiwitten.  
Daarnaast hebben we bestudeerd of de verhoogde mRNA levels van de MHC II 
componenten een correlatie vertonen met klinische uitkomst. Alleen DOA mRNA 
levels waren significant verschillend als we de overleving na monsterafname 
vergeleken tussen patiënten. Als patiënten werden ingedeeld in een groep met DOA 
mRNA levels < 3.4 en ≥ 3.4, definieerde DOA mRNA levels ≥ 3.4 een subgroep van 
patiënten met een minder gunstige prognose: 6 van de 8 patiënten met DOA mRNA 
levels ≥ 3.4 stierven tijdens follow up vergeleken met 4 van de 12 patiënten met 
mRNA levels < 3.4.  
Aangezien de verandering in transcriptie van de DO genen niet tot uiting komt in 
hun eiwit levels, rijst de vraag waarom DOA mRNA correleert met klinische 
uitkomst. Het is beschreven in B-CLL dat verscheidene serum cytokine gehaltes 
verhoogd zijn en dat zowel CD4+ als CD8+ T cellen significant meer IFN-γ en IL-4 
produceren dan in gezonde controles. Deze ontstekings cytokines kunnen de 
transcriptie van CIITA-PIV initiëren, welke verhoogd is in B-CLL. Dus, overexpressie 
van DOA mRNA zou het resultaat kunnen zijn van een afwijkend immunologisch 
milieu in B-CLL maar kan overleving in B-CLL voorspellen. Dit moet gevalideerd 
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worden in een groter cohort van B-CLL patiënten en bij voorkeur in monsters 
afgenomen op het moment van diagnose.  
 
Veranderde MHC klasse II antigeen presentatie wordt gereflecteerd door 
expansie van het geactiveerde T cel compartiment in B-CLL 
In Hoofdstuk 7 hebben we kwantitatief aangetoond dat eigenlijk zowel DM als DO 
op eiwit niveau lager tot expressie komen in B-CLL in vergelijking met gezonde 
controles. Hoewel we niet de biosynthese snelheid van DM en DO hebben 
bestudeerd, zou een lagere eiwit expressie van DM en DO eiwit in B-CLL patiënten 
een verschil in turnover suggereren vergeleken met gezonde controles. Dit is een 
interessant onderwerp dat meer onderzoek verdient. De relatieve expressie van DM 
ten opzichte van DO was echter hoger in B-CLL patiënten. Expressie van DR op het 
plasma membraan verschilde niet, maar CLIP levels waren significant lager in B-CLL 
patiënten. De correlatie tussen de relatief hogere expressie van DM en de verlaagde 
expressie van het zelf-peptide CLIP suggereert dat door variatie in DM levels het 
peptide repertoire dat gepresenteerd wordt door DR moleculen wordt veranderd, 
aangezien het gecorreleerd is aan een verlaagde expressie van het zelf-peptide 
CLIP. Vervolgens hebben we de differentiatie en activatie status van het T cel 
compartiment bestudeerd. Hoofdstuk 7 laat zien dat het T cel compartiment in B-
CLL patiënten significant verlaagd was in naïeve CD4+ en CD8+ subsets ten gunste 
van verhoogde geactiveerde effector populaties. Het percentage geactiveerde T 
cellen is omgekeerd gecorreleerd met CLIP expressie, wijzend op verbeterde 
antigeen presentatie. Veranderde MHC klasse II antigeen presentatie zou dus een 
nieuwe factor kunnen zijn in de immuun dysfunctie en pathobiologie van B-CLL. 
Nieuwe therapieën tegen B cel maligniteiten omvatten het gebruik van monoklonale 
antistoffen, in het bijzonder tegen CD20 en CD52. Het effector mechanisme van 
anti-CD20 en anti-CD52 antistoffen is voornamelijk gebaseerd op complement 
gemedieerde cellulaire cytotoxiciteit (CDCC) en antistof gemedieerde cellulaire 
cytotoxiciteit (ADCC). Behandeling met deze monoklonale antistoffen lijkt 
veelbelovend, maar in het geval van hoge B cel belasting zou uitputting van de 
effector mechanismes kunnen leiden tot substantiële vermindering van de 
immunotherapeutische efficiëntie. 
De data in dit proefschrift zouden een nieuwe benadering kunnen vormen voor 
therapie tegen B cel kankers. Alle chronische B cel leukemieën en B cel lymphomen 




laten zien dat het richten van deeltjes naar de IgM-BCR leidt tot internalisatie, en 
recent hetzelfde is aangetoond voor IgD, zou het richten van micropartikels met 
anti-kanker middelen naar het constante domein van de BCR een optie kunnen zijn. 
Deze aanpak zou in het bijzonder aantrekkelijk kunnen zijn in het geval van 
mantelcel lymfomen, welke hoge levels IgM en/of IgD tot expressie brengen en 
waar patiënten de slechtste prognose hebben van alle B cel kankers. 
Anti-kanker middelen verpakt in micropartikels zijn minder schadelijk voor de 
patiënt en gericht naar het constante domein van de BCR brengt dit de drugs direct 
binnen in de kankercellen. Zo kunnen hoge concentraties drugs bereikt worden in 
de target cellen, zonder andere cellen in het lichaam te schaden. Deze strategie zou 
dus de ongewilde bijwerkingen van systemische behandeling met anti-kanker 
medicijnen kunnen verminderen.  
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als onderzoeker in opleiding op een gezamelijk project van het NKI-AVL (afdeling 
Tumor Biologie) en het VU medisch centrum (afdeling Pathologie). Onder 
begeleiding van Prof.dr. J.J. Neefjes en dr. S.M. van Ham deed hij 
promotieonderzoek naar MHC klasse II antigeen presentatie door B cellen. In 
november 2003 verhuisde hij mee met dr. S.M. van Ham naar de afdeling 
Immunopathologie van Sanquin om daar het onderzoek voort te zetten en uit te 
breiden met onderzoek naar de fagocytose van bacteriën via de B-cel receptor. De 
resultaten van dit onderzoek staan beschreven in dit proefschrift. Vanaf november 
2006 werkte hij als postdoc op de afdeling Immunopathologie en vervolgde hij het 
onderzoek naar de fagocytose door B cellen en antigeen presentatie aan T cellen. 
Sinds mei 2009 is hij werkzaam als postdoc op de afdeling Celbiologie en Histologie 





























Een proefschrift schrijven doe je niet alleen, ook niet als je er 8 jaar over doet. Ik 
wil iedereen bedanken die een bijdrage heeft geleverd, zowel wetenschappelijk als 
niet-wetenschappelijk. Een aantal mensen in het bijzonder: 
 
Dr. van Ham, copromotor, lieve Marieke. Jij was mijn dagelijkse begeleider en 
zowel jouw onuitputtelijke vermogen om uit resultaten van experimenten altijd iets 
positiefs te halen als je stimulerende manier van coachend leiding geven inspireren 
me nog steeds. Daarom twijfelde ik geen moment toen je in 2003 vroeg of ik 
meeging naar Sanquin. En dat dat voor mij een succes is geworden weet iedereen 
:-). We hebben een bijzondere band: naast dat je mijn wetenschappelijke moeder 
bent hebben we ook prive veel gedeeld: van een vakantie-tripje voorafgaand aan 
een congres, sores in allebei onze liefdeslevens totaan jouw enorme steun voor 
mijn gezin na de geboorte van Ruben. Heel erg bedankt voor alles en ik ben reuze 
blij dat je betrokken bent bij het project waar ik nu aan werk op het AMC. 
Prof. dr. Neefjes, promotor, beste Sjaak. Bedankt voor de prettige samenwerking 
de afgelopen jaren, zelfs op afstand kan dat best. Ik bewonder je omdat je naast 
het leiden van een afdeling ook nog tijd hebt om proeven te doen en zo snel als 
Overtoom bent met het lezen en corrigeren van manuscripten. 
Prof. dr. Meijer, promotor, beste Chris. Bedankt dat je ondanks mijn vertrek naar 
Sanquin toch erg betrokken bent gebleven bij de klinische manuscripten. Ik heb 
een erg leuke tijd gehad bij jou op de afdeling. 
Tineke, al vanaf het begin hebben we samen gewerkt. Je hebt gouden handjes en 
als een proef weer twee keer zo groot werd bleef je zonder morren ook bezig tot 
alles ingezet was. Fantastisch dat je een van mijn paranimfen wilt zijn. 
Jelle, samen op een project gewerkt. Je hebt een bijzondere gave om geweldige 
presentaties te geven met dia’s waar niets teveel op staat. Ik vind het geweldig dat 
jij mijn andere paranimf wilt zijn, stelling 11 zul je vast beamen :-). 
 
Verder ga ik het een beetje chronologisch aanpakken: 
Het begon allemaal op het ASI-lab van de pathologie in het VUmc bij Marieke, 
Marion, Sander, Liesbeth, Tineke en Stephan. We hadden een gezellig kluppie in 
dat kleine hokje en toch alle ruimte om western blotjes te doen toen jullie klinische 
studie een beetje stil viel. Bedankt voor jullie geduld als ik geheel tegen de cGMP 
regels in weer eens vergeten was iets af te tekenen, dat is ook zo niet-research :-). 
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In deze tijd is ook mijn enige student begonnen; maar je bleef wel veel langer dan 
een gemiddelde student doordat je deelnam aan de masterclass oncologie. Jouw 
werk is de basis voor een stuk dat binnenkort geschreven gaat worden. Canan, heel 
veel succes met je promotieonderzoek bij de hematologie van het VUmc.  
 
Toen er een plekje vrijkwam verhuisde ik naar DE AIO-kamer van de pathologie. 
Bart, Denise, Inge, Jeroen, Jettie, Johan, Joost, Kirsten, Maikel, Rieneke, Sas en 
Sas. De tork-rol sessies van de dames zijn onvergetelijk. Alles binnen de deur bleef 
daarbinnen en buiten de deur gingen we soms helemaal los. Het waren twee 
fantastische jaren en de weekendjes daarna bleven leuk! Jettie, bedankt voor alle 
hulp met statistiek en gezellige middagen met onze gezinnen.  
Sas, Cillie, Inge, Rieneke, Bart, Joost en Johan: geheel in stijl van de NS komt de 
2008-is-ons-jaar-dus-we-gaan-allemaal-promoveren iets later aan, maar nu kan 
ons gezamenlijke feest dan toch gepland worden! 
 
Van de afdeling hematologie wil ik Marvin, Martine, Gert en Arjan bedanken voor de 
stimulerende discussies. Sorry dat de stukken lang op zich lieten wachten, maar 
wat in het vat zit verzuurt niet, toch? 
 
Eva, thank you for the two times that Tineke and I were welcome on your lab to 
perform experiments. I enjoyed staying in Tϋbingen very much! 
 
Toen kwam de verhuizing naar Sanquin en werden we opgenomen in de afdeling 
immunopathologie. Angela, Anke, Anneke, Caroline, Dörte, Dorina, Ellen, Gerard, 
Gertjan, Gijs, Gwen, Hanny, Henk, Ineke, Irma, Kaoutar, Margreet, Marja, Martine, 
Mieke, Miranda, Miriam (leuk dat je af en toe nog bij ons thuis komt eten!), 
Ninotska, Patty, Piet, Remco, Rishi, Robert, Rob, Sacha, Shabnam, Steven, Tamara, 
Theo, Theresa. Bedankt voor de leuke tijd op het lab, de labuitjes en borrels. 
Lucien, dank voor je adviezen over B cellen en Els bedankt voor alles dat ik kwam 
‘lenen’. Bouke, bedankt voor het organiseren van alle borrels en het aanvullen van 
(veel) steriele puntjes. Anja en Josine, bedankt voor de gezellige tijd in het 
postdoc-hok. Femke, Jelle, Pauline en Ingrid; altijd in voor Nol of het MPF! 
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De sorters van het NKI, Anita en Frank en de sorters van Sanquin, Floris en vooral 
Erik: bedankt voor de zuivere celpopulaties waar we experimenten mee hebben 
kunnen doen. 
 
Marieke (v/d V.) en Fatima, bedankt voor alle hulp bij de administratieve 
rompslomp rondom mijn promotie. 
 
Alex, bedankt voor de prettige samenwerking. Het zijn (toch twee) prachtige 
stukken geworden, al kostte het veel moeite de referenten te overtuigen dat B 
cellen ook phagocyten zijn. Veel succes nu je voor jezelf begonnen bent. 
 
Merel en Jeroen, bedankt voor de gezellige vakanties, zwemmen met de jongens op 
zondagmorgen en belangstelling naar het afronden van mijn boekje. 
Maaike en Remko, bedankt voor jullie steun en presentjes bij elke gelegenheid. De 
zondagmiddag-bankhang-middag houden we erin. 
 
Karin, schoonzus met dezelfde muzieksmaak. Gezellig dat je zonder zwangere 
Diana toch met mij de stad in gaat op koninginnedag of op vakantie in Spanje.  
Marja en Henk, schoonouders uit duizenden. Bedankt dat jullie altijd klaar stonden 
als ik weer eens op een vrije donderdag of zondag aan het boekje ging klussen. 
Hijko en Rianne, bedankt voor jullie steun en veel plezier met jullie vrolijke 
beestenboel. 
Lieve pap en mam, zonder jullie onvoorwaardelijke steun en liefde was het nooit 
gelukt. Zowel tijdens mijn studie- als promotietijd kon ik altijd op jullie rekenen en 
ik bewonder jullie moeite om te begrijpen waar ik mee bezig ben. Ik hou van jullie! 
 
Lieve Diana, je bent het beste dat me ooit is overkomen. Bedankt voor alle support 
en tips tijdens het afronden van het boekje. Samen zijn we zooo goed! 
Je deelt de eerste plek inmiddels met twee kanjertjes: Ruben, je bent de grootste 
bikkel die rondloopt! Timo, nog zo klein maar vreselijk lief. Binnenkort verhuizen 

























































































































Figure 3A, B and C from Chapter 3, page 66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
